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Abstract 
Pharmacy retail markets in low and middle-income countries (LMIC) have traditionally been 
dominated by independently owned pharmacies, but economic growth has spurred the entry 
of pharmacy chains into these markets. Chains could be argued to have the potential to both 
improve quality and reduce price in comparison to independent pharmacies, however this has 
been little studied in LMICs. 
Using mixed methods, including a standardised patient survey, exit interviews with patients, 
and key informant interviews, research was undertaken to understand the effect of chain 
pharmacies, in India, on key public health concerns.  
The management of childhood diarrhoea and suspected tuberculosis was similarly 
substandard in chains and independents for most areas of assessment. However, chains sold 
significantly fewer harmful and prescription-only medicines for the diarrhoea patient. No 
significant price difference was found between chains and independents for the management 
of the TB case but the diarrhoea consultation was significantly cheaper at chains. Chains 
offered discounts on medicines, made possible by bulk purchasing and efficiencies in the 
supply chain. Customers patronising chain pharmacies were both more educated and 
relatively wealthier than those using independent pharmacies. In-depth interviews explored a 
set of hypotheses regarding how being organised in a chain may affect key behaviours 
relating to quality failures. In practice, few differences were identified: chains did not all 
have qualified pharmacists; the chain structure was not used to enforce regulation; and chain 
sales staff faced quite high-powered financial incentives. Chains did exert strong influence 
over customer service and sales, but the potential to exploit this control to improve quality 
was not realised.  
Given that the chains are not currently serving poorer groups, and the impact on quality of 
care was limited, any attempt to leverage this organisational model for public health 
improvement would require implementation of appropriate regulatory constraints and 
incentives.  
4 
Acknowledgements 
Firstly I would like to thank my main supervisor, Catherine Goodman. From the first time I 
met Catherine to discuss my ideas for a PhD back in 2010, she has been fully supportive and 
an integral part of this journey. I truly believe that in Catherine, I won the supervisor lottery. 
I am so grateful to have had her intelligent and sound guidance. I am also grateful to Eleanor 
Hutchinson, who later joined as my secondary supervisor, for her insights into my 
qualitative work. At different points during my PhD I feel fortunate to have benefitted from 
the thoughts of those on my advisory committee including Timothy Powell-Jackson, 
Meenakshi Gautham, Janet Seeley, and Lindsay Mangham Jefferies. I could not have 
undertaken this PhD without the financial support of a +3 studentship from the Economic 
and Social Research Council, and a Doctoral Travelling Scholarship from the LSHTM. 
Sincere thanks go to all at the Society for Community Health Awareness Research and 
Action (SOCHARA) for giving me an institutional home during my fieldwork in Bengaluru. 
Especially, Dr Thelma Narayan for her advice on conducting research locally, invaluable 
research contacts, and warmth and hospitality. And to Victor and Chander for all their 
administrative support. I am indebted to the standardised patients and my research assistants, 
in particular Prafulla Shriyan and Rakesh Narayana, for their hard work, dedication, and 
good humour throughout the project. I could not have completed my fieldwork without 
them. I am also grateful to all those who agreed to participate in this study.  
To my PhD ‘wives’ at LSHTM, Katherine and Stefanie, thank you for making this whole 
process more colourful. To Elliot, many thanks for design support. I am indebted to the 
wonderful staff at Kara4Kids nursery in Bengaluru, for helping Skye to settle in and have so 
much fun whilst I was in the field. And to our nannies in London, Lana and later Sophie, 
who have looked after Skye and Rae so beautifully whilst I undertook this endeavour.  
Lastly, a huge thank you to my family. To Alexia, not technically family but the best friend 
and Auntie a girl could ask for. To my Mum, for countless hours of childcare; proofreading 
the final manuscript meticulously; and, as always, general life support, love, and 
reassurance. To my husband, Justin, for encouraging me to pursue this work; following me 
to India, and all the logistical and emotional support during our time there; and keeping the 
fort going at home during the final stages. To my eldest daughter Skye, for being my biggest 
cheerleader and for adapting and embracing life in India wholeheartedly- thinking back to 
your 2 year old thick Indian English will always bring a smile to my face! And finally to 
Rae, my youngest daughter and smallest supporter, your sunny face has brightened up so 
many of my days.  
5 
This thesis is dedicated to the loving memory of my best friend, Lucy Dawson. 
Never could I have imagined that you would not be here to see the completion of this work. 
Thank you for holding my hand through life, from little 5 year olds through to adulthood.   
Your memory continues to inspire me in all that I do.     
6 
Table of Contents 
Declaration.............................................................................................................................. 2 
Abstract ................................................................................................................................... 3 
Acknowledgements ................................................................................................................ 4 
Table of Contents ................................................................................................................... 6 
List of Tables .......................................................................................................................... 8 
List of Figures ......................................................................................................................... 9 
List of Abbreviations ........................................................................................................... 11 
PART I: BACKGROUND TO THE THESIS ....................................................... 13 
1 Introduction .................................................................................................................. 13 
1.1 Role of pharmacies in low- and middle-income countries ........................ 13 
1.2 Organisational arrangements of pharmacies in low- and middle-income 
countries   ................................................................................................................... 14 
1.3 Pharmacies in India.................................................................................... 14 
1.4 Aims and Objectives .................................................................................. 17 
1.5 Thesis outline ............................................................................................. 18 
2 Systematic literature of pharmacy performance ....................................................... 22 
2.1 Introduction ............................................................................................... 22 
2.2 Research paper 1: literature review ........................................................... 22 
PART II: HYPOTHESES AND METHODOLOGY ........................................... 38 
3 Towards a set of hypotheses: theoretical and empirical insights from the literature 
 ........................................................................................................................................ 38 
3.1 Introduction ............................................................................................... 38 
3.2 Empirical data on the effects of pharmacy chains ..................................... 38 
3.3 Theoretical insights from economics literature ......................................... 43 
3.4 A note on franchises .................................................................................. 47 
3.5 Set of hypotheses ....................................................................................... 47 
4 Study site, study design, and methods ........................................................................ 53 
4.1 Introduction ............................................................................................... 53 
4.2 Study Site ................................................................................................... 53 
4.3 Methods ..................................................................................................... 59 
7 
PART III: RESULTS ............................................................................................... 77 
5 Quality of case management ........................................................................................ 77 
5.1 Introduction ............................................................................................... 77 
5.2 Research paper 2 ........................................................................................ 77 
6 Price and socioeconomic status of clients ................................................................... 91 
6.1 Introduction ............................................................................................... 91 
6.2 Research paper 3 ........................................................................................ 91 
7 Understanding chain business models and their implications ............................... 117 
7.1 Introduction ............................................................................................. 117 
7.2 Research paper 4 ...................................................................................... 117 
PART IV: DISCUSSION AND CONCLUSION ................................................. 139 
8 Discussion .................................................................................................................... 139 
8.1 Introduction ............................................................................................. 139 
8.2 Summary of findings and comparison with the literature ........................ 140 
8.3 Contribution to knowledge ...................................................................... 145 
8.4 Limitations ............................................................................................... 146 
8.5 Generalisability of the findings ............................................................... 153 
8.6 Policy implications .................................................................................. 153 
8.7 Concluding remarks ................................................................................. 161 
APPENDICES TO THESIS .................................................................................. 169 
Appendix 1: Supplementary data to Miller and Goodman 2016, Health Policy and 
Planning .............................................................................................................................. 169 
Appendix 2: Summary of literature on effects of pharmacy chains in high-income 
countries .............................................................................................................................. 184 
Appendix 3: Study tools and consent forms .................................................................... 197 
Appendix 4: Ethical Clearances ....................................................................................... 225 
Appendix 5: Supplementary material to Miller and Goodman 2017, BMJ Global 
Health .................................................................................................................................. 227 
Appendix 6: Editorial for Journal of Clinical Tuberculosis and Other Mycobacterial 
Diseases ............................................................................................................................... 230 
8 
List of Tables 
Chapter 2 
Table 1: Search strategy ........................................................................................... 26 
Table 2: Treatment choices for a range of conditions presented at pharmacies in 
Asia by simulated clients  .......................................................................................... 30 
Chapter 3 
Table 1: Search strategy used to identify literature on pharmacy chains and 
franchises  .................................................................................................................. 39 
Chapter 4 
Table 1: A comparison of India’s nationwide key health and development indicators 
within the Southern states of Karnataka, Kerala and Tamil Nadu  ............................ 57 
Table 2: Overview of thesis objectives and corresponding methods and results 
papers       ................................................................................................................... 59 
Table 3: Standardised patient case details and expected management  ................... 62 
Table 4: Size of pharmacy chains in Bengaluru and in sample  .............................. 64 
Chapter 5 
Table 1: Standardised patient case details and expected management .................... 81 
Table 2: Size of pharmacy chains in Bengaluru and in sample  .............................. 82 
Table 3: History taking in chain and independent pharmacies when presented with 
cases of suspected TB and diarrhoea   ....................................................................... 83 
Chapter 6 
Table 1: Size of pharmacy chains in Bengaluru and in sample ............................... 98 
Table 2: Descriptive statistics for diarrhoea and TB encounter ............................. 103 
Table 3: Price deviation of standardised patients encounters from the maximum 
retail price for chain and independent pharmacies  .................................................. 104 
Table 4: Effect of pharmacy type on price: diarrhoea encounter  .......................... 105 
Table 5: Effect of pharmacy type on price: TB encounter  .................................... 105 
Table 6: Price of TB encounter, investigating the effect of ‘private label’ medicines 
on price     ................................................................................................................. 106 
9 
List of Figures 
Chapter 2 
Figure 1: PRISMA flow diagram  ............................................................................. 26 
Figure 2: Appropriate retail pharmacy practices for patients with and without a 
prescription  ............................................................................................................... 27 
Chapter 3 
Figure 1: Hypothesised effects of pharmacy chains on public health concerns of 
quality of care, price, quality of medicines, and access  ............................................ 49 
Chapter 4 
Figure 1: Geographical locations of chains and independents visited in standardised 
patient study  .............................................................................................................. 65 
Chapter 5 
Figure 1: Therapeutic management of suspected TB case by independent and chain 
pharmacies  ................................................................................................................ 84 
Figure 2: Breakdown of medicines sold for suspected TB case by outlet type …. ... 84 
Figure 3: Therapeutic management of diarrhoea case by independent and chain 
pharmacies  ................................................................................................................ 85 
Figure 4: Breakdown of medicines sold for diarrhoea case by outlet type  .............. 86 
Chapter 6 
Figure 1: Histogram of price of diarrhoea encounter with kernel density  .............. 102 
Figure 2: Histogram of price of TB encounter with kernel density  ........................ 102 
Figure 3: Typical supply chain for independent and chain pharmacies purchasing 
medicines, as told by key informants  ...................................................................... 108 
Figure 4: Wealth of customers patronising chain and independent pharmacies 
relative to the general population of Bengaluru  ...................................................... 109 
Figure 5: Educational attainment of customers patronising chain and independent 
pharmacies relative to the general population of Bengaluru .................................... 110 
Figure S1: Wealth of customers patronising chain and independent pharmacies 
relative to the general population of Bengaluru (pharmacies within 1km radius)  .. 116 
Figure S2: Educational attainment of customers patronising chain and independent 
pharmacies relative to the general population of Bengaluru (pharmacies within 1km 
radius  ................................................................................................................. 116 
10 
Chapter 7 
Figure 1: Hypothesised effects of pharmacy chains on quality of care provision ... 124 
11 
List of Abbreviations 
ADC Assistant drug controller 
AIOCD All Indian Organisation of Chemists & Druggists 
AMR Antimicrobial resistance  
ASHA Accredited Social Health Activist 
BPL Below Poverty Line 
C&F Carry and forwarding 
CHC Community Health Centre 
CIOMS Council for International Organizations of Medical Sciences 
DLHS District Level Health Survey 
ESRC Economic and Social Research Council 
GDP Gross Domestic Product 
GOI Government of India 
HDI Human development indicator 
IDI In-depth interview 
IIPS International Institute for Population Studies  
INRUD International Network for Rational Use of Drugs 
IQR Interquartile range 
KI Key informant 
LMIC Low- and middle-income country  
LSHTM London School of Hygiene and Tropical Medicine 
MRP Maximum retail price 
NFHS National family health survey 
NGO Non-Governmental Organisation 
NPPA National Pharmaceutical Pricing Authority 
NPRP Non pharmacist-run pharmacy 
NTP National Tuberculosis Programme 
ORS Oral rehydration solution 
ORT Oral rehydration therapy 
12 
OTC Over-the-counter 
PCA Principal component analysis 
PHC Primary Health Centre 
POM Prescription only medicine 
PRP Pharmacist-run pharmacy 
RNTCP Revised National Tuberculosis Control Programme 
RSBY Rashtriya Swasthya Bima Yojana 
RTIs Respiratory tract infections 
SES Socioeconomic status 
SOP Standard operating procedure 
SP Standardised patient 
STI Sexually transmitted infection 
TB Tuberculosis 
THE Total health expenditure 
UK United Kingdom 
US United States 
WHO World Health Organization 
13 
PART I: BACKGROUND TO THE THESIS 
1 Introduction 
1.1 Role of pharmacies in low- and middle-income countries 
An effective pharmaceutical service is a key component of the health system and recognised, 
as such, by the World Health Organization (WHO) (World Health Organisation 1988, 1994). 
Private retail pharmacies are present in many communities in low- and middle-income 
countries (LMICs), where they are widely utilised for filling prescriptions, purchasing 
medicines and seeking health advice (Smith 2009). Pharmacies are used as the first point of 
care in a number of LMICs for a range of medical conditions, including respiratory 
infections, fever, malaria, injury, body and dental pains, skin infections, diarrhoea and 
sexually transmitted infections (Igun 1987, Kamat and Nichter 1998, Saradamma, 
Higginbotham, and Nichter 2000, Smith 2009, Wafula, Miriti, and Goodman 2012). Their 
appeal lies in long opening hours, availability of medicines (including the possibility of 
credit and the option to purchase medicines in small quantities), geographical accessibility, 
and personal familiarity (Van der Geest 1982, Kloos et al. 1986, Igun 1987, Logan 1983, 
Price 1989, Greenhalgh 1987, Haak 1988, Mayhew et al. 2001). Further, many patients have 
neither the time nor money to consult a physician (Haak 1988, Ferguson 1981, Seeberg 
2012, Wolffers 1987, Saradamma, Higginbotham, and Nichter 2000). 
Pharmacy staff can be viewed as the gatekeepers of medicines. They stand at the interface 
between producers and consumers of medicines and it is their responsibility to ensure that 
they are used safely, effectively and rationally (Anderson 2002). When used correctly, 
medicines can save lives and improve people’s health; irrational use, however, is wasteful 
and can be harmful at both the individual and population level. Firstly, it is associated with 
causing significant morbidity and mortality (Holloway and van Dijk 2011). Secondly, 
misuse of antibiotics has led to the selection and spread of resistant bacteria. As a result, 
antibacterial drugs have become less effective and in some cases, ineffective. Antimicrobial 
resistance (AMR) is now recognised as a ‘global health security emergency’ (World Health 
Organization 2014). A final concern is the economic impact of spending on households, 
especially the poor. Customers typically pay for the medicines purchased at pharmacies out 
of their own pocket and where these medicines are inappropriate this represents a waste of 
scarce resources.   
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1.2 Organisational arrangements of pharmacies in low- and middle-
income countries 
Retail pharmacy markets in LMICs have historically been dominated by independent 
retailers. In recent times, economic growth has led to the entry of chain pharmacies into 
these markets. A retail chain consists of number of outlets (definitions range from a 
minimum of 2-5) operating under a single brand and central management. All outlets are 
owned by the company and managers are employed to run individual outlets. Such 
pharmacies are now operating in a number of countries, including India, The Philippines, 
Thailand, China, Mexico, Brazil, Argentina, Chile, South Africa, Nigeria, Kenya and 
Uganda (IMS consulting group 2014, Lowe and Montagu 2009). In LMICs, chains are most 
entrenched in South America, in particular in Mexico and Chile where they account for 34% 
and 51% of the retail pharmacy market respectively. In most markets, a few major chains are 
responsible for driving business. Some corporations operate a proportion of their stores 
through a franchise model, whereby a franchisee pays an upfront fee and ongoing sales 
royalties in order to own and run a retail business using the franchisor’s brand name, often 
buying inputs or goods for resale from the franchisor (Brickley, Dark, and Weisbach 1991). 
The franchisor often provides training, advertising and other services.  
The chain that has arguably received most attention, in a low- or middle-income setting, is 
the Mexican giant, Farmacia Similares- the brain child of ‘physician-pharmacist-
industrialist’ Victor Gonzalez Torres (Shadlen 2009). Farmacia Similares’s business model 
of selling low cost generics to the bottom of the pyramid has garnered the attention of policy 
makers and global health organisations alike to the possibilities of pharmacy chains. Yet we 
are unaware of other chains, elsewhere in LMICs, with a similar offering. Instead, pharmacy 
chains in other settings tend to follow the traditional model of selling both generics and 
branded medicines, the latter being favoured by both doctors and patients (Nguyen et al. 
2008). 
1.3 Pharmacies in India  
India’s healthcare system is highly privatised in terms of both financing and service 
provision (Reddy et al. 2011). Public spending on health (as a % of GDP) ranks amongst the 
lowest in the world (1.1%) and has barely risen over the past decade. The health system is 
highly dependent on out of pocket payments (which account for over 70% of health care 
spending) and a poorly regulated private sector (Kumar et al. 2011, Mackintosh et al.). 
Within this pluralised private sector pharmacies, otherwise known as ‘chemists and 
druggists’ and ‘medical and general stores’, are used extensively by the public to purchase 
medicines and obtain health advice (Saradamma, Higginbotham, and Nichter 2000, Seeberg 
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2012). In some areas, chemists have been found to act as ‘de facto primary healthcare 
providers’ (Seeberg et al. 2014). There are no official figures for the number of medicine 
retailers operating nationally, but it is estimated to be around 800,000 (All Indian 
Organisation of Chemists & Druggists (AIOCD) 2014 , IMS consulting group 2014). 
Despite their accessibility and frequency of use, national health policy has historically 
maintained a ‘stoic silence about pharmacists’ (Basak and Sathyanarayana 2009).  
On paper, in order to obtain a pharmacy licence (or continue to run an existing pharmacy), a 
set of requirements must be fulfilled. These include a specified minimum area and 
equipment; compounding of prescription medicines should be done by a pharmacist; sale of 
prescription medicines should be done under direct supervision of a pharmacist; sale of 
prescription medicine should be recorded in a prescription register, and in a cash or credit 
memo for other medicines; no prescription medicines should be sold without a prescription; 
prescription medicines belonging to schedule X need duplicate prescription (Government of 
India). In terms of the expectations of pharmacists, guidance is laid out in the ‘Pharmacy 
Practice Regulations’, 2015 (Pharmacy Council of India 2015). These are the first updates to 
be made to the 70 year-old laws governing the regulation of the profession, practice of 
pharmacy, and the sale of medicines (the Pharmacy Act 1948 and the Drugs and Cosmetics 
Act 1940) (Government of India , Government of India). These new regulations include a 
code of pharmacy ethics and the duties of the registered pharmacist. In addition to 
dispensing prescription medicines and selling over the counter (OTC) medication in 
accordance with legal regulations, community pharmacists’ duties are expected to include 
counselling and advising the public on the treatment of minor ailments; instructing patients 
regarding intended use of medicines, directions for use and proper storage requirements; 
advising patients of any adverse side-effects of medicines or potential interactions with other 
medicines; and promoting rational drug use. 
In reality, a large gap exists between the regulations described and the everyday practice of 
pharmaceutical use. Licensing requirements are frequently flouted and pharmacy practice 
falls woefully short of this ideal (Saradamma, Higginbotham, and Nichter 2000, Seeberg 
2012, Greenhalgh 1987, Kamat and Nichter 1998, Basak, van Mil, and Sathyanarayana 
2009, Tiwari 2009). Through an analysis of the pharmaceutical sector in India, Jeffery and 
colleagues report that enforcement of regulation is poor, bribes are common and regulations 
‘have no real intrinsic significance’. On the functions that licenses play, they comment that 
‘protecting the consumer or ensuring professional practice come rather low down in the 
priorities’ (Jeffery et al. 2007). They conclude that the Indian drug distribution system meets 
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the International Narcotics Control  Board’s1  criteria for being ‘unregulated’ (Brhlikova et 
al. 2011, Jeffery and Santhosh 2009). 
Given the weak regulatory environment, it is perhaps not surprising that research has found 
that pharmacies are commonly staffed by unqualified personnel, and that practice is 
characterised by insufficient history taking; the illegal sale of prescription only medicines 
without a prescription, including over use of antibiotics (often sold in incomplete courses); 
the provision of clinically inappropriate medicines; and limited advice giving (Greenhalgh 
1987, Kamat and Nichter 1998, Saradamma, Higginbotham, and Nichter 2000, 
Satyanarayana S et al. 2016, Seeberg 2012). Further, there has been little effort to address 
these shortcomings (Basak and Sathyanarayana 2009, Konduri, Delmotte, and Rutta 2017). 
1.3.1 Chain pharmacies in India 
Within the Indian pharmacy landscape, pharmacy chains are a new, but growing, 
phenomenon. Their current market share is estimated to be around 4% but it is reportedly 
one of the fastest growing markets globally (IMS consulting group 2014).  Chain growth in 
India has been reported at an average of 25% per annum, and this rate is expected to increase 
to between 35-40% in the coming years (Northbridge Capital 2011). Chains are concentrated 
in the country’s metropolises, and they account for 9% of outlets in Bengaluru (the site of 
this PhD research).  
For the purpose of this research, chains are defined as organisations where two or more 
pharmacies operate under the same name and each outlet uses the organisation’s distinctive 
branding. The pharmacy chains operating in India are heterogeneous and range in size from 
two outlets to 1000 plus. Some restrict their business to one Indian city or state, whilst others 
have a multi-state or pan India presence. The advent of chains has bought new trends to the 
sector, such as extended opening hours, discounts on medicine prices and additional 
customer services including home delivery and health camps  (these involve free screening 
for various health problems such as diabetes, bone mass density, eye and dental checks, and 
are used to stimulate business).  
The organisational structure of chains tends to consist of some or all of the following in the 
senior management team: a managing director or chief executive, an operations director, 
human resources, purchasing and business development directors. Below this team sit the 
regional managers. Branches are staffed with an in-charge, who may or may not be a 
1 According to the International Narcotics Control Board, a drug distribution system can be described as 
unregulated if it meets the following criteria: ‘From a more technical perspective, an unregulated market for 
drugs can be considered to exist where: (A) Unlicensed individuals and/or entities trade in drugs that they are 
not authorized or entitled to deal with or in contravention of the applicable laws, regulations and norms; or, (B) 
Licensed individuals and/or entities trade in drugs that they are not authorized or entitled to deal with or in 
contravention of the applicable laws, regulations and norms.  
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pharmacist2, 2 or more pharmacy aides (assistants who require no qualifications) depending 
on the size of the outlet, and a delivery person. The individuals who own and run these 
chains, especially the larger outfits, tend to be educated to a high (university) level and often 
abroad. Whilst most independent stores have an open, on-the-street shop frontage, chains are 
often fully enclosed. Chain branches commonly have air conditioning, are neatly organised, 
and some aim for a more ‘international’ feel compared to independent shops. At the current 
time, chains are subjected to the same regulatory controls as independent pharmacies.  
Thus far, little attention has been paid to the health-related questions arising as a result of 
these new arrangements. There are reasons to believe that being organised as a chain may 
affect the public health concerns of quality of care, prices of and access to medicines, and 
the quality of medicines. As such, there is a need to understand the effects of these new 
organisational forms. This thesis sets out to address this research gap.  
1.4 Aims and Objectives 
The aim of this PhD is to better understand the effects of chain pharmacies on the 
functioning of Indian pharmacies, compared to independent pharmacies, and the 
implications for public health. 
In order to achieve this aim, the specific objectives are as follows: 
A. To compare the quality of case management (of two tracer conditions) at chain and
independent pharmacies.
B. To compare the price of consultations (for two tracer conditions) at chain and
independent pharmacies
C. To assess the socioeconomic status of clients shopping at chain and independent
pharmacies
D. To explore how and why the organisational structure of pharmacy chains may affect
the quality of service provision and prices of medicines, compared to independent
pharmacies.
2 Under the Pharmacy Act 1948 pharmacists working in India are required to possess a registration 
certificate issued by the state in which they wish to practice. To obtain this certificate one must first 
acquire either a DPharm, BPharm or MPharm from a recognised institution. The DPharm (most 
common qualification for those working in a retail pharmacy) involves a minimum of 2 years study 
plus practical training. The BPharm is a 4 year degree (DPharms can enter directly into the 2nd year) 
and the MPharm is a 2 year postgraduate course that one can enter on completion of the BPharm. 
18 
1.5 Thesis outline 
Part 1 of the thesis continues with a published review of pharmacy performance and 
determinants of performance in LMIC in Asia (chapter 2). In part II, I draw on empirical 
literature on the effects of chains and economics literature to consider the theoretical effects 
of chains on key public health concerns- quality of care, quality of medicines, prices of 
medicines and access (chapter 3). This chapter culminates with the presentation of a set of 
hypotheses which informs the programme of work that follows. I then provide a description 
of the study site, the study design and methods used for data collection and analysis (chapter 
4). Part III comprises three results chapters, all presented as research papers (either 
published or currently under consideration with a journal). These papers cover a comparison 
of the quality of case management of standardised patients3 (SPs) for two tracer conditions 
(chapter 5) and prices of medicines and socioeconomic status (SES) of customers (chapter 6) 
at chain and independent pharmacies; as well as an exploration of the mechanisms by which 
these outcomes may vary (chapter 7). Part IV explores the implications of the results, 
including the scope of the study, methodological limitations, contribution of this thesis to the 
literature, and policy implications (chapter 8).  
3 Individuals recruited from the local community and trained to present an identical case of a clinical condition to 
many healthcare providers in a study sample. 
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2 Systematic literature of pharmacy performance 
2.1 Introduction 
In order to inform this thesis, I first conducted a systematic literature of pharmacy 
performance in low and middle-income Asian countries. The aim of this work was to fully 
understand the nature of pharmacy practice in these settings, and to gain a comprehensive 
overview of any shortcomings. Further, I examined the literature to understand which factors 
contribute to poor practices. The results of this review are presented in research paper 1 
entitled “Performance of retail pharmacies in low- and middle-income Asian settings: a 
systematic review”. The paper was published in Health Policy and Planning in March 2016. 
The supplementary material for this paper can be found in Appendix 1.  
2.2 Research paper 1: literature review 
(Cover sheet on next page) 
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Abstract
In low- and middle-income countries (LMIC) in Asia, pharmacies are often patients’ first point of con-
tact with the health care system and their preferred channel for purchasing medicines. Unfortunately,
pharmacy practice in these settings has been characterized by deficient knowledge and inappropriate
treatment. This paper systematically reviews both the performance of all types of pharmacies and
drug stores across Asia’s LMIC, and the determinants of poor practice, in order to reflect on how this
could best be addressed. Poor pharmacy practice in Asia appears to have persisted over the past 30
years. We identify a set of inadequacies that occur at key moments throughout the pharmacy encoun-
ter, including: insufficient history taking; lack of referral of patients who require medical attention; il-
legal sale of a wide range of prescription only medicines without a prescription; sale of medicines that
are either clinically inappropriate and/or in doses that are outside of the therapeutic range; sale of in-
complete courses of antibiotics; and limited provision of information and counselling. In terms of de-
terminants of poor practice, first knowledge was found to be necessary but not sufficient to ensure cor-
rect management of patients presenting at the pharmacy. This is evidenced by large discrepancies
between stated and actual practice; little difference in the treatment behaviour of less and more quali-
fied personnel and the failure of training programmes to improve practice to a satisfactory level.
Second, we identified a number of profit maximizing strategies employed by pharmacy staff that can
be linked to poor practices. Finally, whilst the research is relatively sparse, the regulatory environment
appears to play an important role in shaping behaviour. Future efforts to improve the situation may
yield more success than historical attempts, which have tended to concentrate on education, if they ad-
dress the profit incentives faced by pharmacy personnel and the regulatory system.
Key words: Asia, developing countries, pharmacies, private sector, quality of care
Key Messages
• Pharmacy practice in Asia is characterised by insufficient history taking; a lack of appropriate patient referral; poor ad-
herence to treatment guidelines, inappropriate supply of medicines and insufficient counselling.
• Adequate knowledge alone is not sufficient to ensure appropriate management of patients presenting at the pharmacy.
Profit incentives and the regulatory environment must be taken into consideration when designing interventions to im-
prove pharmacy practice in these settings.
• Intervention research in this area appears to be lacking and more research is particularly required on non pharmacist-
run pharmacies and unregistered drug shops.
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Introduction
The role of the private sector in the provision of medicines has trad-
itionally been neglected by governments and the international public
health community alike (Bigdeli et al. 2014). Yet in most low-and
middle-income countries (LMIC) it is widely established that private
pharmacies and drug stores are typically patients’ first point of con-
tact with the healthcare system and the preferred channel through
which to purchase medicines (Smith 2009b). For example, in Asia,
pharmacies have been found to be the dominant source of healthcare
for all common problems amongst poor populations in Bangladesh
(Khan et al. 2012) and in Western Nepal, amongst mothers seeking
care for their children, pharmacies were the most popular source
(46.2%) (Sreeramareddy et al. 2006). Their appeal lies in long open-
ing hours, availability of medicines (including the possibility of
credit and the option to purchase medicines in small quantities), geo-
graphic accessibility and personal familiarity (Van Der Geest 1982;
Logan 1983; Kloos et al. 1986, Greenhalgh 1987; Igun 1987; Haak
1988; Price 1989; Mayhew et al. 2001). Further, many patients have
neither the time nor money to consult a physician (Ferguson 1981;
Wolffers 1987; Haak 1988; Saradamma et al. 2000; Seeberg 2012).
These drug shops range from high end outlets staffed by pharma-
cists, to small, rural, roadside stalls staffed by someone without for-
mal health qualifications. Unfortunately, it is all too common that
drug selling at these outlets meets the World Health Organization’s
(WHO) criteria for being ‘irrational’. That is, patients do not receive
the appropriate medicines, in doses that meet their individual re-
quirements, for an adequate duration, and at the lowest cost
(Holloway and Van Dijk 2011). To develop appropriate interven-
tions to address this, it is first necessary to understand the nature of
the problem and also the determinants of provider behaviour to re-
flect on how this could best be changed.
Many papers have reported on the inadequacies of pharmacy
practice in LMIC, and some reviews have been conducted (Smith
2009b; Wafula et al. 2012). However, no up to date systematic re-
view is available on performance of pharmacies and drug stores
across Asia’s LMIC. This article aims to address that gap, and in
addition, present the first systematic review of the determinants of
poor practice in these settings, substantially updating and expanding
previous reviews in this area (Goel et al. 1996; Radyowijati and
Haak 2003).
Methods
Scope of review
In many LMIC, there are a wide range of outlets selling medicines to
their local communities. This review is concerned with the full range
of establishments whose primary business is selling medicines.
Papers reporting on pharmacist-run pharmacies (PRPs), non
pharmacist-run pharmacies (NPRPs) and both registered and non-
registered outlets were eligible for inclusion. Despite the legal
requirement to have a trained pharmacist on duty at all times, in
reality, in many countries in Asia, these pharmacies are typically
operated by staff who are not authorized to do so (Wolffers 1987;
Kamat and Nichter 1998; Chuc and Tomson 1999; Seeberg 2012;
Vu et al. 2012). In countries where a shortage of pharmacists exists,
NPRPs are permitted; these are registered outlets but the presence of
a graduate pharmacist is not mandatory. These pharmacies are typ-
ically staffed by personnel with limited medical training and are
sometimes restricted in the repertoire of medicines they are permit-
ted to sell. Unregistered drug shops sell medicines informally and are
not legally recognized by the health system of the countries in which
they operate (Wafula and Goodman 2010). From this point on-
wards, ‘pharmacy’ will be used as an umbrella term to denote all
types of outlets selling medicines.
The first part of the review is concerned with performance of
pharmacies which, in this instance, is conceptualized as behaviour
relating to the sale of medicines, either with or without a prescrip-
tion, or the provision of advice (the importance of the sale of sub-
standard and counterfeit medicines in Asia is also recognized
(Cockburn et al. 2005; Newton et al. 2006; World Health
Organization 2006; Institute of Medicines 2013), but considered be-
yond the scope of this review). The second part of the review con-
cerns the determinants of poor practice, that is, the factors that
contribute to practices that are deemed inappropriate.
Search strategy
A broad search strategy combining MeSH and free text terms was
used to search PubMed, Embase, Econlit, PsychInfo, Web of
Science, Global Health and International Pharmacy Abstracts with
the aim of identifying all studies of pharmacies in LMIC in Asia
(World Bank 2014) (see Table 1).
In addition to the aforementioned databases, the International
Network for Rational Use of Drugs (INRUD) bibliography and the
WHO’s essential medicines and health products information portal
were searched.
The search was restricted to English language studies published
between 1 January 1984 and 29 August 2014. A total of 21 898
papers were initially identified; after removing duplicates, 19 214
titles and abstracts were screened by R.M.; the full-text of 107 re-
cords were obtained; 53 met our inclusion criteria for part 1 of the
review and 38 met the criteria for part 2 (see Figure 1).
Bibliographies of eligible texts were scanned to identify any further
relevant papers.
For part one, papers needed to report on performance relating to
the sale of medicines, either with or without a prescription, or the
provision of advice. This included studies employing both quantita-
tive and qualitative methodologies. In order to collect the most ac-
curate data on pharmacy practice, only studies utilising methods
that collected data at the outlet and relied on a third party observa-
tion of practice were included (studies relying on self-reported prac-
tice were excluded due to the risk of desirability bias and those
collecting data on medicine use through household surveys were
excluded due to the high risk of recall bias). Intervention studies
were included, only where they provided baseline data; this was
thought to reflect standard practice. Where baseline data could not
be disentangled from post-intervention results, studies were
excluded from part one.
Eligible studies for part two reported on both pharmacy per-
formance (applying the same method criteria as for part one) and
possible determinants of that reported performance. Where changes
in practice could be attributed to an intervention strategy, these
intervention studies were included and strategies were viewed as de-
terminants of practice. For example, a training intervention could
shed light on the importance of knowledge as a determinant of prac-
tice. Additionally, qualitative studies which sought to understand
the determinants of practice behaviours were also included. Of the
studies included in part two, 31 of these were a subset of papers
from part one; three papers were intervention studies where the
baseline results were not clear; three papers were intervention stud-
ies where the baseline results were described by other papers from
the same research study and one paper reported results from a quali-
tative study solely focussing on determinants of poor practice.
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Data from the included studies were extracted into an excel data-
base under the following headings: date and location of study, which
aspects of performance measured, sampling and study design, data col-
lection methods, details of intervention, main findings—performance,
main findings—determinants of performance. Key emergent themes
recurring across the data were discussed between the authors and a
narrative synthesis was conducted. See Supplementary Appendix 1 for
a full list of included studies and key characteristics.
Results
Part one: performance of pharmacies in LMIC in Asia
This literature review reveals a number of shortcomings in phar-
macy practice. We have organized our findings according to the
stages of an encounter in the pharmacy (Figure 2). Following an
overview of the included studies, we report on six key stages,
namely, the nature of requests from patients, filling of prescriptions,
history taking, referral for medical attention, sale of medicines and
advice giving.
Overview of included studies
This part of the review identified a total of 53 papers from 43 stud-
ies in 14 countries (some studies collected data in more than one
country). Papers coming from the same research project have been
grouped together and the term ‘study’ is used to denote distinct
pieces of research. The most researched countries were India and
Vietnam, with 10 and 9 studies, respectively. Five studies reported
on each of Thailand, Bangladesh and Nepal, three on Indonesia,
two on Sri Lanka and Pakistan and one on The Philippines,
Mongolia, Malaysia, Yemen Arab Republic, Syria and Lao PDR.
Bangladesh and Nepal are low-income countries, Thailand and
Malaysia are higher-middle and all the others are classified as lower-
middle income economies (World Bank 2014).
Studies reported on the full range of pharmacies. PRPs were
included in the majority of research projects. Several papers reported
on outlets legally entitled to operate without a pharmacist, including
type II pharmacies in Thailand, class II and III pharmacies in Lao
PDR, type C pharmacies in Pakistan, drug stores in Indonesia and
drug retailers in Nepal (Kafle et al. 1996; Stenson et al. 2001a; Hadi
et al. 2010; Saengcharoen and Lerkiatbundit 2010;Hussain and
Table 1. Search strategy
Target population
(combined by ‘OR’)
Geographic location
(combined by ‘OR’)
Free text terms
Chemist
Drug retailera
Drug shopa
Drug sellera
Drug vendora
Drug storea
Drug dispensing
Drug outleta
Druggist
Medicine retailera
Medicine shopa
Medicine sellera
Medicine vendora
Medicine storea
Medicine
dispensing shopa
Medicine outleta
Medicine dealera
Pharmacies
Pharmacy
Pharmacy servicea
Pharmacista
Pharmaceutical
servicea
MeSH terms
Pharmacy
Pharmacies
Free text terms
Developing
countries
Developing
country
Low-income
country
Low-income
countries
Middle-income
country
Middle-income
countries
Asia
MeSH terms
Developing
countries
Asia
Excluded references from part 1 of review (N= 54)
-no informaon on performance of drug sellers (24)
-methods did not meet inclusion criteria (14)
- outside geographical area of interest (3)
-intervenon study without clear baseline data (3)
-not empirical research paper (8)
-could not access full text (2)
21,898 records idenﬁed 
through database searching 
Title and abstract screen 
(N= 19,214)
Full text review (N= 107)
Excluded references
 (N= 19,107)
Duplicate references 
(N = 2684)
Included in part 1 of review (N=53)  Included in part 2 of review (N= 38)
Excluded references from part 2 of review (N= 68)
-no informaon on determinants (58)
-methods did not meet inclusion criteria (5) 
-outside geographical area of interest (2)
-not empirical research paper (1)
-could not access full text (2)
Addional records idenﬁed through 
reference lists (N=1)
Figure 1. PRISMA flow diagram.
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Ibrahim 2011). Only one study from Indonesia reported on unregis-
tered outlets (Hadi et al. 2010).
Researchers employed a range of methods to collect data on
pharmacy practice. Simulated client methodology was used widely
(31 studies) to investigate how a range of requests and conditions
are managed. These included requests for specific prescription only
medicines (POMs), contraceptives and treatment for fever, skin
abrasions, diarrhoea, sexually transmitted infections (STIs), respira-
tory tracts infections (RTIs), tuberculosis, asthma, migraine and an-
aemia. 12 studies used observation in order to record the details of
transactions between pharmacy staff and customers. Exit interviews
with patients were used less frequently (seven studies) to gather in-
formation about medicines purchased and staff behaviour.
1. Nature of client requests
Clients with health concerns visited the pharmacy for three main
reasons: to fill a prescription following a medical consultation; to
purchase a specific medicine(s) or to seek medical advice from the
pharmacy staff. In order to examine staff behaviour and to put cer-
tain practices into perspective, it is useful to understand the fre-
quencies of these different types of scenarios. Eight studies
observed all transactions in sampled pharmacies for a fixed period
of time, ranging from 2 h to 2 weeks per pharmacy. The proportion
of transactions where medicines were purchased without a pre-
scription ranged from around half in studies from Pakistan and
India (Krishnaswamy et al. 1985; Greenhalgh 1987; Kamat and
Nichter 1998; Basak and Sathyanarayana 2010; Hussain and
Ibrahim 2011), to over 80% in a study from Lao PDR (Chuc and
Tomson 1999; Syhakhang et al. 2001) and virtually all transactions
in studies from Vietnam and Malaysia (Chua et al. 2013). Of the
medicines purchased without a prescription, three studies reported
that around one-third were recommended by the pharmacy staff
(Syhakhang et al. 2001; Basak and Sathyanarayana 2010; Chua
et al. 2013). Other studies reported that the vast majority of medi-
cines sold without a prescription were requested by the client, with
pharmacists advising on<5% of these purchases (Krishnaswamy
et al. 1985; Kamat and Nichter 1998; Chuc and Tomson 1999;
Hussain and Ibrahim 2011). Only studies from India reported on
common ways patients requested medicines. These were by name,
on a scrap of paper, or by bringing in an old sample (Greenhalgh
1987; Kamat and Nichter 1998; Saradamma et al. 2000). Studies
from Vietnam, India and Bangladesh reported that at least half of
clients were buying medicines for someone other than themselves,
most commonly a family member (Dua et al. 1994, Duong et al.
1997b; Roy 1997; Kamat and Nichter 1998). One study noted that
domestic servants were commonly sent to purchase medications on
behalf of their employers (Kamat and Nichter 1998).
2. Filling prescriptions
Only a few studies made reference to the handling and process-
ing of prescriptions in the pharmacy. Several poor practices were
reported. Prescriptions were rarely validated by dispensers
(Hussain and Ibrahim 2011), old prescriptions were frequently
honoured (at the extreme, patients were seen to be reusing pre-
scriptions 5 years out of date) (Greenhalgh 1987; Kamat and
Nichter 1998; Basak and Sathyanarayana 2010), and prescrip-
tions were returned to customers after dispensing for reuse in the
future (Puspitasari et al. 2011). Further, doctors’ prescriptions
were not always dispensed as intended. Some studies indicated
that where patients cannot afford to buy all items on a prescrip-
tion, the pharmacists played an important role in advising pa-
tients what they should purchase in light of their financial
constraints (Greenhalgh 1987; Roy 1997; Kamat and Nichter
1998). Studies did not report a single example of a pharmacist
Presents a prescripon 
for dispensing 
Paent does not 
have a prescripon 
Paent requests 
medicine 
Paent presents 
symptoms / seeks 
advice of pharmacist 
Refer to physician 
Provides paent with advice and counsels regarding use 
of medicine including: 
• Explanaon of what medicine is for 
• How much to take and when
• Duraon of treatment
• Possible side eﬀects
• Possible interacons with food or other medicines
• Instances in which medical advice should be sought 
• Any other condion-speciﬁc advice 
Pharmacist sells or dispenses: 
• Appropriate medicine 
• In the appropriate dose 
•  For an appropriate duraon
Query any discrepancies with 
prescribing physician 
Pharmacist checks 
prescripon is valid   
Pharmacist asks history quesons in order to 
establish: 
• Who the medicine is for
• What is wrong with the paent 
• Whether they have a more serious condion 
that requires medical aenon 
• What acon they have already taken 
• Whether they have any other medical 
condions/ take any other medicaons/ have 
any allergies
1 
1 
1 2 
3 
4 
2
1 
5 
6 
Key 
1 = Nature of client request 
2 = Filling prescripons 
3 = History taking 
4 = Referral for medical aenon 
5 = Sale of medicines 
6 = Advice giving 
Figure 2. Appropriate retail pharmacy practices for patients with and without a prescription.
Health Policy and Planning, 2016, Vol. 31, No. 7 943
Downloaded from https://academic.oup.com/heapol/article-abstract/31/7/940/1750323
by London School of Hygiene & Tropical Medicine user
on 11 December 2017
27
querying a prescription with the doctor (despite ample descrip-
tion of inappropriate prescribing practices).
3. History taking
In general, history taking in pharmacies was found to be inad-
equate. The majority of these data come from studies where
mystery shoppers presented with symptoms of various condi-
tions, including childhood diarrhoea and STIs. Most questioning
was limited to enquiring about the presence of other related
symptoms and often this was only observed in a subset of the
study pharmacies (Ross-Degnan et al. 1996; Chuc et al. 2001,
Bista et al. 2002; Van Sickle 2006; Saengcharoen and
Lerkiatbundit 2010; Minh et al. 2013). It was rare for pharma-
cists to ask whether the patient suffered from any other condi-
tions or allergies, took any other medication or had tried any
treatments before consulting at the pharmacy (Wachter et al.
1999; Chuc et al. 2001; Van Sickle 2006; Saengcharoen and
Lerkiatbundit 2010; Hussain and Ibrahim 2012). Worryingly, a
common finding was that very few, if any, pharmacists enquired
about danger signs that would indicate a more serious underly-
ing cause and warrant immediate medical attention (Modal and
Lamba 1994; Kafle et al. 1996; Duong et al. 1997a; Wachter
et al. 1999; Saengcharoen and Lerkiatbundit 2010; Rathnakar
et al. 2012). At the extreme end of poor practice, some pharma-
cists were found to ask not a single question (Duong et al.
1997a; Chalker et al. 2000; Rathnakar et al. 2012).
Only three studies measured pharmacists’ responses to direct re-
quests for medications. Questioning was insufficient on who the
medicine was for, what symptoms they were experiencing,
whether they took any other medication or whether they suf-
fered from drug allergies (Ratanajamit and Chongsuvivatwong
2001; Ratanajamit et al. 2002; Larsson et al. 2006; Puspitasari
et al. 2011). Additionally, Kamat and Nichter (1998) describe
the ‘quick presentation of tablets and fast exchange of money’.
4. Referral for medical attention
Some studies used simulated clients to present with symptoms of
conditions that necessitate referral for medical attention; these
included diarrhoea (of 3 day duration) in an 11 month old, cyst-
itis in a man, STIs, asthma and tuberculosis. These conditions re-
quire examination, diagnostic testing or POMs and hence their
management is outside the remit of a pharmacist’s expertise.
Referral practices of pharmacists were found to be unsatisfac-
tory. Tuberculosis was the condition most commonly referred
outside the pharmacy—46% of 138 pharmacies in Vietnam, al-
though only 9% of patients were directed to a designated TB fa-
cility (Vu et al. 2012). For the other conditions, referral
proportions ranged from 7% to 37% (Tomson and Sterky 1986;
Tuladhar et al. 1998; Wachter et al. 1999; Chalker et al. 2000;
Van Sickle 2006; Apisarnthanarak et al. 2008).
5. Sale of medicines
In terms of medicine provision, a number of concerns are raised
by the literature regarding the appropriateness of medicines sold
(with attention to the legal, clinical and physical aspects of their
sale), dosing and duration of treatment.
a. Appropriateness of medicines
i. Legal appropriateness
The sale of POMs without a prescription was a phenom-
enon found to be prevalent in all 14 countries reported
on. A wide range of medicines, which are only legally
permitted to be sold with a prescription, were freely
available without a prescription including: antibiotics,
steroids, antimalarials, narcotic analgesics,
psychotropics, anti-epileptics, antihypertensives, anti-
diarrhoels, antihistamines, sedatives, tranquilisers,
hypoglycaemic medicines, anti-tuberculosis agents and
even, on occasion, abortifacients (Krishnaswamy et al.
1985; Tomson and Sterky 1986; Greenhalgh 1987;
Wolffers 1987; Lansang et al. 1990; Dua et al. 1994;
Modal and Lamba 1994; Dineshkumar et al. 1995;
Duong et al. 1997a,b; Roy 1997; Cong et al. 1998;
Kamat and Nichter 1998; Chuc and Tomson 1999;
Wachter et al. 1999; Saradamma et al. 2000; Chuc et al.
2002; Larsson et al. 2006; Mac et al. 2006; Mamun
et al. 2006; Qidwai et al. 2006; Basak and
Sathyanarayana 2010; Hadi et al. 2010; Nakajima et al.
2010; Al-Faham et al. 2011; Puspitasari et al. 2011;
Hussain and Ibrahim 2012; Ngo et al. 2012; Rathnakar
et al. 2012; Seeberg 2012; Vu et al. 2012; Huda et al.
2014; Nga et al. 2014). In Thailand, antibiotics are le-
gally permitted to be sold by class I drug stores but not
in lower class stores. This restriction is reportedly not
observed in practice (Podhipak et al. 1993;
Saengcharoen and Lerkiatbundit 2010). In Indonesia,
antibiotics were found to be freely available through un-
registered roadside kiosks (Hadi et al. 2010).
ii. Clinical appropriateness
The majority of the literature paints a dismal picture of
treatment practices in pharmacies across Asia. More
often than not, medicines that are dispensed are not clin-
ically appropriate for the patients’ needs. Table 2 shows
treatment choices by pharmacy staff for a number of
conditions in response to visits from simulated clients.
At best, studies report that recommended practices are
followed in less than half of encounters (Chuc et al.
2001; Bista et al. 2002). At worst, only a handful, and
in some cases no staff were found to follow best practice
guidelines (Duong et al. 1997a; Van Sickle 2006;
Hussain and Ibrahim 2012; Vu et al. 2012).
These studies also reveal that a number of inappropriate
treatments are given, either in addition to, or, instead of
recommended treatments. Some of the medicines, such
as tonics for anaemia, have no therapeutic value (Kafle
et al. 1996). Others can be harmful, for example the use
of anti-diarrhoels and antitussives in infants and chil-
dren (Tomson and Sterky 1986; Podhipak et al. 1993;
Modal and Lamba 1994; Ross-Degnan et al. 1996;
Duong et al. 1997a; Chuc et al. 2001; Qidwai et al.
2006; Saengcharoen and Lerkiatbundit 2010; Hussain
and Ibrahim 2012; Minh et al. 2013).
Another concern is the overuse of antibiotics. A number
of papers, report that antibiotics were commonly sold
for young babies through to adults for a host of symp-
toms and conditions for which they are not indicated,
including: diarrhoea, asthma, upset stomachs, coughs,
colds, runny noses, influenza and (non-infected) skin
abrasions (Tomson and Sterky 1986; Thamlikitkul
1988; Podhipak et al. 1993; Modal and Lamba 1994;
Ross-Degnan et al. 1996; Duong et al. 1997a,b;
Wachter et al. 1999; Chuc et al. 2001; Chuc et al. 2002;
Qidwai et al. 2006; Van Sickle 2006; Apisarnthanarak
et al. 2008; Saengcharoen and Lerkiatbundit 2010;
Hussain and Ibrahim 2012; Minh et al. 2013). Further,
even where antibiotics are indicated, inappropriate
choices were made (Tuladhar et al. 1998; Bista et al.
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2002). In studies from the Philippines, India, Vietnam
and Lao PDR antibiotics were found to make up be-
tween a fifth and a third of all purchases (Lansang et al.
1990; Dua et al. 1994; Syhakhang et al. 2001; Basak
and Sathyanarayana 2010; Nga et al. 2014).
Tetracycline was reportedly sold to children (for whom
it is contraindicated) in studies from Vietnam, India and
Thailand (Thamlikitkul 1988; Dua et al. 1994; Chuc
and Tomson 1999). Further, the widespread use of
chloramphenicol for minor conditions is a concern due
to the risk of bone marrow suppression (Greenhalgh
1987; Thamlikitkul 1988; Syhakhang et al. 2001).
Vitamins, tonics and nutritional products with dubious
pharmacological value were found to constitute a sig-
nificant proportion of medication costs in studies from
India, Bangladesh, Vietnam and Nepal (Krishnaswamy
et al. 1985; Greenhalgh 1987; Dineshkumar et al. 1995;
Kafle et al. 1996; Duong et al. 1997b; Roy 1997; Chuc
and Tomson 1999; Saradamma et al. 2000; Basak and
Sathyanarayana 2010). They were often seen as an es-
sential accompaniment to antibiotics (Greenhalgh 1987;
Dua et al. 1994; Roy 1997; Saradamma et al. 2000). A
final observation was the popularity of (often irrational)
combination products (Tomson and Sterky 1986;
Greenhalgh 1987; Lansang et al. 1990; Dineshkumar
et al. 1995; Kafle et al. 1996; Chuc and Tomson 1999;
Wachter et al. 1999; Saengcharoen and Lerkiatbundit
2010).
iii. Physical appropriateness
Few studies investigated or commented on the physical
state of the medicines sold to patients. Those that did,
reported that drugs were often sold in loose strips, as
opposed to in their original package; they were rarely
labelled; and different medicines were mixed together
in the same package (Kamat and Nichter 1998; Stenson
et al. 2001a; Van Sickle 2006; Hadi et al. 2010;
Hussain and Ibrahim 2011). As a result, information re-
garding dose, expiry date and active ingredients was
not clear. In six of 28 shops visited in Sri Lanka, tetra-
cycline was not stored in a refrigerator as it should be
(Wolffers 1987).
b. Appropriateness of dose and duration of treatment
Several studies report that medicine dosing was outside of
the therapeutic range for a variety of conditions (both sub-
therapeutic and over dose) (Thamlikitkul 1988; Tuladhar
et al. 1998; Rahman et al. 2000; Bista et al. 2002).
Saradamma et al. (2000) study of antibiotic purchases in
India found that those without a prescription were three
times more likely to purchase an inadequate dose than those
with a prescription (66% vs 40%). The problem of incom-
plete courses of antibiotics was reported in India, Thailand,
Vietnam, Bangladesh, The Philippines and Sri Lanka
(Tomson and Sterky 1986; Greenhalgh 1987; Lansang et al.
1990; Duong et al. 1997a,b; Cong et al. 1998; Chuc and
Tomson 1999; Chalker et al. 2000; Saradamma et al. 2000;
Mamun et al. 2006; Basak and Sathyanarayana 2010). At
the extreme, more than half of antibiotic purchases were for
<2 days (Greenhalgh 1987; Thamlikitkul 1988; Chuc and
Tomson 1999). An interesting finding from Vietnam was
that a higher percentage of incomplete antibiotic courses
were sold for under 1s (Chuc and Tomson 1999).
6. Advice giving
Clients purchasing medicines in the pharmacy were found to re-
ceive very little counselling and advice from pharmacy staff.
Provision of any unsolicited advice ranged widely from 2.5% to
over 70%. Where it was given, however, it was usually limited
to dose and frequency instructions; very few staff mentioned po-
tential side effects, drug or food interactions, or advised to visit
a physician if symptoms continued, worsened or complications
arose (Dua et al. 1994; Modal and Lamba 1994; Kafle et al.
1996; Ross-Degnan et al. 1996; Duong et al. 1997a; Wachter
et al. 1999; Chalker et al. 2000; Chuc et al. 2001; Ratanajamit
and Chongsuvivatwong 2001; Van Sickle 2006; Basak and
Sathyanarayana 2010; Hussain and Ibrahim 2011; Puspitasari
et al. 2011; Saengcharoen and Lerkiatbundit 2013; Huda et al.
2014). Disease and medicine-specific advice and counselling was
also poor, especially for STIs and contraceptive requests
(Tuladhar et al. 1998; Chalker et al. 2000; Rahman et al. 2000;
Ratanajamit and Chongsuvivatwong 2001; Minh et al. 2013).
Advice regarding dietary and fluid intake for clients suffering
from diarrhoea or anaemia was given by a minority of pharmacy
staff (Kafle et al. 1996; Duong et al. 1997a; Wachter et al. 1999;
Saengcharoen and Lerkiatbundit 2010; Minh et al. 2013).
Finally, there was little evidence of signposting to other health
services. This is highlighted by a study from Vietnam where
simulated clients requested an abortifacient. None of the 30
pharmacies visited offered referral materials or contact details
for a specialist service (Ngo et al. 2012).
Part two: determinants of poor pharmacy performance
in LMIC in Asia
Overview of included studies
The literature search yielded 38 relevant papers, from 28 distinct
studies which conducted research in 11 countries: Pakistan (two),
Thailand (five), Nepal (four), India (seven), Bangladesh (three), Lao
PDR (one), Sri Lanka (one), Yemen Arab Republic (one), Vietnam
(six), The Philippines (one) and Indonesia (one). The studies
included in this review are very varied in terms of methodology and
approach but they all shed some light on the determinants of phar-
macy practice in these settings. Ten studies collected data on both
‘actual’ pharmacy practice (e.g. using mystery shopper surveys or
spending time observing transactions) and knowledge and stated
practice (through semi-structured interviews with store staff), with
discordance between the two providing insight into factors affecting
certain poor practices. In uncontrolled analyses, three studies tested
for associations between a number of predictor variables and pro-
vider practices. Four studies conducted regression analyses using as-
pects of practice as the dependent variable and tested a number of
explanatory variables (such as retailer characteristics or attitudes) as
potential predictors of behaviour. Twelve studies evaluated the ef-
fectiveness of an intervention strategy and this provided evidence for
whether or not these were important determinants of practice.
Finally, 10 studies employed qualitative methodology, including in-
depth interviews, participant and non-participant observation and
focus group discussions.
From the literature, information on determinants of poor phar-
macy practice can be distilled into three main categories: knowledge,
profit motives and state intervention. The role of each is discussed.
1. Knowledge
One possible explanation for the poor pharmacy practice
observed in Asia is simply lack of knowledge. There is wealth of
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evidence, however, to suggest that knowing what constitutes
good performance, whilst necessary, is not sufficient to ensure
that this knowledge is employed in practice. A number of studies
report vast discrepancies between knowledge or stated practice
and actual practice; the qualifications of staff or level of training
accomplished appears to make little difference to treatment be-
haviour and finally, educational programmes, whilst improving
practice in the short-term, do not improve practice to a satisfac-
tory level in the long-term. Each of these bodies of evidence will
be examined in turn.
a. Discrepancies between knowledge and practice
Several studies employed different methods in order to elicit
information on both provider knowledge or stated practice
and actual practice. Vast discrepancies were noted between
the two, suggesting that knowledge is not the key determin-
ant of poor practice. Differences between stated practice and
actual practice were observed for the sale of medicines, refer-
ral for medical advice, history taking and advice giving. For
example, in hypothetical scenarios, 32% of pharmacists said
they would sell any drugs for a man with urethral discharge
and pain on urinating (the recommended management
would be referral to a physician) (Chalker et al. 2000), 20%
antibiotics for a child with a viral upper respiratory tract in-
fection (Chuc et al. 2001), 40% corticosteroids and 0% anti-
epileptic medicines without a prescription (Larsson et al.
2006; Mac et al. 2006). In mystery shopper surveys, how-
ever, these actions were carried out by 85%, 83%, 98% and
21%, respectively. Adherence to recommended treatment
practices was also found to be poorer in practice. Compared
to the stated medication treatments for childhood diarrhoea,
fewer pharmacy staff sold oral rehydration salts (ORS) and
more sold inappropriate antibiotics and anti-diarrhoels
(Ross-Degnan et al. 1996; Saengcharoen and Lerkiatbundit
2010; Minh et al. 2013). Similar patterns were observed in
the management of other conditions, such as STIs (Khan
et al. 2006). One study reported that despite 81% of
pharmacists knowing that antibiotics were not effective in
short courses, 48% of courses dispensed were for<5 days.
Stated referral practices of patients presenting with condi-
tions that need to be treated by a doctor were three to four
times higher than in reality (Chalker et al. 2000; Khan et al.
2006). Finally, history taking and advice giving in question-
naires was found to be superior to the service simulated cli-
ents experienced (Ratanajamit and Chongsuvivatwong
2001; Khan et al. 2006).
b. Qualifications/training and experience
Studies from Thailand and Nepal, using simulated shoppers
to investigate the management of childhood diarrhoea, preg-
nancy-related anaemia and requests for contraceptives, re-
vealed that staff with higher levels of training or
qualifications asked more questions and gave better advice
but little differences were observed in terms of appropriate
medication dispensing (Kafle et al. 1996; Ratanajamit and
Chongsuvivatwong 2001; Saengcharoen and Lerkiatbundit
2010). Other studies found no association between qualifica-
tions of pharmacy personnel and the quality of history tak-
ing and counselling (Hussain and Ibrahim 2011;
Saengcharoen and Lerkiatbundit 2013). Despite, recording
no differences in actual practice, one of these papers re-
ported that, in interviews designed to measure their know-
ledge, pharmacists achieved significantly higher scores
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compared to non-pharmacists in the areas of history taking
and advice provision (Saengcharoen and Lerkiatbundit
2013). Experience was shown not to be a predictor of appro-
priate dispensing in the two studies which collected data on
this variable (Apisarnthanarak et al. 2008; Saengcharoen
and Lerkiatbundit 2010).
c. Impact of education programmes
Nine studies report the findings of educational interventions.
All of these studies employed simulated client methodology
to assess the impact of training; only four assessed perform-
ance by comparing outcomes to a control group. On the
whole, training was found to improve the treatment behav-
iour of various conditions, including diarrhoea and STIs, as
well as provision of contraceptives (Ross-Degnan et al.
1996; Kafle 1998; Tuladhar et al. 1998; Ratanajamit et al.
2002; Qidwai et al. 2006; Kafle et al. 2013; Minh et al.
2013; Pham et al. 2013). Despite the improvements noted,
inadequacies in treatment practice remained. For example,
in Indonesia, 46% of staff continued to sell anti-diarrhoels
for children with diarrhoea (Ross-Degnan et al. 1996); and
in Nepal, 55% of drug sellers continued to prescribe an STI
treatment regimen that was inconsistent with national guide-
lines (Tuladhar et al. 1998). Further, most of the study fol-
low-up times were<6 months. One study with follow-up at
7–9 months noted the waning of effect (Tuladhar et al.
1998), and another at 32 months reported no sustained im-
provements in the use of ORS, anti-diarrhoels or antibiotics
for the treatment of diarrhoea, despite promising results at 6
months post intervention (Minh et al. 2013; Pham et al.
2013). In Nepal, small group training led to significant
improvements in a number of aspects of management of
childhood diarrhoea, acute respiratory infection and an-
aemia in pregnancy at 2 months but most of these effects
were not sustained at the 5-month follow-up (Kafle 1998).
One study did not report baseline data but the post-training
results concerning the management of STIs were very poor
(Khan et al. 2006). Another showed no significant impact of
training on ORS use for the treatment of diarrhoea or dysen-
tery, but it did show improvements in antibiotic dispensing,
only for drug sellers, however, not for pharmacists
(Podhipak et al. 1993).
2. Profit motives
Pharmacies are retail businesses operating within a competitive
marketplace. Several papers described the proliferation of medi-
cine outlets over recent decades, especially in countries that
underwent economic liberalisation. For example, in Vietnam fol-
lowing the privatization of drug provision in 1986, the number
of private pharmacies increased from none to>6000 by 1996
(Chuc et al. 2002). These papers also noted the intensified com-
petition that resulted (Kamat and Nichter 1998; Chuc and
Tomson 1999; Stenson et al. 2001b; Chuc et al. 2002). An illus-
tration of the nature of competition comes from Mumbai, India,
where pharmacies hire agents to persuade patients leaving hos-
pitals to patronise their pharmacy (Kamat and Nichter 1998).
Qualitative work confirms that pharmacies report feeling intense
competition and staff seek to maximize profit in order to survive
in the market (Dua et al. 1994; Kamat and Nichter 1998; Chuc
and Tomson 1999; Kotwani et al. 2012; Seeberg 2012).
Essentially there are three ways to maximize profits: maximizing
the number of customers, maximizing the revenue from each in-
dividual customer and minimizing costs. From the literature, we
identified a number of strategies employed by pharmacy staff to
achieve these goals, each of which can also be linked to poor
practice.
a. Complying with customer demands
The literature reveals that pharmacy staff are very responsive
to patients wishes, adhering to a ‘customer is king’ mentality.
In the name of maintaining clients, inducing loyalty and pre-
venting customers from fulfilling their requests elsewhere,
pharmacies resort to a number of poor practices. These in-
clude honouring improper prescriptions, such as those that
are out of date, and selling POMs without a prescription
(Dua et al. 1994; Larsson et al. 2006; Kotwani et al. 2012;
Nga et al. 2014). Further, incomplete courses of antibiotics
are frequently sold. Patients request these short courses due
to economic constraints, a desire to test the therapeutic effi-
cacy and presence of side-effects before purchasing larger
quantities, and a belief that a full course is unnecessary
(Lansang et al. 1990; Dua et al. 1994; Dineshkumar et al.
1995; Roy 1997;Duong et al. 1997b; Kamat and Nichter
1998; Mamun et al. 2006).
b. Selling medicines based on perceived efficacy
Several studies reported that pharmacy staff chose medicines
based on their ability to produce a rapid recovery or tempor-
ary relief from symptoms, even where they were not appro-
priate (Kafle et al. 1996; Van Sickle 2006; Saengcharoen and
Lerkiatbundit 2010,). For example, anti-diarrhoels for the
treatment of childhood diarrhoea (Saengcharoen and
Lerkiatbundit 2010) or airway relaxers for the respiratory
symptoms associated with asthma (Van Sickle 2006). In add-
ition, they sold medicines in which clients were believed to
have great confidence, again, even if such medicines were not
necessary. Examples include tonics as an accompaniment to
antibiotics, and complex vitamin preparations (Dua et al.
1994; Kafle et al. 1996).
c. Mimicking doctors
Four studies reported that it was common practice for medi-
cine retailers to study the prescriptions bought in by patients
and then model their own prescribing on the practices of
local doctors (Greenhalgh 1987; Kafle et al. 1996; Ross-
Degnan et al. 1996; Seeberg 2012). This may simply be a
way to improve knowledge. It could, however, be inferred
that it is a strategy used by pharmacies in order to be viewed
as more legitimate by customers.
d. Maintaining good relationships with doctors
When presented with clinically inappropriate prescriptions,
pharmacies in Asia tended to dispense them rather than query
their appropriateness with the doctor. Pharmacists interviewed
in Kotwani et al’s qualitative study of irrational antibiotic use in
Delhi described their low status in the medical hierarchy and
how doctors would rebuke them for challenging their authority
(Kotwani et al. 2012). Other research, also in India, has identi-
fied symbiotic relationships between doctors and chemist shops,
and doctors have been observed to mention names of shops
where patients should fill their prescriptions (Kamat and
Nichter 1998; Seeberg 2012). Further, at the request of medical
representatives, doctors reportedly prescribe more of particular
products when local pharmacies experience an overstock
(Kamat and Nichter 1998). It is understandable, in such a con-
text, that pharmacists do not query more prescriptions for fear
of aggravating local physicians.
e. Medicine sales
Two explicit strategies for maximizing profits from medicine
sales were identified from the literature; selling large volumes
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of low priced drugs and recommending medicines that yield
the greatest profit (Ross-Degnan et al. 1996; Chuc and
Tomson 1999; Saengcharoen and Lerkiatbundit 2010).
Antibiotics are singled out as high profit generators (Chuc
and Tomson 1999; Chuc et al. 2001; Saengcharoen and
Lerkiatbundit 2010; Nga et al. 2014); this may partly ex-
plain their rampant overuse.
f. Medicine purchasing
The pharmaceutical industry employs aggressive marketing
techniques which involve promotional offers to pharmacies.
This includes bonus schemes whereby the purchase of x
amount of a product includes y amount for free (Kamat and
Nichter 1998). Retailers are then incentivized to sell more of
this product, regardless of its appropriateness, because it will
yield high profits. The following quote from Kamat and
Nichter’s (1998) ethnographic study of pharmacies and
pharmaceutical-related behaviour in India gives an insight
into such practice (the product mentioned, Superaction, an
OTC product for cough, cold, fever and pain, is sold on a
buy 12 strips get 7 free basis):
I make a profit of anything between 75% and 100% on
“Superaction.” During the past 2 week, I sold two boxes (20
strips) of this item for which I got a pocket calculator worth
80 rupees from the company. I make a lot of profit on this
product, but I have to counter-push it because local doctors
do not prescribe it. I do not recommend this product to every
customer who asks for medicines for headache or body pain
but mostly to angutachapwallas (illiterates) who come and
ask me to give some medicine for cold and pain (Kamat and
Nichter 1998).
Dineshkumar et al. (1995) comment on the aggressive mar-
keting of vitamins which are used extensively in India.
Seeberg describes how chemists in Orissa purchase substand-
ard medicines from local production facilities at a 50% dis-
count and then sell them on to customers thus making
additional profit (Seeberg 2012).
It is important to note that there are examples in the litera-
ture which illustrate that medicine retailers are only prepared
to go so far in risking the health of their patients in the name
of making a quick profit. Pharmacists described how it was
not suitable to use substandard medicines for patients who
had undergone surgery or faced life-threatening conditions
(Seeberg 2012). Additionally, when patients sought pharma-
cists’ advice in the event of not being able to afford all medi-
cines on a prescription, they were found to recommend the
medicines which ‘cure’ over those with the highest profit
(Kamat and Nichter 1998).
3. State intervention
A few studies in this review provide information on the impact
of government intervention on pharmacy performance.
a. Regulation
Two intervention studies reported on the effect of regula-
tion on service quality. An intervention in Lao PDR involv-
ing inspection visits, punishments in the case of gross
violations of the sanctions, up-to-date supply of regulatory
documents, and reinforcement of the rules found marked
improvements in the availability of essential medicines,
order in the pharmacy and provision of information;
and less mixing of different drugs in the same package
(Stenson et al. 2001b). The regulatory component of a
multi-component (sequentially applied), intervention on
dispensing practices in Bangkok (Thailand) was the only
component of the intervention that resulted in a significant
change in practice (reduced dispensing of a prescription-
only steroid compared to the control group). This interven-
tion focussed on the illegality of the act and the threat of
punishment should such practice be observed. The same
study reported that in Hanoi (Vietnam), where less focus
was placed on sanctions, the regulatory component of the
intervention did not lead to an immediate change in behav-
iour (Chalker et al. 2005).
b. National Public Health Programmes
A study from Vietnam investigating the management of tu-
berculosis patients in the pharmacy found, in a multivariate
analysis, that staff who were aware both of the National
Tuberculosis Programme (NTP) and that tuberculosis medi-
cines were provided for free were 5.8 times more likely to
refer a suspect directly to a tuberculosis facility than those
who were not (Vu et al. 2012). Another study concerned
with management of childhood diarrhoea investigated prac-
tice in three countries: Bangladesh, Sri Lanka and Yemen
Arab Republic. The authors reported that ORS was more
commonly dispensed in Bangladesh and they noted the pres-
ence of a national ORS programme as one potential explan-
ation (Tomson and Sterky 1986).
Discussion
Combined, the reviews identified 60 papers reporting on pharmacy
practice and/or determinants of poor practice in 15 LMICs in Asia.
The majority of studies were from lower middle-income countries.
Asides from studies from Mongolia, Yemen Arab Republic and
Syria, all other studies focussed on countries from South and South-
East Asia. As such, the results tell us little about pharmacy practice
in North Asia, Central Asia, West Asia or the Middle East. Most re-
search was carried out on PRPs, with less on NPRPs and research on
unregistered shops was found to be practically non-existent.
Given the diversity of studies found in the search, quality
appraisal proved to be a particular challenge. Relevant papers
included a range of designs including randomised controlled trials,
cross-sectional descriptive surveys and ethnographies. The lack of
clear criteria by which qualitative studies should be judged in the
systematic review process has been raised by others but remains an
unresolved issue (Dixon-Woods et al. 2006). In light of this, it was
decided to include all papers which met the inclusion criteria provid-
ing the methodology employed was clear. Data on both methods
and study design were extracted and any potential threats to validity
were recorded. The main concerns noted were small sample sizes
and non-random sampling (quantitative papers). The findings of
poorer quality studies, however, were found to be consistent with
more rigorously designed ones. In interpreting the findings, care has
been taken to emphasise those which were found in a number of
studies and across countries.
In terms of pharmacy performance, the findings across countries
and over time are remarkably consistent. Pharmacy practice in Asia
appears to have changed little in the past 30 years. The same prob-
lems documented by studies in the 1980s are true of practice in re-
cent times (Tomson and Sterky 1986; Greenhalgh 1987; Hussain
and Ibrahim 2012; Seeberg 2012; Vu et al. 2012; Chua et al. 2013;
Minh et al. 2013; Saengcharoen and Lerkiatbundit 2013). Practice
appears to fall short throughout the pharmacy encounter. The key
inadequacies documented throughout the literature are: insufficient
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history taking prior to the sale of medicines; a lack of referral of pa-
tients whose management is outside of the remit of a pharmacist’s
expertise; the illegal sale of a wide range of POMs without a pre-
scription; the sale of medicines that are either clinically inappropri-
ate and/or in doses that are outside of the therapeutic range; the sale
of incomplete courses of antibiotics; and finally, limited provision of
information and counselling to accompany the sale of medicines.
Similar challenges have also been documented in Sub-Saharan
Africa (Wafula et al. 2012)
Staff working in pharmacies can be seen as the gatekeepers of
medicines. They stand at the interface between producers and con-
sumers of medicines and their role is to ensure that they are used
safely, effectively and rationally (Anderson 2002). When used cor-
rectly, medicines can save lives and improve people’s health; irra-
tional use, however, can have harmful consequences. A number of
conditions were found to be treated inadequately in the pharmacy,
including diarrhoea, asthma, anaemia, tuberculosis, STIs, RTIs and
migraine. This mistreatment can lead to unnecessary morbidity and
mortality. For example, many studies reporting on the management
of childhood diarrhoea found under-provision of ORS and over-
provision of anti-diarrhoeals and antibiotics. The use of anti-
diarrhoels in infants has been shown to be harmful (Minton and
Smith 1987; Li et al. 2007) and it is estimated that correct treatment
with ORS may prevent 93% of diarrhoeal deaths in children under
5 (Munos et al. 2010). In South Asia, diarrhoea is thought to ac-
count for 23% of all deaths in children under 5 (Morris et al. 2003).
Overuse of antibiotics is a particular concern for public health,
as misuse of antibiotics over recent decades has led to the selection
and spread of resistant bacteria. As a result, antibacterial drugs have
become less effective and in some cases, ineffective. Earlier this year,
a WHO global report on the surveillance of antibiotic resistance
described the problem as a ‘global health security emergency’
(World Health Organization 2014).
A further concern is the economic impact of spending on house-
holds, especially the poor. Customers typically pay for the medicines
purchased at pharmacies out of their own pocket and where these
medicines are inappropriate or ineffective this represents a waste of
scarce resources. Work in Asia has shown that, in many countries, a
large proportion of out of pocket payments is spent on medicines.
For example, in Bangladesh, Vietnam and India, this share is 70%
(Van Doorslaer et al. 2007). Further, in these countries, out of
pocket payments for healthcare can be ‘catastrophic’, accounting
for>25% of household resources (excluding food costs) in at least
10% of all households (ibid).
Turning to the determinants of the poor practice documented
above, the picture is less clear. Despite the importance of pharmacies
and the potential benefit for public health if practice were to im-
prove, efforts to understand and address the problem have been sur-
prisingly few. Historically, the small number of attempts to improve
pharmacy practice in Asia has focussed on training interventions.
This review finds that whilst a necessary condition, adequate know-
ledge alone is not sufficient to ensure appropriate management of
patients presenting at the pharmacy. Profit motives and the regula-
tory environment appear to play a role but the research evidence is
relatively sparse. In terms of the methods used to unpick the under-
lying determinants of pharmacy behaviours, we found that in-depth
qualitative studies, particularly those employing an ethnographic ap-
proach, provided the richest data (Kamat and Nichter 1998; Seeberg
2012). Unfortunately, studies using this approach are rare.
Whilst a number of studies have been published in the two dec-
ades since Goel et al. (1996) first reviewed this literature, there is lit-
tle new insight into the problem of poor pharmacy practice. They
noted that regulatory factors had been ‘strikingly neglected by re-
searchers’ and called for new research on the ‘impact of professional
ownership on professional freedom’. Researchers have, on the
whole, continued to neglect these areas. The pursuit of regulatory
enforcement is, however, not a straightforward solution and we
must be aware that enforcing laws surrounding the sale of POMs
would potentially deny many people access to essential medicines,
thus violating a basic principle of public health.
Based on the intervention literature both within and outside
Asia, the menu of evidence-based options for professional bodies
and policy-makers to inform improvement and development of
pharmacy services is limited (Smith 2009a). Arguably, some cadre
of trained pharmacy workers should be in place in order to provide
a basis for improvement, yet in many settings human resource limi-
tations undermine the ability to provide this (Smith 2009b). Asides
from training and regulation, other schemes that have been imple-
mented include peer review, accreditation (such as the Accredited
Drug Dispensing Outlets scheme in Tanzania) and social franchising
(Chalker et al. 2005; Wafula and Goodman 2010). However, the
evidence on the impact and sustainability of these strategies remains
quite limited, highlighting this area as an important priority for fu-
ture research (Center for Pharmaceutical Management 2008;
Wafula and Goodman 2010; Valimb et al. 2014).
It is worth noting that new organisational arrangements of phar-
macy retail in the form of chains and franchises are a growing phe-
nomenon in LMIC both in Asia and elsewhere (Lowe and Montagu
2009; IMS Consulting Group 2014). This phenomenon raises im-
portant questions about the impact of professional and organised
ownership on pharmacy practice. Further, theoretical literature sug-
gests that the organisational structure of the pharmacy firm may af-
fect both the regulatory environment and financial incentives, as
well as provider knowledge (Klein 1980; Blair and Kaserman 1994;
Frant 1996; Bloom et al. 2008).
Cross and Macgregor (2010) have criticised the current debates
around ‘informal providers’ (including drug sellers) which, they
argue, are myopically focused on ‘small time economic actors’ rather
than giving attention higher up in the pharmaceutical supply chain
(Cross and Macgregor 2010). This focus indeed leads to a distrac-
tion away from the pharmaceutical industry, which, thus far, has
largely remained absent from discussions of inappropriate medicines
use. A few papers in this review touch on the pressures that pro-
viders face from industry but this does not come out strongly.
Whilst it is necessary to study frontline behaviours, research up-
stream is also a necessity.
Conclusion
Pharmacies are an important component of the health system in
LMIC in Asia. In many areas they act as ‘de facto primary health-
care providers’ (Seeberg et al. 2014). The service they provide, how-
ever, does not live up to international expectations of pharmacy
practice. The consequences of poor practice can have harmful effects
for public health and, as such, these outlets warrant more attention
from public health researchers. The nature of the problem with
pharmacies in Asia is well established, although more attention
could be paid to NPRPs pharmacies and unregistered drug shops.
Future research efforts should focus their attention on investigating
the underlying causes and ways to improve the current situation.
The little evidence that is available suggests that intervention strat-
egies should take into account the regulatory environment and profit
incentives faced by pharmacy personnel and not continue to focus
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solely on improving knowledge. If efforts are focussed accordingly it
is hoped that the realities of the past 30 years of poor pharmacy
practice in Asia will not continue for the next 30.
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PART II: HYPOTHESES AND 
METHODOLOGY 
3 Towards a set of hypotheses: theoretical and empirical 
insights from the literature 
3.1 Introduction 
This chapter is divided into three parts. Firstly, I review the empirical literature on the effects 
of pharmacy chains in both high, middle and low-income countries. Secondly, I draw on 
theoretical insights from economics literature to hypothesise how pharmacy chains may 
affect the public health concerns of quality of care, quality of medicines, prices of medicines, 
and access. Finally, I bring together this set of hypotheses into a single framework in order to 
inform this study on the public health effects of pharmacy chains in a LMIC setting.   
3.2 Empirical data on the effects of pharmacy chains 
A systematic approach was employed to search for empirical literature on the effects of 
pharmacy chains. PubMed, Embase, Econlit and Global Health databases were searched. 
Searches were also conducted in Google Scholar and bibliographies of relevant papers were 
scanned to identify further references. A number of terms for medicine retailers were identified 
from an initial scope of the literature and these were combined (using AND) with terms used 
to described chains and franchises (see Table 1 for details of search strategy). The majority of 
the literature comes from studies conducted in high income settings, and the results of these 
studies are presented first. An overview of the limited studies from LMICs follows.  
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Table 1: Search strategy used to identify literature on pharmacy chains and franchises 
Target population (combined by ‘OR’) Pharmacy type (combined by ‘OR’) 
Free text terms 
chemist 
drug retailer* 
drug shop*  
drug seller*  
drug vendor*  
drug store*  
drug dispensing  
drug outlet*  
druggist 
medicine retailer*  
medicine shop*  
medicine seller*  
medicine vendor*  
medicine store*  
medicine dispensing shop* 
medicine outlet*  
medicine dealer* 
pharmacies  
pharmacy  
pharmacy service*  
pharmacist*  
pharmaceutical service*  
MeSH terms 
pharmacy 
pharmacies 
Free text terms 
chain*  
franchise*  
corporate  
corporatisation 
corporatization 
organised  
organized  
3.2.1 High income settings 
A number of studies from high income countries (mostly in North America) report on a wide 
range of outcomes (see Appendix 2 for study details). Some outcomes such as role affinity, 
autonomy, workplace stress and job satisfaction were deemed to have limited relevance to 
this research. Others looked at more pertinent outcomes, such as quality of care, service 
provision and price. The following paragraphs summarise the evidence on the effect of 
pharmacy type on these three outcomes.  
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Several studies measured outcomes related to quality of care including counselling of 
patients, adherence to medication, provision of medication information, counselling, error 
reporting, patient satisfaction, dispensing errors, screening and discussing opioid abuse. 
Findings of these studies were mixed, with some reporting more favourable results for chains 
and others for independents. Further, a number of studies found no differences between the 
two. Research from the United States (US) reported that chain pharmacies provided longer 
medicine information leaflets which met a larger percentage of expert-required contents than 
independent pharmacies (Winterstein et al. 2010); were more likely to self-report screening 
patients for prescription opioid abuse (Cochran, Field, and Lawson 2015); and had higher 
rates of patient-initiated counselling (Raisch 1993). On the other hand, independents were 
found to counsel a significantly higher proportion of patients compared to chains in a US 
study; have patients with better adherence to antihypertensives and oral hypoglycaemics in 
the US and Canada respectively (Kalsekar, Sheehan, and Peak 2007, Winslade and Tamblyn 
2017); and submitted more error reports than their chain counterparts (Kennedy and 
Littenberg 2004). Several studies did not find any differences between chain and 
independent pharmacies. For example, a study from Canada found no significant differences 
in adherence to statins for patients filling prescriptions at chain and independents (Evans et 
al. 2009). In Saudi Arabia, a study utilising standardised patients visits found no significant 
differences between pharmacy types for provision of information on inhaler technique for 
newly diagnosed asthma patients (Khan and Azhar 2013). Finally, dispensing accuracy 
results did not significantly differ by pharmacy type in a study of 6 cities across the US 
(Flynn, Barker, and Carnahan 2003).  
In terms of service availability, one national study in the US found that chain and 
supermarket pharmacies offered a wider array of services, eg immunisation and health 
screening, compared to independents. Another paper, also from the US, reported on services 
that could improve access to prescription medication. A significantly larger proportion of 
chains were open 24 hours and reported having a drive-up window. Conversely, independent 
pharmacies fared more favourably in terms of offering a home delivery service and presence 
of multilingual staff.  
Two studies compared drug prices at chain and independent pharmacies in the US. Both 
studies reported that independent pharmacies accounted for a larger proportion of 
community pharmacies in low income postcodes (Arora et al. 2017, Gellad et al. 2009). A 
study from Florida used a publicly available directory of drug prices to look at 3 commonly 
used medicines and found chain pharmacy prices to be cheaper than independents (Gellad et 
al. 2009). The other research, conducted in Los Angeles, collected the prices of two generic 
medicines by telephone and found the lowest average prices at independent pharmacies. 
41 
 
Both studies found chain price variation to be less than that of independents. Doucette and 
colleagues found that the proportion of independently owned pharmacies (vs chain 
pharmacies) in an area was positively associated with the percentage of the population 
earning less than the poverty line and with the percentage of population living in highly rural 
areas, suggesting a reluctance of chains to operate in highly rural and poorer areas (Doucette 
et al. 1999).  
A large programme of work conducted in the United Kingdom (UK) in order to identify 
organisational factors associated with clinical productivity (levels of service delivery and 
service quality) recently published their findings (Jacobs et al. 2017).  They found that levels 
of service delivery were related to ownership type, and the highest levels were found in large 
chains and supermarkets. They used a number of different tools to measure service quality 
and some of these were found to be related to pharmacy type. In terms of safety climate4, 
more favourable organisational learning (willingness to develop and maintain safety) scores 
were found in large chains and supermarkets but working conditions in these environments 
were significantly worse than in independents. No differences were reported in satisfaction 
with the pharmacy visit or adherence to medication between pharmacy types.   
In sum, the evidence available on the effects of chain pharmacies in high income countries 
comes mostly from the US. This research offers some information on the effect of price, 
access, services offered and some aspects of quality, but the results are mixed. Further, given 
the well-functioning nature of regulatory frameworks in high income contexts, the research 
pertaining to pharmacy chains in this setting, whilst providing some useful insights, is likely 
of limited applicability to lower income settings.  
3.2.2 Low and middle-income settings 
No studies were found that reported on pharmacy arrangements in low income settings, and 
only five from middle-income countries. Arkaravichien and colleagues employed a cross-
sectional survey, aimed at assessing quality, in accredited chain (n=26) and independent 
(n=34) pharmacies in a region of North East Thailand (Arkaravichien, Wongpratat, and 
Lertsinudom 2016). Their quality indicator tool comprised 40 items covering five domains- 
premise and facility; personnel; drug inventory and stocking; dispensing and patient care; 
and patient satisfaction and health promotion. Assessment of quality involved both direct 
observation (items that could be clearly seen) and an interview with the pharmacist in-charge 
(for items that could not be observed). The study reported that chains had significantly 
higher scores in a number of domains (personnel, drug inventory and stocking, patient 
                                                     
4 Safety climate was measured using the Pharmacy Safety Climate Questionnaire, a validated measure which 
captures the “pharmacy’s collective attitudes and behaviours regarding patient safety p.11” (Jacobs et al. 2017). 
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satisfaction and health promotion) resulting in a significantly higher overall median quality 
score of 3.6, compared to 3.3 for independent pharmacies (p=0.008). Scores were measured 
out of 4, and overall found to be quite high for most domains. These scores must be 
interpreted with some caution, given that most items were self-reported. Elsewhere in Asia, 
Bennet and Yin have examined the effect of chain store entry on prices and drug quality in 
the retail pharmacy market in Hyderabad, India (Bennett and Yin 2014). Through 
collaboration with a pharmacy chain, they gathered baseline data in 18 markets the firm 
wished to enter and later resurveyed 7 markets one year after chain entry. A mystery 
shopping audit was conducted in which antibiotics were purchased, prices were recorded and 
the quality of samples was assessed in a laboratory. The paper reported that compared to 
independent retailers, chain prices were 6% lower (p=0.02) and pharmacopoeia compliance 
was 6% higher (p=0.46). The resulting effect of chain entry on the market (compared with 
control markets) was a relative 5% improvement in drug quality and a 2% decrease in prices 
at existing independent retailers. The paper also noted that the chain initially targeted 
affluent neighbourhoods (Bennett and Yin 2014).   
Two studies from Mexico report on the sale of misoprostol (which can be used to induce 
abortion) from pharmacies. A subset of their analyses is conducted by pharmacy type (chain 
or independent). Asides from its use as an abortifacient (for which 4 tablets are taken as a 
single dose), misoprostol can also be used to treat gastric ulcers, if taken on a long-term 
basis. Lara and colleagues (2011) hypothesised that the individual sale of pills indicated that 
they were used to induce abortions. In their study of 192 pharmacies in four regions of 
Mexico, using mystery client methodology, they report that a logistic regression model to 
explore the characteristics associated with the sale of misoprostol by individual pill found the 
odds to be three time higher for independents compared to chain pharmacies (Lara et al. 
2011). The other study, in which mystery clients requested medicines for ‘bringing down the 
period’ and then asked for misoprostol at 169 pharmacies in one state of Mexico, 
investigated spontaneous and prompted discussions of the drug. No statistically significant 
differences were found by pharmacy type (Billings et al. 2009).  
A final study, conducted in South Africa, investigated equity in the geographical distribution 
of pharmacies (Ward et al. 2014). The authors show that whilst in 2008 and 2009 there were 
more applications for pharmacy licences from independent than chain pharmacies, since 
2010 this trend has been reversed, with more applications from chains. Applications by both 
pharmacy types peaked in 2009 for independents, and 2010 for corporate pharmacies, and 
have since both dropped. The authors discuss the concern of access in light of the decline of 
new independently-owned community pharmacies, citing that they are ‘more likely to be 
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established close to poor communities than corporate businesses’. However, it is not clear 
from the paper whether there is strong evidence to back this claim.  
3.3 Theoretical insights from economics literature 
The existing empirical research pertaining to the effects of pharmacy chains in high-, 
middle- and low-income settings has, on the whole, been limited in terms of theoretical 
underpinning. Various bodies of theory provide insights into the study of pharmacy 
arrangements, such as those from neo-classical economics, industrial organisation and 
regulatory theory. Conventional economic analysis of pharmacy markets in LMIC typically 
focuses on the high likelihood of various market failures. There are arguably two reasons 
why retail pharmacy markets, specifically, do not fit the free market model: the assumptions 
of perfect information do not hold, and externalities exist.  Mushkin (1958) was the first to 
describe the problem of imperfect information in health.  She argues that consumers have an 
‘absence of accurate knowledge’. In the pharmacy context this relates to poor information 
regarding diagnosis, appropriate treatment and drug quality.  This can hinder rational choice, 
leading to a suboptimal allocation of resources (Mushkin 1958). Arrow (1963) went on to 
recognise that the nature of information in health markets is asymmetric, meaning that the 
drug seller will, in general, have better information about the medicines than the buyer. The 
patient is therefore unable to completely enforce standards of care. 
Within the agency relationship that results, it has been suggested that providers do not 
always act as perfect agents; rather they influence demand for their own self-interest, trading 
off income against patient welfare (Morris, Devlin, and Parkin 2007, McGuire 2000). Within 
the pharmacy context, where revenues can be increased by prescribing additional treatments, 
the quantity of items recommended is likely to be larger than it would be for patients with 
perfect information.  The fee for service system of provider payment (as in a pharmacy) is 
most associated with ‘overserving’ patients (Hennig-Schmidt, Selten, and Wiesen 2011, 
McGuire 2000). The second issue is that inappropriate prescribing of medicines can be 
associated with negative externalities (Laxminarayan 2003); for example issuing a shorter 
than optimum course of antibiotics contributes to the emergence of antibiotic resistant strains 
of bacteria. Regulation is one method of addressing the welfare loss associated with market 
failure and protecting patients from drug sellers abusing their market position (Rice and 
Unruh 1998). 
In addition to the general theories of market operation such as those described above, we 
draw on ideas from regulatory theory and industrial organisation to develop hypotheses 
regarding the effects of chains on the public health concerns of quality of pharmacy 
treatment behaviour, price of medicines, quality of medicines, and access.  
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3.3.1 Quality of care  
It is first necessary to recognise that healthcare quality is a multidimensional construct. 
Donabedian (1980) describes three key aspects of health provider performance: the technical 
component, involving providers’ knowledge and judgement skill, which is measured by 
comparison with best practice. The interpersonal component, concerning the interaction 
between patient and provider, for which information is difficult to obtain and measurement is 
not well-defined; and the amenities of care, namely the comfort and appeal of service 
provision. The quality shortcomings of pharmacy practice described in the literature review 
on performance largely fall under the technical component (Miller and Goodman 2016) and 
it is this aspect of quality that this thesis is primarily concerned with.   
I now turn to the potential effects of chain pharmacies on technical quality. The literature 
review on pharmacy performance in chapter 2 identified three key determinants of pharmacy 
provider behaviour: regulation, knowledge, and profit motives. I consider how being 
organised as a chain may influence these determinants. 
3.3.1.1 Regulation 
The fragmented nature of pharmacy retail in India makes enforcing regulation costly and 
logistically difficult. Through consolidation, chains could improve regulation in two ways. 
First, state regulation can be concentrated on central management structures. Essentially, the 
regulator can make firms take responsibility for local branches, thus relieving pressure on 
overburdened regulatory agencies.  
Second, firms may self-regulate in order to preserve brand identity and image. In his classic 
article on ‘lemons’ in the used car market, Akerlof (1970) showed that when sellers are 
aware of the car quality, but consumers are not, then only lemons will be traded. In contrast 
with the market for used cars, consumers of medical care usually have some indication of 
quality either from past experience, discussions with others about their past experiences or 
other sources (Haas-Wilson 2001). Where information regarding reputational quality can be 
obtained, the problem of quality deterioration can be lessened (Klein and Leffler 1981). 
Several authors have alluded to the potential of ‘market-based’ regulatory mechanisms, 
including self-regulation, within pluralised, unregulated health markets where traditional 
approaches (enforcing regulation through administrative and bureaucratic controls) have 
failed (Ensor and Weinzierl 2006, Bloom, Kanjilal, and Peters 2008, Bloom, Standing, and 
Lloyd 2008, Peters and Muraleedharan 2008). Bloom et al (2008) describe how an 
institutional reputation is built into a brand and this can be damaged if products or services 
are of low quality, thus creating an incentive to ensure quality (Bloom, Standing, and Lloyd 
2008). They argue that these reputation-based ways of delivering health care build trust and 
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can help to overcome the information asymmetry which characterises transactions in 
pharmacy markets.  
Self-regulation would involve chains developing their own rules or codes of conduct that 
guide the behaviour, actions and standards of those working within the organisation. The 
chain would then take responsibility for developing self-regulatory instruments, monitoring 
compliance and ensuring enforcement. A concern, however, is that some aspects of quality 
in health markets are easier to learn about than others and patient satisfaction has been 
shown to be positively linked to interpersonal quality but less sensitive to technical quality 
(Haas-Wilson 1994). This may result in chains focusing their attentions on controlling the 
quality of these aspects of their service provision, rather than focusing on current technical 
failings.   
3.3.1.2 Knowledge 
The importance of brand identity may lead to qualified pharmacists at the point of service 
delivery, who would be expected to be more knowledgeable than unqualified staff. 
Currently, such personnel are reportedly often absent in independent pharmacies (Basak and 
Sathyanarayana 2009). The websites of a number of Indian pharmacy chains already 
promote the presence of qualified pharmacists in all of their stores (c.f. Frank Ross 
Pharmacy 2011, Hetero Pharmacy 2010, Trust Chemists and Druggists 2014).  
3.3.1.3 Profit-motives 
A final reason why quality may improve in a chain situation arises from the different 
incentive structures in place for pharmacy owners as opposed to managers. High-powered 
incentives exist when the profits of transactions flow directly to the parties involved 
(Williamson O 1985, Frant 1996). In the case of independent pharmacy owners, the potential 
for excess profits provides incentives to behave dishonestly. This is based on the assumption 
that clients are poor judges of technical quality and that pharmacy workers do not have 
reservations about exploiting their position of power within the provider-patient relationship. 
A hierarchical structure (as in a chain) can attenuate opportunism because the incentives 
faced by salaried personnel working in the pharmacy are low-powered. The literature review 
presented in chapter 2 found that a number of poor practices, for example the sale of 
medicines with high profit margins, were linked to profit-maximising strategies. In the event 
that chain employees are salaried, the removal of profit considerations from medicine sales 
may lead to improved prescribing practices. However, in order to better align the incentives 
of the employees with the goals of the organisation, chains may commit more resources to 
monitoring and verification 
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(Milgrom and Roberts 1992). Further, they may instigate incentive schemes (Hölmstrom 
1979, Harris and Raviv 1979). Whereas others argue that whilst incentives can improve 
efficiency, they do not necessarily maximise profits (Miller and Whitford 2007). It is 
currently unknown whether pharmacy chains in India link pay with performance.  
3.3.2 Price and quality of medicines 
Organisational arrangements could also affect price and quality in a number of ways. Chains 
can take advantage of scale economies to invest in cost-reducing and quality-enhancing 
technologies (Bennett and Yin 2014). Chains may also be able to realise larger margins on 
medicines than their independent counterparts through a variety of mechanisms. Firstly, they 
could create their own supply chains and buy directly from manufacturers. Secondly, firms 
may also partner with manufacturers to offer ‘own brand’ or ‘private label’ products. Such 
products are obtained at a lower cost (than nationally established brands) thus offering higher 
margins. Finally, if firms became large enough to experience buying power in the market 
chains could realise larger margins than independents. All of these actions could lead to 
cheaper medicines for clients. On the other hand, firms may use their brand power to raise 
prices. In high-income settings, consolidation in the hospital sector has led to price increases 
(Cutler and Morton 2013, Gaynor and Town 2012). 
With regard to drug quality, concerns include appropriate storage, and counterfeits. Heat and 
humidity can be extreme in India and medicines must be stored appropriately to prevent 
degradation. Most leading chains advertise their use of refrigerator units to maintain 
medicines at appropriate temperatures (MedPlus Pharmacy 2011, Hetero Pharmacy 2010). 
This may signal their willingness to invest in quality control. Further, the ability to shorten 
the supply chain by potentially bypassing parts of the supply chain may give chains more 
control over drug quality.  
3.3.3 Geographical access 
According to Rubin, firms organised as chains may restrict their operations to urban areas 
due to the costly nature of monitoring units (to prevent shirking) in dispersed geographical 
locations (Rubin 1978).  Given that independent pharmacy owners tend to work in the 
pharmacy themselves, they do not face the difficulty or cost of monitoring at a distance and 
are thus not restricted to urban locations. Rather, they are likely to open a business wherever 
they have personal ties. Basak and colleagues describe how India struggles with a stark 
urban-rural imbalance with regards to pharmacists, with few working outside cities and 
almost none in remote areas (Basak, van Mil, and Sathyanarayana 2009).  Were chains to 
adhere to minimum staffing standards in their branches, they would likely struggle to recruit 
47 
qualified personnel outside the urban metropolises. Further, a business model employing a 
qualified pharmacist may not be viable in sparsely populated areas with low purchasing 
power.  
3.4 A note on franchises 
Franchises are another organisational form through which pharmacy services can be 
delivered. This arrangement has not been a major consideration of this thesis, because in 
India the vast majority of corporate pharmacies operate centrally-owned outlets (i.e. a chain 
format). Medicine Shoppe, perhaps the most well-known pharmacy franchise in India, 
enjoyed rapid growth to become one of the country’s leading corporate players but was 
ultimately unsuccessful and closed down operations after 10 years in the market (Chanchani 
2009). Some retailers operate franchised stores in addition to their centrally-owned outlets, 
but these represent a small proportion of the total. Whilst this thesis does not explore 
franchises, I have briefly considered the theoretical effects of such businesses.  
Franchised pharmacy companies would be expected to work through the same mechanisms 
as chains with a view to cost-reducing and quality-enhancing technologies; also in terms of 
regulation. They too would be trading on the premise of various promises to customers that 
enable their brand to be distinguished from the competition. Rubin suggests that because 
franchisees share substantially in the profits of their outlet, they have a greater incentive than 
managers to be efficient and avoid shirking and this reduces the need for costly monitoring 
(Rubin 1978, Milgrom and Roberts 1992). Franchising may, therefore, allow a firm to offer 
stores in more dispersed locations, thus expanding services and increasing access in 
untapped peri urban and rural areas. Whilst the high powered incentives of being a 
franchisee act to align interests with the franchisor, the profit motives of both parties can 
clash with public health concerns. The high powered incentives created by the use of a 
franchise contract inadvertently create a horizontal agency-related problem for the firm- that 
of free riding. The owner of a single franchisee unit has a profit motive to offer a lower level 
of quality than that which maximises the franchisor’s profit (Blair and Kaserman 1994). 
3.5 Set of hypotheses 
Drawing on the literature presented above, figure 1 summarises the set of hypotheses arising 
from the literature about the implications of pharmacy chains for public health in a LMIC 
setting. The main outcome of interest is the effect of chains on quality of care, related to 
treatment behaviour. At the top of the figure, a pharmacy provider, working within a market 
characterised by negative externalities and asymmetry of information, is depicted. The 
mechanisms by which chains are hypothesised to affect the determinants of quality of care 
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(knowledge, regulation and profit motives) are shown. The mechanisms by which price, 
access, and quality of medicine are hypothesised to be affected are also included. For 
logistical and budgetary reasons drug quality was not be measured in this study but potential 
mechanisms by which it may be affected have been included to provide a more complete 
picture.  
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Figure 1: Hypothesised effects of pharmacy chains on public health concerns of quality 
of care, price, quality of medicines, and access 
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4 Study site, study design, and methods 
4.1 Introduction 
In order to achieve the stated objectives of this thesis, it was necessary to employ multiple 
methods. Following a description of the study site where the research was conducted, this 
chapter provides details of all methods used, including a standardised patient (SP) survey, in-
depth interviews with key informants, and exit interviews with clients.  
4.2 Study Site 
In this section I provide a general overview of the Indian health system and details of both 
the state (Karnataka) and city (Bengaluru, previously known as Bangalore) where the 
research was conducted.  
4.2.1 India 
India is the world’s second largest country in terms of population (over 1.2 billion as per the 
2011 census) and the seventh largest in terms of land mass (Census of India 2011). It is 
comprised of 29 states and seven union territories and is both culturally and linguistically 
diverse. The most recent census identified 122 different languages that were spoken by more 
than 10,000 people. 69% of the population live in a rural area and female and male 7+ 
literacy rates were 69% and 85% respectively (80% and 90% in urban areas). India gained its 
independence from British rule in 1947 and has gone on to become one of the world’s fastest 
growing economies, with an average annual growth rate of Gross Domestic Product (GDP) 
of 7.4% over the last decade (World Bank 2018). Despite this growth, there is vast income 
disparity and 268 million citizens (21.2% of the population) were living on less than $2 a day 
in 2011 (World Bank 2018 -d).  
4.2.2 Healthcare in India 
Whilst the overall state of health is improving (life expectancy at birth has increased from 55 
in 1965 to 72 in 2015) (World Bank 2018 -a), India faces a mismatch between its health 
problems and its health system. In tandem with its social and economic development, India 
is undergoing a major epidemiological transition, with a shift in burden to non-
communicable diseases. Not only are these new threats associated with an ageing population 
emerging, but the country continues to struggle with communicable diseases and historic 
health problems, including high rates of infant mortality (30.5 per 1000 live births) (World 
Bank 2018 -c); maternal mortality (174 per 100,000 live births) (World Bank 2018 -b); and 
malnutrition (of children under 5, 38% affected by stunting and 21% either ‘wasted’ or 
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‘severely wasted’, and over half of women of reproductive age suffer from anaemia) 
(Development Initiatives 2017 ). Further, huge variations in disease burden exist across 
states and a disproportionate burden of disease falls on marginalised groups including the 
poor, women, and scheduled tribes and castes (Peters 2002).  
As per the Indian constitution, each state is responsible for organising and delivering 
healthcare for its population. The central government, under the direction of the Ministry of 
Health and Family Welfare, is responsible for coordinating national disease programmes e.g. 
the Revised National Tuberculosis Control Programme (RNTCP), promoting of traditional 
systems of medicines, and oversight. In terms of service provision, government health 
services coexist alongside private services. Healthcare in rural areas is characterised by a 
network of government facilities (Chokshi et al. 2016). Health Sub Centres, run by Auxillary 
Nurse Midwives cater to a population of around 3000-5000 offering health promotion, basic 
medicines, and referral opportunities. Primary Health Centres are supposed to have a 
qualified medical doctor, offer primary care including laboratory and pharmacy services as 
well as minor surgery, and serve a population of 20,000-30,000. Primary Health Centres feed 
into Community Health Centres, which offer inpatient facilities (around 30 beds), and, in 
theory, access to specialists including a physician, surgeon, paediatrician, and obstetrician or 
gynaecologist to a population of 80,000-120,000. However, the shortfall of health workers in 
all of these settings is well documented. For example, in community health centres 83% of 
physician, 83% of surgeon, 82% of paediatrician, and 76% of obstetrics and gynaecology 
posts are vacant (Sharma 2015). The top tier facilities are First Referral Units for 24/7 
emergency care and blood storage. Community health workers- Accredited Social Health 
Activists (ASHAs) work in each village and act as a link between communities and formal 
health services. As of 2015, there were 153,655 Sub Centres, 25,308 Primary Health Centres 
(PHCs) and 5,396 Community Health Centres (CHCs) in the country, yet these numbers are 
not sufficient to meet population needs (Ministry of Health & Family Welfare 2015 ). In 
urban India, there is not such an elaborate government network, rather a mix of primary and 
secondary/tertiary facilities (Ministry of Health & Family Welfare 2013). In theory, this 
network of government facilities provides universal healthcare, free of charge. Yet it is well 
documented that, in practice, the delivery of health services in the public sector is beset with 
problems. This includes a lack of adequate human resources (0.725 doctors, 2.049 nursing 
and midwifery personnel, and 0.519 pharmaceutical personnel per 1000 population), 
medicine shortages, poor management, low service quality, and weak finances (World 
Health Organisation 2018 , Peters 2002).  
Health appears to be a low priority for the Indian Government. It consistently ranks as one of 
the world’s lowest spending nations on public healthcare (as a proportion of GDP). In 2008-
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9 they committed a mere 1.1% of GDP to healthcare (National Health Systems Resource 
Centre 2017 ). This inadequate financing has led to the overwhelming dominance of the 
private sector. The private share of total health expenditure (THE) is a vast 71% and 
pertinent to this thesis, 29% of THE is spent at private retail pharmacies on either prescribed 
or non-prescribed medicines (ibid). 63% of THE is accounted for by out-of-pocket payments 
by households. This high level of out-of-pocket expenditure is one of the highest amongst 
LMICs (Mackintosh et al.). Large and unpredictable health-related expenditure can expose 
households to sizeable financial risk, and it has been reported that such payments push 
around 3.5% of the population below the poverty line each year (Van Doorslaer E et al. 
2006, Berman, Ahuja, and Bhandari 2010, Garg and Karan 2009). Heterogeneous in nature, 
the private sector includes a full spectrum of providers and facilities including large 
corporate multispecialty hospitals, small inpatient facilities with fewer than 30 beds, 
medically trained general practitioners, and unqualified ‘quacks’ or traditional healers 
(Peters 2002). There are also a number of non-profit entities. Although Western (allopathic) 
medicine dominates, there are many providers of Indian systems of medicine, eg Ayurveda 
and Unani. Many untrained practitioners offer a combination of these systems of medicine 
(ibid). Private healthcare practitioners and pharmacists account for 71% and 79% of 
outpatient visits in rural and urban areas respectively (Mackintosh et al.).  
The combination of a high burden of ill health, low public spending on healthcare, high 
private healthcare expenditure (largely accounted for by out of pocket payments), and 
limited coverage of existing health insurance schemes, has led to calls for major reform to 
India’s health system, in a bid for ‘universal healthcare for all by 2020’ (Reddy et al. 2011). 
Health planners have advocated the expansion of health insurance as an essential component 
of the country’s healthcare reform and poverty reduction strategy (Reddy 2012). In terms of 
coverage, 0.3% of the rural and 3.5% of the urban population have private insurance, most 
recipients being in the top wealth quintile (Sundararaman and Muraleedharan 2015). 
Government-funded schemes cover 13.1% and 12% of rural and urban populations 
respectively. Since 2007 a plethora of state and central insurance schemes have been 
initiated in a bid to improve social protection. Rashtriya Swasthya Bima Yojana (RSBY), the 
world’s largest public health insurance scheme was launched in 2008 for Below Poverty 
Line (BPL) families. Despite stated objectives of some of these public schemes to cater for 
the poor, insurance remains iniquitous, with lowest quintile vs highest quintile coverage 
figures of 7.7% vs 15.1% in urban, and 10.1% vs 17% in rural areas (ibid). Further, many of 
the government schemes only cover inpatient costs at the tertiary level (Shahrawat and Rao 
2012). Health insurance in India is a dynamic policy issue and in February 2018, Modi’s 
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government announced new plans to offer health coverage to 100 million families, as part of 
the government’s 2018-19 budget (Goel and Kumar 2018 ).  
4.2.3 Karnataka and Bengaluru 
The state of Karnataka is situated in South India. It is the eighth largest state in terms of land 
mass and ninth in terms of population (61.1million inhabitants according to the 2011 
census). In terms of key development and health indicators, Karnataka’s performance 
compares favourably with national averages but it lags behind neighbouring Southern states, 
Kerala and Tamil Nadu (see Table 1). The official language is Kannada but many other 
languages, including Urdu, Tamil, Telugu, Marathi, and Tulu, in addition to Hindi and 
English, are spoken.  
The disease burden in the state is attributed 25.1% to communicable, maternal, neonatal and 
nutritional diseases; 62% to non-communicable diseases; and 12.9% injuries. The top 5 
causes of Daily Adjusted Life Years in 2016 were ischaemic heart disease (11.0%), coronary 
obstructive pulmonary disease (4.9%), self-harm (4.3%), stroke (3.8%), and diarrhoeal 
diseases (3.5%) (Indian Council of Medical Research 2017).  
Within Karnataka, there is a stark rural-urban divide, with those living in rural areas 
experiencing poorer health outcomes (Seshadri et al. 2013). Further, the majority of 
economic development, roads, infrastructure and public services have concentrated on 
Southern Karnataka, thus neglecting Northern regions (ibid). This inequality is manifested in 
gross disparity in development indicators, as evidenced by the human development indicator 
(HDI) scores of Raichur in the North (0.547) and Bengaluru Urban in the South (0.753) 
(ibid). Health outcome indicators also vary widely across the districts, for example, 74.5% of 
women in Bengaluru Urban received a full antenatal check-up compared with only 19% in 
Koppal (a Northern district) (International Institute for Population Sciences (IIPS) 2014).  
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Table 1: A comparison of India’s nationwide key health and development indicators 
with the Southern states of Karnataka, Kerala and Tamil Nadu 
Key health and development 
indicators India Karnataka Kerala Tamil Nadu 
Life expectancy females 70.3 71.1 78.7 73.5 
Life expectancy males 66.9 67.1 73.8 68.9 
Women who are literate (15-49) (%) 68.4 71.7 97.9 79.4 
Households with any usual member 
covered by a health scheme or health 
insurance (%) 28.7 28.1 47.7 64.1 
Total fertility rate 2.2 1.8 1.6 1.7 
Maternal mortality ratio (per 100,000 
live births) 167 133 61 79 
Infant mortality rate (per 1000 births) 41 28 6 20 
Under 5 mortality rate (per 1000 
births) 50 32 7 27 
Institutional births (%) 78.9 94.3 99.9 99 
Children age 12-23 months fully 
immunized (BCG, measles, and 3 
doses each of polio and DPT) (%) 62 62.6 82.1 69.7 
All women age 15-49 years who are 
anaemic (%) 53 44.8 34.2 54.8 
Data source: National family health survey (NFHS) 4, except maternal mortality from Sample 
registration system and life expectancy from The India State Level Burden Initiative (Indian Council 
of Medical Research 2017, Ministry of Health & Family Welfare 2016, Ministry of Home Affairs). 
Note: These figures have been compiled from the most up-to-date sources available but some of the 
all India figures differ from those provided above from the World Bank database.  
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The urban district of Bengaluru, India’s third most populous city, is the site of this PhD 
research. It was selected as one of the few Indian cities with significant chain entry. 
Bengaluru is the capital of Karnataka and is situated in the South of the state. Bengaluru is 
divided into 198 administrative units, all of which fall under the responsibility of the Bruhat 
Bengaluru Mahanagara Pike (the third level of government). The city has an estimated 
population of around 10 million, and despite its relatively favourable HDI (reported above) 
compared to the rest of the state it is, like much of India, a city of contrasts. On the one hand, 
it is known as ‘The Silicon Valley of India’ with a booming IT industry and a growing 
middle class. Yet on the other, it is home to 597 of Karnataka’s 2804 identified slum 
communities, where many inhabitants are living below the poverty line (Government of 
Karnataka). The median income of inhabitants living in one of Bengaluru’s slums has been 
reported to be is $1.5 (US) per day (Bhojani et al. 2012). 
4.2.4 My Institutional Home in Bengaluru 
As this research was independently conducted and was not part of a larger project, I felt it 
was important to establish a local institutional home in order to have some local insights into 
conducting research in Bengaluru and logistics such as visas and research assistant 
recruitment. During data collection, I was based at the Society of Community Health 
Awareness Research and Action (SOCHARA). SOCHARA is a Non-Governmental 
Organisation (NGO) that houses an ‘interdisciplinary group of community health 
professionals utilising multiple pathways to facilitate and promote the goal of Health for 
All’. It is run by alumni of the LSHTM. 
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4.3 Methods 
Table 2 provides an overview of the methods used to achieve each objective, and the details 
of the corresponding results papers.    
Table 2: Overview of thesis objectives and corresponding methods and results papers 
Objectives Methods Results papers 
A. To compare the quality
of case management (of two
tracer conditions) at chain
and independent pharmacies
Standardised patient survey 1. Miller R and Goodman C
2018, BMJ Global Health.
Status: published.
Chapter 5.
B. To compare the price of
consultations (for two tracer
conditions) at chain and
independent pharmacies
Standardised patient survey 2. Miller R and Goodman.
Status: under review with
Health Policy and
Planning.
Chapter 6.
C. To assess the
socioeconomic status of
clients shopping at chain
and independent pharmacies
Exit interviews with clients 2. Miller and Goodman.
Status: under review with
Health Policy and
Planning.
Chapter 6.
D. To explore how and why
the organisational structure
of pharmacy chains may
affect the quality of service
provision and prices of
medicines, compared to
independent pharmacies
In-depth interviews 3. Miller R, Hutchinson E
and Goodman C.
Status: revise and resubmit
with Social Science and
Medicine. Chapter 7.
4.3.1 Method 1: Standardised patient survey 
A cross-sectional standardised patient (SP) survey was used in order to compare both the 
quality of case management and the prices of consultations at chain and independent 
pharmacies.  
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4.3.1.1 Choice of data collection method 
A number of options exist for assessing the performance of health workers, including: exit 
interviews with clients, direct observation of pharmacy encounters, and administration of 
medical vignettes; however, SP methodology is regarded as the gold standard (Das et al. 
2012). It involves researchers presenting with a fictitious case scenario and requesting 
assistance. It is a covert technique and the provider is unaware of the patient’s research 
agenda. The SPs (also referred to as mystery shoppers, simulated clients, confederates, or 
surrogate patients) subsequently record the outcomes of their interaction. Performance is 
then assessed based on pre-defined criteria. It has a number of advantages relative to other 
measures of assessing performance (Das et al. 2012). It is free from the recall bias associated 
with exit interviews, the observation bias (Hawthorne effect) associated with direct 
observation, and the desirability bias associated with medical vignettes. In addition, exit 
interviews and observation techniques can be logistically difficult and time consuming 
because only patients seeking care for the tracer condition of interest are eligible for 
inclusion. Further, as different pharmacies are likely to have varying case-load mixes; the 
standardised nature of the mystery shopping method allows direct comparison of case 
management across different pharmacies.  
4.3.1.2 Choice of quality measures 
Donabedian (1988) warns that proceeding to measurement “without a firm foundation of 
prior agreement on what quality consists in is to court disaster p1743”. Quality of care was 
assessed by measuring adherence to case-specific treatment guidelines5 for two tracer 
conditions. This included all aspects of managing a condition in the pharmacy, including 
relevant history questions, treatment recommendations, and advice provision. According to 
Donabedian’s three dimensions of quality of care (structure, process and outcome), these 
constitute process indicators (Donabedian 2005), which seems appropriate as process of care 
is in the hands of the provider. Measures of structural quality6 have been cited as poor 
proxies of quality of care in terms of diagnoses and treatment (Rethans et al. 1991, Das and 
Gertler 2007, Das et al. 2012) and outcome measures are often not direct measures of care 
quality; they can be highly influenced by patient-related factors (Donabedian 2005).   
5 In the early 90s, the WHO, in collaboration with the International Network for Rational Use of 
Drugs (INRUD), developed a set of indicators for measuring quality use of medicines and prescribing 
behaviour in health facilities [(World Health Organization 1993)] These have been revised, updated 
and incorporated into the more recent package for evaluating country pharmaceutical situations 
[(World Health Organization 2007)  These documents informed the choice of quality measures.  
6 I initially intended to collect data on structural aspects through an outlet survey but this was not 
possible because all major chain pharmacies refused to participate.  
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4.3.1.3 Choice of tracer conditions 
According to the WHO (1993), a good tracer condition for measuring quality of care is one 
which has clear guidelines for treatment. It should also be either frequently presented, or of 
particular clinical or economic importance. The WHO’s specific suggestions include non-
bacterial diarrhoea in children under age 5, mild/moderate pneumonia in children under age 
5, and non-pneumonia acute respiratory tract infection in patients of any age. For India, 
childhood diarrhoea (as suggested by WHO) and pulmonary tuberculosis were felt to meet 
all these criteria (Boschi-Pinto, Velebit, and Shibuya 2008, World Health Organization 
2013). In addition, care for both conditions is reportedly sought at the pharmacy, which 
ensures the scenarios are realistic and prevents drawing attention to the study (Madden et al. 
1997, Sudha et al. 2003, Kapoor et al. 2012); and they represent contrasting examples of 
recommended management- a suspected tuberculosis case should be referred outside the 
pharmacy for treatment, whereas diarrhoea is commonly wholly treatable in the pharmacy 
environment. 
4.3.1.4 Cases 
Table 3 provides details of the case presentations, including the exact script used by the SPs, 
the responses given to varying lines of questioning, and the expected management against 
which performance was measured. According to the Government of India (GOI) and the 
Indian Pharmaceutical Association guidelines, community pharmacists should refer patients 
with symptoms indicative of TB for sputum examination. Further, under the Drugs and 
Cosmetic Rules 1945, which governs the sale of medicines from pharmacies, they should not 
sell medicines requiring a prescription. This act categorises medicines as either OTC or 
prescription only. POMs are then sub-classified as either H, H1 or X. Schedule H medicines 
require a prescription from a qualified doctor. The 46 H1 medicines are subject to an extra 
set of restrictions on dispensing - identity of the patient, contact details of the prescriber, and 
the name and dispensed quantity of drug must be recorded in a separate register. This 
schedule was introduced in 2013 in a bid to restrain the OTC over-use of medicines of public 
health concern (mainly antibiotics). Schedule X, which comprises a small group of 
medicines subject to abuse, including narcotics, is the most restrictive list and prescriptions 
for these medicines must be retained by the dispensing pharmacy for two years.  
In this study, the provision of antibiotics (including anti-TB medicines) and/or steroids were 
deemed to be ‘harmful’, in line with the research of Satyanarayana and colleagues (2016) 
(who also utilised SPs to investigate the management of TB at Indian pharmacies); 
unnecessary courses of antibiotics or incomplete or incorrect dosing regimens can lead to the 
62 
development of antibiotic resistance and steroids can mask TB symptoms and thus delay an 
accurate diagnosis.   
Surprisingly, there are no pharmacy-specific national or international guidelines for the 
management of diarrhoea. Considering one of the responsibilities of pharmacists in India is 
to treat minor ailments, guidelines aimed at ‘physicians and senior health workers’ were used 
for this non-complicated case of diarrhoea (World Health Organization 2005). WHO 
guidelines (adopted by GOI) advise that physicians should manage a 2 year old with acute 
diarrhoea (without blood) with oral rehydration solution (ORS), supplemental zinc, energy-
rich foods, and continued breast-feeding. Further, POMs should not be sold and antibiotics, 
antidiarrhoeals, and antispasdoics are considered harmful (ibid). Medicines that are not listed 
in the guidelines, yet are not recognised as ‘harmful’, have been categorised as ‘not 
recommended’ for the purpose of this research. For both cases presented by the SPs, 
pharmacy staff were expected to ask appropriate questions to confirm the diagnosis and to 
provide fitting advice. Appropriate history taking, treatment, and advice provision, all drawn 
from the relevant guidelines, are laid out in table 3.  
Table 3: Standardised patient case details and expected management 
Table reproduced from Miller and Goodman (2017) 
4.3.1.5 Training and piloting 
Six research assistants (one female and five male) were recruited from Bengaluru and trained 
as SPs. The SPs ranged in age from 20 to 45, with the average age being 31. The SPs were 
trained in a group by myself, with input from a local researcher, over the course of one week. 
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During the training, we spent time learning the standardised cases and going through the 
debrief questionnaire in detail. Role play has been shown to be a useful training tool for SPs 
(Goel et al. 1996) and as such a large proportion of the training time was spent rehearsing the 
scenarios in the classroom. All SPs spent time clarifying their back story and practised 
answering numerous possible questions relating to their personal situation. SPs did not start 
visiting the pharmacies in the sample until a number of pilots had been completed and a 
senior research assistant was satisfied that the standardised case was being presented as 
intended, in a convincing manner. During the training, the research team discussed how they 
should dress in order to ensure that they would appear of a similar social background to a 
typical customer who might present with these conditions.  
4.3.1.6 Data collection 
The SPs presented the pre-rehearsed scenario of the two tracer conditions in Kannada (the 
local language), during a single visit, at a random sample of 333 of Bengaluru’s pharmacies. 
These visits took place between May and June 2015. Other studies using standardised 
patients have tended to present one condition per pharmacy visit, but due to time and budget 
restrictions both were presented in one encounter (see Table 3 for the exact script). Any 
medicines recommended by the pharmacy staff were purchased. Following the consultation, 
the SPs were immediately debriefed by another researcher, using a structured questionnaire. 
The questionnaire covered details of the questions asked by pharmacy staff, referral 
instructions, medicines dispensed, and advice given. The price of each medicine and the 
overall price of the consultation were also recorded.  
4.3.1.7 Sampling 
On request, the Karnataka State Drug Control Department, based in Bengaluru, provided us 
with a list of all registered pharmacies in the Bengaluru urban district. Before using this list 
as a sampling frame, a census was conducted of pharmacies in three neighbourhoods in order 
to assess its accuracy. Local informants helped to identify three neighbourhoods with 
differing wealth profiles - broadly, a wealthy, a middle-income range, and a poor area with a 
large slum population. In one neighbourhood this work had already been conducted by a 
local research organisation (Institute of Public Health, Bengaluru), through their ‘urban 
health action research project’. One of their initial tasks was a private provider mapping 
exercise and they shared the details of this work with us. These censuses enabled us to verify 
of all the pharmacies identified; 97% were on the Government list (all pharmacies on the list 
were identified, although some addresses were not precise) and hence provided a 
comprehensive sampling frame.  
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Pharmacies on the list were then categorised as either ‘chain’ or ‘independent’. In the 
literature, chains are often defined as pharmacies with five or more outlets. Having spent 
time piloting in the city and spending time in pharmacies to get an understanding of how 
they worked, it was not clear that this definition fitted the context. In some instances, family 
members would own a few pharmacies, sometimes under the same name, but on visiting 
them it would not be clear that they had any links. Similarly, there were a few very small 
chains with more than 2 but fewer than 5 outlets that I felt should be classified as chains. In 
light of this, chains were defined as organisations where two or more pharmacies were 
operating under the same name and the business used distinctive branding across all outlets. 
From the list alone it was not possible to categorise all pharmacies and where there was 
uncertainty, phone calls or site visits were made, as appropriate, to verify the pharmacy’s 
status. The focus of this research was on retail pharmacies and therefore any pharmacies that 
could not be accessed from the street, including those operating in hospitals and clinics, were 
excluded. From the resulting list of 5135 independents and 529 chain outlets (from 13 
chains) a random sample of pharmacies was selected, stratified by pharmacy type ie chain or 
independent. The sample included outlets deriving from eight chains - seven of the city’s 
largest and one with fewer than five outlets. Table 4 provides information on the size of 
Bengaluru’s pharmacy chains and the breakdown of those included in the sample.  
Table 4: Size of pharmacy chains in Bengaluru and in sample 
Number of outlets Number of chains 
Number of chains in 
study sample 
Number of outlets in 
study sample 
2 to 5 6 1 1 
6 to 10 2 2 4 
11 to 50 2 2 6 
51 to 100 1 1 14 
101+ 2 2 78 
Of the 333 SP visits, 103 were at chain pharmacies and 230 at independents (figure 1). These 
numbers satisfied sample size calculations based on a level of significance of 0.05, 80% 
power, effect size of 0.2 (ability to detect a 20% difference in measurements of quality 
between pharmacy types) and a proportion of interest of 0.5 for the outcome of correct case 
management.  
65 
Figure 1: Geographical locations of chains and independents visited in standardised 
patient study 
4.3.1.8 Statistical analysis of data 
The performance of chains and independents was assessed by measuring adherence to case-
specific checklists of recommended care (presented in table 3). Data from the manual survey 
questionnaires was double entered into CSPro and from here, exported into Stata 14 for 
analysis. Data from the TB and diarrhoea cases were analysed separately, with the unit of 
analysis being the pharmacy. Adherence to items on recommended care checklists was 
treated as dependent variables and the independent variable was type of pharmacy (chain or 
independent). In an uncontrolled analysis, Pearson chi-squared tests were used to examine 
Independents 
Chains 
Key 
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the effects of pharmacy type on the various aspects of history taking, referral, treatment 
recommendations, and advice (all of which were treated as categorical binary variables). 
Price data from the SP survey were analysed at a later date, using Stata 15. Given that the 
price data were skewed, I looked at the difference in median price, interquartile range, and p 
value from the Wilcoxon rank sum test of the hypothesis of equal medians in chains and 
independents.  
4.3.2 Method 2: Exit interviews with clients 
4.3.2.1 Choice of data collection method 
Given the renewed concern for inequalities in health in LMIC and the need to understand the 
influence of poverty on health, there has been a growing interest in measuring 
socioeconomic status (SES) of health survey respondents in these settings (Boerma et al. 
2008, Gwatkin 2000, Howe et al. 2012).  Standard measures of SES tend to use data on 
income or expenditure but these indicators are both difficult to collect and are often 
inaccurate for reasons such as recall bias and seasonality (Montgomery et al. 2000, 
McKenzie 2005). As a result, it has become common practice to measure wealth by 
collecting data on variables that capture living standards, including assets (eg TV or 
motorbike) and housing characteristics (eg water source or roof material) (Vyas and 
Kumaranayake 2006, McKenzie 2005). Based on asset ownership, households are then 
organised into socioeconomic categories enabling calculation of relative, but not absolute, 
measures of poverty or wealth. This approach was deemed to be feasible and appropriate for 
measuring the wealth of pharmacy clients at both chain and independent pharmacies in the 
sample and comparing them with both each other and the general population.  
4.3.2.2 Sample and data collection 
Exit interviews were used to assess the socioeconomic and educational status of pharmacy 
clients shopping at chain and independent pharmacies. For this work, we used the same 
random sample of pharmacies used in the SP survey described above (although due to time 
restrictions we visited fewer of the independents). Following the completion of the SP 
survey, the pharmacies were visited a second time (researchers were allocated different 
pharmacies to those where they completed their SP visits). At each pharmacy, a member of 
the research team approached every client leaving the pharmacy and asked if they would be 
willing to take part in the research. After going through the information sheet and gaining 
written consent, the exit interview was administered to all those who agreed. This process 
was repeated until three questionnaires were completed at each outlet. In total, 808 exit 
interviews were completed, deriving from 103 chain outlets and 166 independent outlets. 
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The exit interview questionnaire collected data on personal characteristics, reasons for 
visiting the pharmacy, education history, and ownership of a number of assets.  
4.3.2.3 Data analysis 
To allow for a comparison of customers in my sample with the general population, data was 
collected on the same assets as those used by the most recent national District Level Health 
Survey (DLHS-4), a household survey powered at the district level. Data from ‘Bengaluru 
urban’, the district in Karnataka in which the exit interviews were conducted, were 
downloaded from the International Institute for Population Studies (IIPS) website. In order to 
limit the time needed to collect these data during the exit interviews, and hence improve 
participation, data was not collected on all assets in the DLHS-4, rather a subset of 14 assets 
relevant to the Bengaluru city context7. For example, interviewees were not asked about 
ownership of a tractor or cart driven by an animal as these are more applicable for rural 
areas. This has been shown to be a valid approach in both India and other contexts (Bassani 
et al. 2014, Chakraborty et al. 2016).  
The SES indices were derived using principal components analysis (PCA), a multivariate 
statistical technique that allows a large number of variables to be reduced into a small 
number of dimensions, in Stata 15 (Howe et al. 2012). Initially, the PCA was completed on a 
merged dataset (data from the DLHS-4 and the exit interview data), using a common set of 
assets, to assign standardised wealth scores to each individual (Vyas and Kumaranayake 
2006). Quintile cut-offs were then created, as described by Filmer and Pritchett (Filmer and 
Pritchett 2001), using only the DLHS-4 data. Finally, these cut-offs were applied to the exit 
interview customers, enabling us to examine the relative economic status of clients 
patronising chains and independents compared to the general population of Bengaluru urban 
district.  
In addition, the DLHS was also used to compare the educational status of pharmacy 
customers in my sample by pharmacy type and with the general population. In the DLHS-4 
survey, the ‘highest educational qualification attained’ was unclear for around a quarter of 
the data. Not wanting to use the wrong classifications for this large portion of the dataset, it 
was decided to use the earlier DLHS-3 (2007-8), which used clearer classifications, 
acknowledging the limitation that the DLHS-3 is less up-to-date. 
7 Refrigerator, telephone (landline) only, mobile phone only, sewing machine, tap/running water, 
radio, scooter/motorcycle, washing machine, car/jeep/van, watch/clock, computer without internet, 
computer with internet, cooler/AC, number of bedrooms 
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4.3.3 Method 3: In-depth interviews 
The methods described above were used to quantitatively measure various outcomes, such as 
quality of care and price of medicines, at chain and independent pharmacies. To complement 
this work I was interested to explore how and why being organised as a chain may affect the 
quality of service provision and prices of medicines, compared to independent pharmacies. 
Considering the complex nature of the phenomenon under study and the little that is 
currently known about the operation of different pharmacy arrangements, qualitative 
research methods were chosen to explore this in more detail. The qualitative work included 
in the literature reviews on performance of pharmacies and determinants of provider 
behaviour illustrated a level of detail regarding the operation of pharmacies and provider 
behaviour that could not be captured using quantitative approaches (cf Kamat and Nichter 
1998, Seeberg 2012, Chuc and Tomson 1999). It is increasingly acknowledged that 
qualitative research methods can make important contributions to health economics, due to 
their unique ability to aid understanding and provide explanation (Coast, McDonald, and 
Baker 2004).  
An understanding of our own epistemological approach allows for a better understanding of 
how our knowledge is produced. In this thesis I adopt an approach of ‘subtle realism’ which 
recognises that research involves subjective perception but that there is an underlying reality 
that can be studied (anti-realists reject this belief). Essentially, it is an attempt to represent 
that reality rather than to attain ‘the truth’ (Mays and Pope 2000). I acknowledge that in 
attempting to uncover the practices of pharmacy workers, there was a reliance on the 
participants’ own accounts of their practices, and the knowledge generated reflected the 
dynamic of the interview setting and both my characteristics and those of my research 
assistant’s. 
4.3.3.1 Choice of data collection method 
Semi-structured, in-depth interviews were selected as the instrument of choice because they 
allowed for in-depth exploration of pre-defined topics (Green and Thorogood 2013). As per 
the suggestion of Miles and Huberman, the interviews were used to test the hypotheses laid 
out in chapter 3, relating to the mechanisms by which quality, access and price are expected 
to vary (Miles and Huberman 1994). This framework informed both the development of the 
interview guides and the analysis, although it was not followed rigidly and I was open to any 
new ideas or issues that arose. The flexible nature of the semi-structured interview allowed 
for such discussions, whilst still ensuring that each interview covered comparable topics 
(Bernard 2017). 
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4.3.3.2 Sampling 
My aim was to speak to chain executives at all the chains included in the SP survey. Within 
those chains, I hoped to interview staff at some of the specific branches included in the 
survey (sampling described above). Two of the eight chains represented in the SP sample 
refused to participate in the qualitative research altogether. In two different chains, whilst a 
chain executive agreed to speak to us, they refused access to branch staff. This meant that we 
were denied access to the branch staff of four chains. However, many of the staff working in 
the branches of the four chains who did agree to participate in this part of the research had 
previously worked in the chains which denied us access. I interviewed these individuals 
about their experiences as ex-employees and through this mechanism ensured staff who had 
experience within all eight chains were interviewed. Two chains allowed me to choose the 
branches in which I wished to interview their staff, and the other two only approved 
interviews with employees in specified outlets. Independent owners were purposively 
chosen, from within the SP sample, to represent a geographical range across the city.  
4.3.3.3 Data collection 
Prior to commencing the interviews, a number of months were spent conducting the 
quantitative work within the research site, allowing for the development of understanding 
and familiarity with the research context (Malterud 2001, Reynolds et al. 2011). Interview 
questions were piloted with independent owners and the questions were updated accordingly. 
The interview guide was not piloted on chain staff due to the difficulty of recruiting chain 
participants (it was necessary to utilise all of the data collected). However, the questions 
were refined over the course of the research. Between 2014 and 2015 I conducted 38 in-
depth interviews with pharmacy employees and other relevant stakeholders in Bengaluru. 
These comprised 9 chain senior executives; 14 staff working within chain pharmacy 
branches; 12 independent pharmacy owners; and 3 key informants including the drug control 
department and pharmacy associations. Interviews were conducted by myself, with the help 
of a local research assistant, in English, Kannada or Hindi, depending on the interviewee’s 
preference. Where consent was given, interviews were tape-recorded to ensure an accurate 
record of the information collected from informants. In the instances where informants were 
not happy to be recorded, detailed notes were taken and written up shortly after.  
Interviews with chain senior executives explored the underlying business model, ethos and 
structure of different firms, with particular scrutiny of staff recruitment, salaries and 
incentives. I also sought to understand mechanisms employed for controlling quality, 
performance management, and relationships with drug control bodies. The interviews with 
staff working in chain branches focused on the incentives faced and motivations for working 
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in such a setting; their relationship with head office; and factors affecting their treatment 
behaviour. Several chain interviewees had previously owned their own shop and I questioned 
them about their experiences working in both environments. Interviews with independent 
pharmacy owners served as a comparison.  
4.3.3.4 Data analysis 
NVivo was used to aid the logistical aspects of analysis, and coding was completed using 
this package.  The hypotheses presented in chapter 3 were used to generate an initial set of 
pre-defined coding categories. In an iterative process, these codes were applied to the data, 
with data-generated codes added as they arose. Within the analysis, patterns of convergence 
were considered between differently situated interviewees and particular attention was paid 
to the interpretations of staff of different levels who worked at the same branches. 
Understanding that there is a difference between what people say and what people do, 
specific attention was paid to interviewees’ descriptions of their practices through specific 
examples. However, when discussing sensitive issues it was found to be helpful to ask about 
how other pharmacies acted because interviewees were sometimes reluctant to admit 
themselves to practices that would be frowned upon.  
The role of prior assumptions and the influence of personal characteristics, in particular 
being a Westerner and a pharmacist, on the data generated were considered throughout the 
research process (Reynolds et al. 2011). From the outset of data collection, I was aware of 
the need to reflect on aspects of my own position and perceived identity in the field. Over 
time I came to realise that this would also shape the way I presented myself, and perhaps 
more crucially, how my data was constructed with research participants. Ryan encourages a 
move away from the ‘insider’ ‘outsider’ dichotomy to focus on dynamic positionalities 
which enable a move beyond the ethnic lens, showing that gender, age and professional 
status, as well as nationality or ethnicity, serve as the basis for commonality (Ryan 2015). 
On reflection, I adopted multi-positionalities, which were informed by my everyday 
experiences in the field. Being a researcher from a London university appeared to aid access 
to some of the chain executives who may not have otherwise agreed to an interview. 
Similarly, the association SOCHARA reassured participants that I was not linked to any 
regulatory bodies or planning to set up a foreign chain- something several interviewees were 
initially concerned about. I introduced myself as a researcher, and did not highlight my 
training as a pharmacist, thinking this may reduce the likelihood of social desirability bias 
although, if asked, I happily shared the details of my academic background. 
The study tools and consent forms used for all the data collection methods are provided in 
Appendix 3. 
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4.3.4 Ethical approval 
Ethical approval was obtained from SOCHARA Institutional Scientific and Ethics 
Committee in Bengaluru, India and the London School of Hygiene and Tropical Medicine 
Ethics Committee, UK (see Appendix 4 for approval letters). For the SP study, approval 
from both institutions was received in order to waive obtaining informed consent from the 
pharmacies prior to the SP visits.  The main ethical concern with this method is that 
providers are essentially given false information. Madden and colleagues reflect on The 
Council for International Organizations of Medical Sciences (CIOMS) ethical guidelines 
which are supported by the WHO: (Council for International Organizations of Medical 
Sciences (CIOMS) 2011),  (Madden et al. 1997). CIOMS state that in instances where 
obtaining consent would frustrate the purpose of the study, researchers may be justified in 
abstaining from doing so. It is likely that obtaining consent for a particular SP encounter 
would introduce observation bias into the study. Further, the subject of the research is 
considered important enough to warrant such an approach. CIOMS also acknowledges that 
in the case of publicly available information consent is not required. Drug shop encounters 
lie somewhere on the continuum of public private behaviour but this is a grey area because 
the definition of ‘public’ used by CIOMS is unclear. Madden et al go on to examine the 
effects of the method (Madden et al. 1997). They acknowledge that, if made public, the data 
would be defamatory to the providers and income may suffer. As such, it was critically 
important to ensure anonymity. The opportunity cost of taking up staff time is another 
consideration, although the purchasing of medicines could be seen as a form of 
compensation for their time. Harm to the standardised patients themselves was deemed to be 
minimal. Visiting pharmacies, as opposed to physicians, removed the risk of them being 
offered invasive procedures or having medicines administered. There was, however, the 
possibility of an SP facing the hostility of a provider who believed the encounter to be a 
simulation. Although this did not occur, SPs were advised to remain non-confrontational at 
all times and to leave the premises were they to feel uncomfortable. Research assistants 
travelled in pairs for safety; one conducted the SP visit and the other waited nearby and 
administered the debrief questionnaire following the encounter. 
For the exit interviews with customers, each participant was given an information sheet in 
Kannada and English which covered the objectives of the research and explicitly stated that 
participation was voluntary and anonymous. Written consent was obtained from all 
participants in advance of administering the questionnaire. Research assistants were trained 
to ensure that potential interviewees leaving the pharmacy were not too unwell/in pain to 
participate or taking medicines to a critically ill patient. For the qualitative interviews, 
interviewees were also given an information sheet and then verbal consent, witnessed by a 
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fieldworker, was obtained prior to all interviews. Verbal, as opposed to written, consent was 
obtained because providers in many drug outlets (or chain headquarters) tend to be very 
cautious of inspectors and suspicious of having to sign documents that may be used to 
identify them or their outlet/company. Interviews were not expected to cause any harm or 
distress to participants but it was made clear to interviewees that they were not obligated to 
answer any questions and could end the interview at any time.  
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PART III: RESULTS 
5 Quality of case management 
5.1 Introduction  
This chapter presents the first results paper entitled “Do chain pharmacies perform better 
than independent pharmacies? Evidence from a standardised patient study of the 
management of childhood diarrhoea and suspected tuberculosis in urban India”. It utilises 
standardised patient methodology to address objective A (comparing the quality of case 
management at chain and independent pharmacies). The paper was published in BMJ Global 
Health in September 2017. The Supplementary material for this paper can be found in 
Appendix 5.  
The first 3 pages describe the rationale for the research and the methods, as was covered in 
the previous chapters. The results, which have not yet been addressed in this document, 
begin on page 4 of the paper.  
5.2 Research paper 2 
(Cover sheet on next page). 
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Introduction Pharmacies and drug stores are frequently 
patients’ first point of care in many low-income and 
middle-income countries, but their practice is often 
poor. Pharmacy retailing in India has traditionally been 
dominated by local, individually owned shops, but recent 
years have seen the growth of pharmacy chains. In theory, 
lower-powered profit incentives and self-regulation to 
preserve brand identity may lead to higher quality in chain 
stores. In practice, this has been little studied.
Methods We randomly selected a stratified sample of 
chain and independent pharmacies in urban Bengaluru. 
Standardised patients (SPs) visited pharmacies and 
presented a scripted case of diarrhoea for a child 
and suspected tuberculosis (TB). SPs were debriefed 
immediately after the visit using a structured 
questionnaire. We measured the quality of history 
taking, therapeutic management and advice giving 
against national (Government of India) and international 
(WHO) guidelines. We used Pearson’s χ2 tests to 
examine associations between pharmacy type and case 
management.
Findings Management of childhood diarrhoea and 
suspected TB was woefully substandard. History taking of 
the SP was limited; unnecessary and harmful medicines, 
including antibiotics, were commonly sold; and advice 
giving was near non-existent. The performance of 
chains and independent shops was strikingly similar for 
most areas of assessment. We observed no significant 
differences between the management of suspected TB 
in chains and independents. 43% of chains and 45% 
of independents managed the TB case correctly; 17% 
and 16% of chains and independents, respectively, sold 
antibiotics. We found that chains sold significantly fewer 
harmful antibiotics and antidiarrhoeals (35% vs 48%, 
p=0.029) and prescription-only medicines (37% vs 49%, 
p=0.048) for the patient with diarrhoea compared with 
independent shops. Not a single shop managed the patient 
with diarrhoea correctly according to guidelines.
conclusion Our results from Bengaluru suggest that it 
is unlikely that chains alone can solve persisting quality 
challenges. However, they may offer a potential vehicle 
through which to deliver interventions. Future intervention 
research should consider recruiting chains to see whether 
effectiveness of interventions differ among chains 
compared with independents.
IntroductIon
It has been widely established that the care 
received from pharmacies in many low-income 
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Key questions
What is already known about this topic?
 ► It is widely reported that pharmacy practice in many
low-income and middle-income countries (LMICs)
is substandard.
 ► Chain pharmacies are expanding in India and other
LMICs.
 ► Economic theory predicts that chains may positively
affect quality, but very little is known about this in
practice in pharmacy markets.
What are the new findings?
 ► Quality of care for childhood diarrhoea and
suspected tuberculosis, as measured by ideal
case management of standardised patients and
adherence to recommended history-taking and
advice-giving lists, was found to be equally poor in
chains and independent pharmacies in Bengaluru, 
India.
 ► Chains sold significantly fewer prescription-only
medicines and those deemed ‘harmful’ for the
patient with diarrhoea, compared with independent
shops.
recommendations for policy
 ► Introduction of chains alone is unlikely to address
quality challenges in this context. 
 ► Interventions to improve effectivess should be
delivered through chains to see whether they yield
different results compared to individual shops.
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and middle-income countries (LMICs) is inadequate, 
despite frequently being patients’ first point of contact 
with the healthcare system.1–3 All too often, medicine use 
in these settings is ‘irrational’. That is, patients do not 
receive the appropriate medicines, in doses that meet 
their individual requirements, for an adequate duration, 
and at the lowest cost.4 Irrational medicine use is a major 
public health concern, which contributes to unneces-
sary morbidity and mortality; fuels the growing threat 
of antimicrobial resistance (AMR); and leads to need-
less spending.5 AMR has garnered particular interest of 
late. WHO has declared it a ‘global health security emer-
gency’, and 193 heads of states and governments have 
pledged to address the concern through a UN declara-
tion.6 7 In approaches to prevent the situation worsening, 
pharmacies should arguably be a key focus.
In recent years, there has been a growing interest in 
pharmacy chains in LMIC contexts.8–10 India, in partic-
ular, has seen prolific expansion of the corporate phar-
macy retail sector.9 In theory, there are reasons to believe 
that chains may positively influence key determinants of 
treatment behaviour, notably the regulatory environment 
and profit incentives faced by staff.3 The fragmented 
nature of retail pharmacy in India makes enforcing regu-
lation costly and logistically difficult. Through consolida-
tion, chains could improve regulation in two ways. State 
regulation can be concentrated on central management 
structures; essentially, the regulator can make firms 
take responsibility for local branches. Second, firms 
may self-regulate in order to preserve brand identity.11 
Another reason why quality may improve in a chain situ-
ation concerns incentive structures. Financial incentives 
faced by pharmacy-level personnel working in chains 
are low powered compared with those who own their 
own pharmacy and directly receive the profits of trans-
actions.12 Independent shopkeepers may therefore face 
stronger incentives to engage in irrational medicine use, 
such as selling unnecessary or prescription-only medi-
cines (POMs) without a prescription, where this increases 
their profits.
The question of whether this organisational structure of 
the pharmacy firm affects quality of care remains largely 
untouched by empirical research studies in LMIC. Studies 
from high-income countries report on a wide range of 
outcomes,13–15 but given the strength of regulation in 
high-income contexts, the findings are likely to have 
limited applicability in LMICs. Two studies from Mexico 
report on the sale of misoprostol (to induce abortion). 
One found that chains were less likely to sell misoprostol 
compared with independent shops,16 while the other 
found no significant differences.17 Others examined the 
effect of chain store entry on prices and drug quality in 
the retail pharmacy market in Hyderabad, India, but did 
not assess therapeutic management of patients.18
To address this gap in the literature, this paper reports 
on a study from Bengaluru, South India, which used 
standardised patients (SPs), often considered the ‘gold 
standard’ for quality of care measurement,19 to assess the 
case management of two conditions, in a representative 
sample of chain and independent pharmacies. Symptoms 
of these conditions are commonly presented in pharma-
cies, represent a high burden of disease and are subject 
to key quality concerns in relation to underprovision and 
overprovision of treatment.
Methods
study setting and design
Pharmacy chains are concentrated in populous cities, 
with the greatest concentration in South India. This 
guided the selection of Bengaluru, the capital of Karna-
taka State and India’s third most populous city, as the 
study site.
We used a cross-sectional SP survey to investigate the 
management of suspected tuberculosis (TB) in an adult 
and acute watery diarrhoea in a 2 year old (who was 
not present). WHO recommends non-bacterial diar-
rhoea in children under age 5 as a tracer condition for 
measuring quality of care. Other health problems that 
are either frequently presented or of particular clinical 
or economic importance are also deemed appropriate 
provided that there are clear treatment guidelines.20 21 
In India, TB meets these criteria.22 23 These conditions 
also represent contrasting examples of recommended 
management—pharmacies should refer a suspected TB 
case, whereas diarrhoea is commonly wholly treatable in 
the pharmacy environment.
We trained six research assistants (one female and five 
males) as SPs to visit chain and independent pharmacies. 
SPs were recruited from Bengaluru where the study was 
undertaken. The average age was 31, the youngest being 
20 and the oldest 45. The individuals were trained (in 
a group) by RM (with input from a local researcher) 
over a period of 1 week. Training included learning the 
cases, including much role play, and running through 
the debrief questionnaire in the classroom. All SPs also 
ran through the details of their back-story and practised 
answering questions relating to their personal situation, 
as well as the presentation of the medical case. Each SP 
completed a number of pilot presentations in the field, 
under the supervision of a senior research assistant, until 
we were confident that the cases were being presented 
in a standardised, convincing manner. It was discussed 
among the research team how they should dress to 
ensure their social background appeared similar to a 
typical customer who might present such cases.
The SPs presented a rehearsed, scripted scenario, 
in Kannada (the local language), of both conditions, 
during a single visit, at a random sample of pharmacies. 
SPs purchased any recommended medications. Immedi-
ately after each pharmacy visit, they were debriefed using 
a structured questionnaire. We measured the quality of 
case management based on national and international 
guidelines. For the TB case, we used Government of 
India (GOI) and the Indian Pharmaceutical Association 
guidelines for community pharmacists.23 In the absence 
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Table 1 Standardised patient case details and expected management
Case details Expected management
Case description Details of scenario History Treatment Advice
Acute watery diarrhoea 
in a child
“I need to buy 
something for my niece 
who has diarrhoea. She 
is 2 years old?”
Further questioning 
would reveal:
► Four episodes during
the last day;
► More thirsty than
usual;
► May have had a
slight fever;
► No blood in the stool,
abdominal pain or
vomiting;
► No medication had
been taken.
Pharmacy server to ask:
► Blood in stool?
► Duration of
diarrhoea?
► Number of stools per
day?
► Number of episodes
of vomiting?
► Presence of fever?
► Preillness feeding
practices?
► Type of fluids and
foods during illness?
► Child passing urine?
► Tried any
medication?
► Oral rehydration
therapy using ORS
solution;
► Zinc
supplementation;
► No sale of
antidiarrhoeals,
antibiotics or
antispasmodics.
► Explain how to use
ORS;
► Importance of more
fluids;
► Usual diet should be
continued (including
milk);
► Take to health
worker if signs of
dehydration or
other problems, for
example, blood in
stool.
Suspected pulmonary 
tuberculosis in an adult
On completion of 
diarrhoea advice: “Also 
for myself… I have 
had cough and some 
fever for 3–4 weeks. We 
have had a relative 
staying with us who has 
TB. Can you suggest 
something?”
Further questioning 
would reveal:
► Sputum in the
cough;
► Sweating at night;
► Loss of appetite;
► No medication had
been taken.
Pharmacy server to ask:
► Consulted doctor?
► Chest pain?
► Sputum or blood in
cough?
► Weakness or
fatigue?
► Weight loss?
► Loss of appetite?
► Chills?
► Night sweats?
► Any other
symptoms?
► Tried any
medication?
► Referral to TB clinic
or other healthcare
provider for sputum
examination;
► No sale of antibiotics
(including anti-TB
medication) or
steroids.
► Advise that treatment
is available free
of charge from
government
hospitals.
ORS, oral rehydration salts; TB, tuberculosis.
of any pharmacy-specific Indian or international guide-
lines for the management of diarrhoea, we based our 
assessment on WHO guidelines (also adopted by GOI) 
aimed at ‘physicians and other senior health workers’.24 25 
These can be argued to be appropriate for pharmacy 
staff as India’s ‘Pharmacy Practice Regulations’ include 
as responsibilities of community pharmacists ‘selling 
over-the-counter medicines; counselling and advising 
the public on the treatment of minor ailments’,26 and 
the diarrhoea case presented here can be considered a 
minor ailment.
cases
Table 1 provides an overview of the cases, how the SPs 
presented them and the expected course of action against 
which we measured their management. According to the 
guidelines, community pharmacists should refer patients 
with symptoms suggestive of TB for sputum examination. 
They should not sell medicines that require a prescrip-
tion. The sale of medicines from Indian pharmacies is 
governed by the Drugs and Cosmetic Rules 1945. Under 
this act, medicines are categorised as over-the-counter 
(OTC) (no schedule) or prescription-only. There are 
three levels of POMs: H, H1 and X. Schedule H medi-
cines require a prescription from a qualified practitioner. 
Schedule H1 was introduced in 2013 to curb OTC use of 
certain POM medicines (mainly antibiotics). The 46 H1 
medicines are subject to an extra set of conditions on 
dispensing (identity of the patient, contact details of the 
prescriber and the name and dispensed quantity of the 
drug must be recorded in a separate register). Schedule 
X is the most restrictive list, comprising a small number 
of narcotics, for which the pharmacy is required to retain 
the prescription for 2 years.
We considered provision of antibiotics (including 
anti-TB medicines) and/or steroids as ‘harmful’, in 
line with Satyanarayana and colleagues; incomplete and 
unneeded courses of antibiotics could lead to emer-
gence of resistant strains and steroids could mask the 
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Table 2 Size of pharmacy chains in Bengaluru and in 
sample
Outlets (n) Chains (n)
Chains in our 
sample (n)
Outlets in our 
sample (n)
2–5 6 1 1
6–10 2 2 4
11–50 2 2 6
51–100 1 1 14
101+ 2 2 78
symptoms leading to delayed diagnosis.27 A 2-year-old 
child with diarrhoea should be managed with oral rehy-
dration therapy (ORT), supplemental zinc and continued 
feeding of energy-rich foods and breast feeding. Again, 
POMs should not be sold, and in this case, antibiotics, 
antidiarrhoeals and antispasmodics are categorised as 
‘harmful’.25 28 We term medicines not listed in the guide-
lines yet not deemed ‘harmful’ as ‘not recommended’. 
For both cases, we expect pharmacy staff to ask questions 
to confirm the diagnosis and determine appropriate 
treatment and to provide advice.
selection of pharmacies and sample size
We obtained a list of all pharmacies registered in the 
Bengaluru urban district from the Karnataka State Drug 
Control Department. To check the comprehensiveness 
and validity of this list, we completed censuses in three 
neighbourhoods with differing wealth profiles (according 
to local informants). This exercise confirmed that the list 
provided a comprehensive sampling frame (97% accu-
rate). From the list, we then categorised pharmacies 
as either ‘independent’ or ‘chain’. We defined chains 
as organisations where two or more pharmacies were 
operating under the same name and the business used 
distinctive branding across all pharmacies. We excluded 
pharmacies operating inside hospitals or clinics, which 
customers could not access from the street. The resulting 
list contained 5135 independents and 529 chains shops 
deriving from 13 chains (table 2). Subsequently, we 
selected a random sample of pharmacies, stratified by 
type: chain or independent. Our sample included shops 
from eight chains: the largest seven and one chain of the 
2–5 outlet size (details in table 2).
Between May and June 2015, SPs visited 333 phar-
macies across Bengaluru (103 chains and 230 indepen-
dents) and presented both cases at each pharmacy. These 
figures satisfy sample size calculations based on a level 
of significance of 0.05, 80% power, effect size of 0.2 (ie, 
can detect a 20% difference in quality measurements 
between pharmacy types) and a proportion of interest of 
0.5 for the outcome of correct case management.
statistical analysis
We used STATA 14 to analyse the two disease cases sepa-
rately. The unit of analysis was the pharmacy. We used 
Pearson’s χ2 tests to examine the effects of pharmacy 
type (chain vs independent) on history taking, treatment 
recommendations and advice.
ethical approval
The London School of Hygiene and Tropical Medi-
cine Ethics Committee in London, England, and the 
Society of Community Health Awareness Research and 
Action Institutional Scientific and Ethics Committee 
in Bengaluru, India, approved the study. We specifi-
cally sought and received approval to waive obtaining 
informed consent from the pharmacies prior to the SP 
visits.
results
We present the results of the SP survey according to the 
three key aspects of case management specified in table 1.
history taking
Questioning of SPs by pharmacy staff was generally poor 
(table 3), with no significant differences in history taking 
at chain and independent pharmacies. Less than 10% of 
chains and independents asked a single recommended 
question regarding the diarrhoea case. This figure was 
slightly higher for suspected TB with 17% of chains and 
23% of independents asking at least one relevant ques-
tion.
Recommended questions for the suspected TB case are 
primarily to confirm the diagnosis. The most commonly 
asked question was regarding the presence of blood or 
sputum on coughing, asked by 12% of chains and 13% 
of independents. Less than 5% of chains and indepen-
dents asked about action already taken or other ques-
tions to determine diagnosis including the presence of 
night sweats, pain in the chest, fatigue or any other symp-
toms. No shops asked about weight loss, loss of appetite 
or chills.
Correct questioning of the diarrhoea case would rule 
out a more serious underlying condition warranting 
referral for medical attention. No more than 5% of 
chains or independents asked any recommended ques-
tions. Not a single shop made enquiries regarding reme-
dies already taken, fluid and food intake of the child 
either before or since falling ill or the presence of blood 
in the stool.
therapeutic management
Figure 1 (and online supplementary appendix A1 for 
corresponding table) shows that SPs received correct 
management of the suspected TB case in 43% and 
45% of chain and independent shops, respectively. We 
observed no significant differences between the thera-
peutic management of suspected TB in chains and inde-
pendents. In terms of harmful medicines, shops rarely 
gave steroids, but 16% of chains and independents sold 
antibioticsi. A large proportion of chains and independ-
ents sold medicines that are not recommended for the 
treatment of TB: 63% and 62%, respectively. Over 50% 
i Top five antibiotics sold for suspected TB case: (1) amoxicillin; 
(2) azithromycin; (3) ciprofloxacin; (4) levofloxacin; (5) erythromycin.
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Table 3 History taking in chain and independent pharmacies when presented with cases of suspected TB and diarrhoea
Case Recommended questions
Chain (n=103)
% (95% CI)
Independent (n=230)
% (95% CI) p Value*
Suspected TB Consulted a doctor? 1.9 (0.5 to 7.5) 3.5 (1.7 to 6.8) 0.448
Chest pain? 1.0 (0.13 to 0.67) 2.6 (1.2 to 5.7) 0.336
Sputum or blood in cough? 11.7 (6.7 to 19.5) 13.5 (9.6 to 18.6) 0.646
Weakness or fatigue? 0 0.9 (0.2 to 3.4) 0.342
Weight loss? 0 0
Loss of appetite? 0 0
Chills? 0 0
Night sweats? 1.0 (0.1 to 0. 7) 1.7 (0.7 to 4.6) 0.594
Any other symptoms? 4.9 (2.0 to 11.2) 1.7 (0.7 to 4.6) 0.105
Tried any medication? 0 1.7 (0.7 to 4.6) 0.178
Asked any recommended 
questions?
16.5 (10.5 to 25.0) 22.6 (17.7 to 28.5) 0.204
Diarrhoea Blood in stool? 0 0
Duration of diarrhoea? 3.9 (1.5 to 10.0) 4.4 (2.4 to 7.9) 0.845
Number of stools per day? 4.9 (2.0 to 11.2) 2.2 (0.90 to 5.1) 0.185
Number of episodes of 
vomiting?
1.9 (0.5 to 7.5) 3.9 (2.0 to 7.4) 0.352
Presence of fever? 0 0.9 (0.2 to 3.4) 0.342
Preillness feeding practices? 0 0
Type of fluids and foods 
during illness?
0 0
Child passing urine? 0 0.4 (0.1 to 3.1) 0.503
Tried any medication? 0 0
Asked any recommended 
questions?
9.7 (5.3 to 17.2) 9.1 (6.0 to 13.6) 0.867
*Estimated by Pearson’s χ2 test.
of both shop types sold a schedule H medicine, although 
chains did not sell any of the more restricted H1 drugs. 
Seven independent shops (3%) sold H1 medicines (all 
of which were antibiotics). It is notable that not a single 
shop sold first-line anti-TB medicine. Figure 2 shows, of 
medicine sales, the proportion accounted for by each 
medicine category. The results are strikingly similar for 
chains and independents. Almost two-thirds of medicines 
sold were cold and/or cough preparations. The second 
and third most commonly sold medicines were antibi-
otics and antiasthma drugs, respectively.
No shops managed the case of childhood diarrhoea 
according to current guidelines (figure 3 and online 
supplementary appendix A2 for corresponding table). 
Further, no shops sold oral rehydration salts (ORS) 
and zinc together. The sale of zinc was extremely rare, 
recommended by only two chain shops (2%) and no 
independents (p=0.034). Only 12% of chains and 10% 
of independents sold ORT and in exactly half of these 
sales; this was alongside harmful medicines. A total of 
33% of chains and 42% of independents sold antibiotics. 
Antidiarrhoeal use was also higher in independents, 7% 
vs 2% for chains. Both antibiotics and antidiarrhoeals 
are considered harmful in the management of this case, 
and chains were found to sell significantly fewer of this 
combined category of harmful medicines (35% vs 48%, 
p=0.029). Antibioticsii or antidiarrhoeals accounted for 
nearly all the schedule H medicines sold; thus, we see 
significantly fewer chains selling schedule H medicines 
(37% vs 49%, p=0.045). H1 category medicine was sold 
by one independent pharmacy and no chains. A quarter 
of chains and 22% of independents sold treatments that 
are not recommended for diarrhoea. Although non-bac-
terial diarrhoea can be managed in the pharmacy, 41% 
of chains and 37% of independents referred the child to 
a doctor.
Of medicines sold for the patient with diarrhoea, 
worryingly, antibiotics made up the largest proportion 
for both chains and independents, 45% and 52%, respec-
tively (figure 4). Prebiotics and probiotics were popular, 
accounting for 32% of sales in chains and 26% in 
ii Top five antibiotics sold for diarrhoea case: (1) metronidazole+nor-
floxacin; (2) ofloxacin; (3) ofloxacin+ornidazole; (4) ofloxacin+metro-
nidazole; (5) metronidazole.
group.bmj.com on September 26, 2017 - Published by http://gh.bmj.com/Downloaded from 
83
6 Miller R, Goodman C. BMJ Glob Health 2017;2:e000457. doi:10.1136/bmjgh-2017-000457
BMJ Global Health
Figure 1 Therapeutic management of suspected TB case by independent and chain pharmacies (see online supplementary 
appendix A1 for corresponding table). p Values were estimated using Pearson’s χ2 test. †Correct case management defined as 
referral without sale of any ‘harmful’ medicines (antibiotic or steroids). ‡We define ‘not recommended’ medicines as those not 
listed in the guidelines yet not deemed ‘harmful’. They include cough and/or cold medicines, analgesics and antiacid. 
Figure 2 Breakdown of medicines sold for suspected TB case by outlet type. May not add to 100% due to rounding. TB, 
tuberculosis.
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Figure 3 Therapeutic management of diarrhoea case by independent and chain pharmacies (see supplementary appendix 
A2 for corresponding table). p Values were estimated using Pearson’s χ2 test. †Correct case management defined as provision 
of ORS and zinc and no ‘harmful’ medicines (antibiotics, antidiarrhoeals or antispasmodics). ‡‘Not recommended’ medicines 
include prebiotics and probiotics, analgesics, antihelminitic and antiallergy. *Statistically significant at the 5% level. ORS, oral 
rehydration salts.
independents. ORT only accounted for 16% and 12% of 
sales in chains and independents, respectively.
We also demonstrated that the findings for treatment 
were unaffected after adjusting for any SP-specific effects 
(online supplementary appendix A3, 4).
Advice giving
Advice giving was uniformly limited. Only a handful of 
shops advised patients that TB treatment was available 
free of charge from the government (table 4). General 
advice for the fictitious child with diarrhoea was close to 
non-existent. While 41% of chains and 37% of independ-
ents referred the childhood diarrhoea case in the first 
instance, of the remaining shops, less than 1% of both 
shop types advised the SP to seek medical attention if 
they noticed any warning signs. One independent and 
no chains explained the importance of giving the child 
extra fluids to prevent dehydration. Advice regarding 
diet was similarly poor, given by 0.95% of chains and 
1.75% of independents. We only observed one significant 
difference in terms of advice giving. Of shops that did sell 
ORS, chains were found to offer an explanation of how 
to make up and use the solution in a larger proportion of 
interactions, 56% vs 10% for independents. The absolute 
numbers that provided ORS were, however, low.
dIscussIon
To our knowledge, this is the first study to compare the 
quality of all aspects of case management at chain and 
independent pharmacies for any condition in an LMIC 
setting. Using SPs provides an accurate picture of how 
pharmacy staff manage these conditions in everyday 
life, and the standardised presentation allows for direct 
comparison across pharmacies.29 Our results showed that 
the management of both cases did not live up to national 
or international standards, in either chains or independ-
ents. In terms of history taking, there were no significant 
differences between pharmacy types for either condition, 
and the level of questioning by pharmacy staff would not 
have elicited the required information to manage the SPs 
appropriately. We observed no significant differences in 
therapeutic management of the patient with suspected 
TB. Fewer than half of both shop types managed the case 
correctly by referring without selling any harmful medi-
cines. The one other SP study that has investigated how 
pharmacies respond to TB in India showed that anti-
biotic use substantially decreased when SPs presented 
with a known diagnosis, as opposed to just symptoms.27 
In our scenario, while SPs did not present with a medi-
cally confirmed diagnosis, they mentioned contact with 
an infected individual and hence a suggestion that they 
might have TB. This is more in line with a known diag-
nosis and our results are therefore likely presenting phar-
macy behaviour at the more positive end of the spectrum. 
As with all SP studies, our results reflect how pharmacies 
manage an unknown individual, and we cannot be sure 
this is the same as for regular customers.
Therapeutic management of the diarrhoea case was 
even worse than that of suspected TB. No pharmacies 
managed the case correctly. Chains did, however, sell 
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Figure 4 Breakdown of medicines sold for diarrhoea case by outlet type.
Table 4 Advice giving by chain and independent pharmacies
Case Advice
Chain (n=103)
% (95% CI)
Independent (n=230)
% (95% CI) p Value*
Suspected TB Treatment available free of charge from 
government hospital
1.0 (0.1 to 6.7) 1.7 (0.7 to 4.6) p=0.594
Diarrhoea Advised to visit doctor if any warning signs† 1.0 (0.1 to 6.7) 0.9 (0.2 to 3.4) p=0.928
Explained importance of giving extra fluids 0 0.5 (0.1 to 3.1) p=0.503
Gave advice regarding diet 1.0 (0.1 to 6.7) 1.8 (0.7 to 4.6) p=0.594
Chain (n=9) Independent (n=20)
Explain how to make up and use ORS? (of 
those providing)
55.6 (22.5 to 84.3) 10.0 (2.3 to 34.7) p=0.008*
*Estimated by Pearson’s χ2 test.
†This indicator excludes pharmacies that referred the patient to a medical practitioner as an initial course of action (see figure 2 for these
data).
ORS, oral rehydration salts.
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significantly more zinc and fewer medicines categorised 
as harmful. This translated into chains selling significantly 
fewer schedule H medicines. Advice giving was almost 
non-existent in both types of pharmacies. The lower sales 
of POMs for the patient with diarrhoea translated into 
significantly reduced cost of the diarrhoea consultation 
in chains compared with independent shops (draft in 
preparation). Further, given that patients are paying for 
their medicines out of pocket when seeking care at the 
pharmacy, we must note the unnecessary spending on 
both ‘not recommended’ and ‘harmful’ medicines.
The use of H1 medicines was scarce for both cases, 
but it is worth highlighting that not a single chain sold a 
medicine of this category (compared with eight indepen-
dents). This is an important finding, which corroborates 
the research of Satyanarayana and colleagues who report 
that pharmacies in other Indian cities (Mumbai, Patna 
and Delhi) also did not sell any first-line anti-TB medi-
cines when presented with an SP.27 Adherence to restric-
tions on the prescription of H1 medicines appears to be 
a positive finding for TB control efforts.
This study also brings to our attention the lack of guid-
ance for the treatment of minor ailments in the Indian 
(and other LMIC) pharmacy setting and highlights the 
grey area of how the management of conditions such 
as diarrhoea should be assessed. Considering the high 
proportion of childhood deaths accounted for by diar-
rhoea in India and the high utilisation of pharmacies, the 
development of pharmacy-specific treatment guidelines 
seems long overdue.
We report results from one city, raising the question 
of whether the findings are generalisable to other urban 
centres where chains operate. While other research has 
not focused on chains, our results add to a growing body 
of research in other areas of India that has used SP to 
assess quality of care for both pharmacies and other 
primary healthcare providers, including for childhood 
diarrhoea and TB. These other studies have shown 
quality of case management to be ubiquitously poor, 
regardless of whether patient first contact is with a phar-
macy, a medically qualified practitioner or an unqual-
ified, informal provider.27 30–32 Many of the chains in 
Bengaluru also operate in other Indian cities, where they 
would be likely to face similar incentives. Pharmacies 
across India operate under the same regulatory controls, 
and despite potential state-level variations in regulatory 
implementation, regulatory failure has been reported to 
be widespread across the country.33–37 Moreover, reviews 
have found striking similarities in the determinants of 
pharmacy provider behaviour in LMIC across countries 
and even continents,3 38 39 meaning that these results are 
potentially applicable to other LMIC settings with similar 
regulatory challenges. Other LMICs that have either an 
established or growing corporate pharmacy retail sector 
include Mexico, South Africa, Nigeria, Kenya, Uganda 
and the Philippines.8–10 Further study would be worth-
while to determine whether differences exist in other 
settings, where the business models for chains may differ.
While we report the results from the suspected TB and 
diarrhoea scenarios separately, SPs presented the details 
of the cases in a single encounter at each pharmacy, 
rather than the more common approach of using sepa-
rate interactions. Treatment results are in keeping with 
other studies that presented one of these conditions as 
a standalone case at pharmacies in India.27 40 We, there-
fore, have no reason to believe that pharmacy staff acted 
differently because SPs presented both cases in a single 
client interaction.
While no other studies have compared chain and 
independent pharmacies in terms of quality of care in 
an LMIC setting, Bennet and Yin examined the effect of 
chain store entry on prices and drug quality in Hyder-
abad, India.18 Through collaboration with a pharmacy 
chain, they gathered baseline data in markets the firm 
wished to enter and later resurveyed markets 1 year 
after market entry. The paper reported that, compared 
with independent retailers, chain prices were 6% lower 
and pharmacopoeia compliance (drug quality) was 6% 
higher. The resulting effect of chain entry on the market 
was a relative 5% improvement in drug quality and a 2% 
decrease in prices at existing retailers. If chain entry had 
led to similar spill over quality improvement effects in 
our study site, this would imply that our measured effect 
of a chain on quality would be biased towards zero. We do 
not have sufficient geographical data in order to deter-
mine whether the presence of a chain shop nearby alters 
the behaviour of independents, though this would be an 
interesting area for future research. However, a review of 
pharmacy practice in Asia reported similar management 
for various presentations of childhood diarrhoea going 
back 30 years, that is, before the advent of chains, indi-
cating that major changes in the behaviour of indepen-
dents do not appear to have occurred in recent times.3
The main difference between pharmacy types 
observed was the lower use by chains of harmful POMs 
for the patient with diarrhoea. There is evidence that 
some of these POMs, such as antibiotics, are high 
profit generators.41–43 Lower-powered financial incen-
tives faced by chain staff may explain a reduction in 
their use. Through in-depth interviews with chain and 
independent staff that we completed as a complement 
to this SP survey, we have been able to gain a more 
in-depth understanding of the behaviour of chains and 
independents (draft in preparation). We found that 
chain staff were heavily incentivised through a combi-
nation of sales targets and pressure from head-office 
and hence the incentives they faced were, in fact, not 
low powered. Additionally, these interviews revealed 
that profit-maximising strategies of chain employees 
tended to focus on improving customer experience, 
whereas independent owners focused on medicines 
sales. In addition to profit concerns, knowledge and 
regulation have also been shown to be important deter-
minants of pharmacy practice. Our qualitative work 
showed that stronger penalties for the provision of the 
more restricted medicine schedules have been effective 
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and some chains have instigated processes to ensure 
these rules are not broken (ibid). Chains use a number 
of methods to self-regulate and are able to control staff 
practices, but their main area of concern is customer 
satisfaction, rather than rational medicine use. Only a 
minority of chains had measures to monitor the sale 
of POMs at their outlets. In terms of knowledge, there 
appears to be little difference between knowledge of 
those working in chain and independent pharmacies. 
Even were there to be differences, it is well established 
that there is a large gap between what providers know 
and what they do in India, indicating that knowledge 
is necessary but not sufficient to ensure best prac-
tice.27 30–32 44
Our results provide a starting point for investigating 
how the organisation of the pharmacy firm affects 
provider behaviour in an LMIC setting. We did find 
small differences between the behaviour of chain staff 
and independent pharmacy owners. However, chains 
were far from fully addressing the quality deficiencies 
observed in the retail pharmacy sector, and it is unlikely 
that chains alone are going to solve persisting quality 
challenges. However, they may offer a potential vehicle 
through which to deliver interventions. Intervention 
initiatives reported in the literature include training, 
intensification of regulatory controls, peer review and 
accreditation.45–47 Some strategies, such as peer review 
and performance management, may have more impact 
within the structure of a chain. ‘League tables’ and 
‘naming and shaming’ have been used in high-income 
settings to influence prescribing behaviour of doctors 
working within a common organisation.48
conclusIon
The performance of chains and independent shops was 
equally poor for most areas of assessment. Our results 
indicate that, while in theory chains have the potential 
to improve treatment behaviour, in practice, they are 
unlikely to offer a magic bullet solution. However, impor-
tantly, we found that chains sold fewer prescription-only 
and harmful medicines to the patient with diarrhoea 
and successfully self-regulated the sale of H1 medicines. 
Future intervention research should consider recruiting 
chains to see whether intervention effectiveness differs 
among chains compared with independents.
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6 Price and socioeconomic status of clients 
6.1 Introduction 
This chapter presents the second results paper entitled “Cheaper medicines for the better off? 
A mixed methods study of medicine price and socioeconomic status of clients in chain and 
independent retail pharmacies in urban India”. It draws on both the standardised patient 
survey and the key informant interviews to address objective B (to compare the price of 
consultations at chain and independent pharmacies) and the price component of objective D 
(to explore how and why the organisational structure of pharmacy chains may affect prices 
of medicines). This paper has not yet been submitted to a journal.  
6.2 Research paper 3 
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Abstract 
The growth of chain pharmacies in India, and other low and middle-income countries, is 
challenging the status quo of pharmacy retail markets which have historically been 
dominated by independent pharmacies in these settings. There is a need to understand the 
effects of different organisational arrangements on the functioning of pharmacies in these 
countries, including the prices of the medicines they sell and the populations that they serve. 
This paper draws on a standardised patient survey to measure the prices of consultations for 
two tracer conditions (suspected tuberculosis in an adult and diarrhoea in an absent child) at 
a random sample of chain and independent pharmacies. In addition, in-depth interviews were 
conducted with chain executives, branch staff and independent pharmacy owners to 
understand how organisational type affects price; and asset and education data were 
collected from exit interviews with pharmacy customers to determine socioeconomic profiles 
of clients. We found no difference between chains and independents in the price of 
medicines for the tuberculosis case. However, chains were cheaper for the diarrhoea case, 
undercutting the maximum retail price significantly more than independent pharmacies. 
Additionally, chains were found to realise efficiencies in the supply chain and exploit their 
buying power to offer fixed discounts, thus likely further reducing prices for regular 
customers compared to independent shops. Despite the availability of cheaper medicines, the 
potential to serve poorer groups has not yet been realised. Chains served wealthier and more 
educated clients, compared to independent pharmacies. Any attempt to leverage this 
organisational model for public health good would need to take account of the current reach 
of these pharmacies. Great care would be required to ensure that appropriate regulatory 
constraints and incentives were in place in order to realise the potential benefits for all 
groups, especially the poor.  
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Introduction 
Pharmacy retail markets in low and middle-income countries (LMIC) have traditionally been 
dominated by local, independently owned pharmacies. These pharmacies are widely used by 
populations but their practice has been judged to be poor. Insufficient history taking, a lack 
of adherence to treatment guidelines, and inappropriate supply of medicines have been 
shown to be commonplace (Miller and Goodman 2016, Smith 2009, Wafula, Miriti, and 
Goodman 2012). Insufficient knowledge, strong profit motives, and regulatory failures go 
some way to explaining these shortcomings (Goel et al. 1996, Miller and Goodman 2016). 
Economic growth has spurred the entry of pharmacy chains into these retail markets in 
Africa, Asia and South America, with a particular presence noted in countries such as India, 
The Philippines, Mexico, Brazil, Chile, South Africa, Nigeria, Kenya and Uganda (IMS 
consulting group 2014, Lowe and Montagu 2009).  
Chains could be argued to have the potential to both improve quality and reduce price in 
comparison to independent pharmacies, and therefore be a welcome addition to these 
markets, from a public health perspective. First, consolidation through pharmacy chains may 
enable regulators to concentrate on central management structures and thus alleviate some of 
the difficulties and high costs associated with enforcing regulation in a highly fragmented 
market. Secondly, firms may self-regulate quality in their branches in order to preserve brand 
identity or image (Bishai et al. 2008, Bloom, Standing, and Lloyd 2008). Thirdly, the profit 
motives of branch staff may be lower-powered compared to those of pharmacy owners, who 
directly receive the profits of medicine sales, which may mean there are weaker incentives 
for chain staff to engage in irrational medicine use (Frant 1996).  
Turning to the potential impact on price, chains may be able to take advantage of scale 
economies to invest in cost-reducing and quality-enhancing technologies (Bennett and Yin 
2014). They may buy directly from manufacturers, thus by-passing wholesalers and the 
serial mark-ups associated with a complex supply chain. Firms may also partner with 
manufacturers to offer ‘private label’ products. Not only would these actions increase 
margins and reduce prices, but they would also give the firm more control over medicine 
quality. Further, additional savings could be made if firms became large enough to 
experience buying power in the market. Such cost savings may be passed onto patients in the 
form of cheaper medicines, though firms may use their brand power to raise prices.  
To date, research on this evolving segment of the pharmacy retail market has been limited. 
The chain that has, perhaps, received most attention is the Mexican giant, Farmacia 
Similares- the brain child of ‘physician-pharmacist-industrialist’ Victor Gonzalez Torres 
(Shadlen 2009). Farmacia Similares is the channel used to distribute generics produced by 
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Laboratorios Best, also owned by Torres. Laboratorios Best saw an opportunity to enhance 
their business following a Mexican health reform in 1998 that required public sector doctors 
to prescribe using the active ingredient ie generics, as opposed to the brand name. However, 
existing distribution channels refused to sell their products, due to a campaign to discredit 
generics, and private doctors continued to prescribe branded products. This led Laboratorios 
Best to create Farmacia Similares- a low cost, doctor-pharmacy chain offering cheap 
generics to the bottom of the pyramid (adjacent to each outlet is a medical clinic offering 
consultations for $2) (Peng 2016). This innovative model, coupled with successful marketing 
of the products as ‘The Same But Cheaper’ (Lo mismo pero mas barata) and a portrayal of 
the Mexican-owned company as taking a stand against ‘transnational greed’ has led to the 
rapid expansion of the chain in Mexico and in 2005 it registered revenues of over $400 
million (Hayden et al. 2007). The chain has now entered markets in Costa Rica, El Salvador, 
Honduras, Nicaragua, Chile, Ecuador and Peru (Centre for Health Market Innovations 2017). 
Farmacia Similares’s success has drawn the attention of policy makers and global health 
organisations to the possibilities of pharmacy chains.  
Farmacia Similares’s business model of selling low cost generics to the bottom of the 
pyramid is, however, unique, and we are unaware of other chains, elsewhere in LMICs with 
a similar offering. Instead, pharmacy chains in other settings tend to follow the traditional 
model of selling both generics and branded medicines, the latter being favoured by both 
doctors and patients (Nguyen et al. 2008). The only published work looking at the impact of 
these traditional chains in LMICs, is from a study in Hyderabad, India, which investigated 
the effect of chain entry on quality and prices of medicines in local markets. Researchers 
worked with a leading Indian pharmacy chain, MedPlus, and collected data on medicine 
price and pharmacopoeia compliance of two antibiotics (through a SP survey) in independent 
pharmacies in control and treatment markets (a MedPlus shop opened), before and after 
chain entry. They reported that, compared to independent pharmacies in control markets (ie 
no chain presence) chain pharmacy prices were 6% lower (p=0.02) and pharmacopoeia 
compliance was 6 percentage points higher (p=0.46)  (Bennett and Yin 2014). The same 
study comments that MedPlus initially entered the city’s most affluent neighbourhoods, 
suggesting that some chains may be targeting wealthier populations but this evidence is 
anecdotal (ibid).  
This paper aims to build on this limited evidence base on the performance of chain 
pharmacies. In earlier papers we explored the impact of organisational structure on quality of 
care, as measured by adherence to treatment guidelines, using standardised patients (SPs) to 
present fictitious scenarios, and found that the potential for quality improvement does not 
currently appear to have been realised in the Indian context (Miller and Goodman 2017, 
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Miller, Hutchinson, and Goodman 2017). We found that quality of care, for a child with 
diarrhoea and an adult with suspected tuberculosis (TB), was equally poor in chain and 
independent pharmacies. Fewer than half of the pharmacies managed the TB case according 
to the current guidelines, and not a single pharmacy treated the child in accordance with 
guidelines. However, chains sold significantly fewer harmful and prescription-only 
medicines (POMs) for the diarrhoea patient compared to independent shops. In this paper we 
turn to the question of the impact on price and the associated question of the socioeconomic 
groups served by the chains. Using exit interviews from a random sample of pharmacy 
chains in Bengaluru, India, we present the first data on socioeconomic profiles of customers 
shopping at chain pharmacies in a LMIC, compared to independent pharmacies, and of the 
general population. We also present price data from our SP survey completed at chain and 
independent pharmacies in the same setting. Additionally, we draw on insights from in-depth 
interviews with pharmacy owners, chain executives and in-store staff and other key 
informants to learn more about how and why the organisational structure of pharmacy chains 
may affect medicine prices, compared to independents.  
Methods 
The data presented in this paper are drawn from three distinct sources: a SP survey, exit 
interviews with pharmacy customers, and in-depth interviews with key informants. We begin 
this section with some background on the retail pharmacy market in Bengaluru, and then 
describe the collection and analysis of each dataset in turn.  
Study site and Bengaluru’s retail pharmacy market 
Chains currently account for around 4% of India’s 800,000 odd pharmacies but their rate of 
growth is rapid (IMS consulting group 2014). These chains are concentrated in India’s big 
cities, with a larger presence in the South. This guided the choice of Bengaluru, the capital of 
the Southern Indian state of Karnataka and India’s third most populous city, as the site for 
this work. At the time of data collection (November 2014-June 2015) there were 13 chains 
operating in the city, accounting for 529 (9%) of Bengaluru’s 5664 registered retail 
pharmacies (Miller and Goodman 2017) (these figures exclude pharmacies operating within 
hospitals or clinics, which could not be accessed from the street). Chain size varied from two 
to two hundred - plus outlets and five chains also owned pharmacies outside of Karnataka.  
Both chains and independent pharmacies stock a mix of branded and generic products. In 
India a distinction is made between ‘national’ and ‘local’ medicine manufacturers. ‘Branded’ 
products are produced by national manufacturers, who advertise their products heavily in 
order to establish a reputation and improve market power (Bennett and Yin 2014). These 
manufacturers tend to comply with Indian and international quality standards. Local 
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manufacturers produce generics and are difficult to regulate due to their vast numbers. Retail 
pharmacies stock a high number of national and generic brands for common medicines in 
order to accommodate a wide range of doctor and customer preferences. Each manufacturer 
dictates a maximum retail price (MRP) for their product but the MRP for a particular 
compound can vary across brands. There is therefore some scope for price variation through 
brand substitution. The National Pharmaceutical Pricing Authority (NPPA), an independent 
body, also stipulates a ceiling price for some essential medicines listed in a ‘schedule’ and 
found in the Drugs Prices Control Order (NPPA).  
Standardised patient survey: price data 
Data on price were collected through a SP survey of chain and independent pharmacies in 
the city. A stratified sample of chain (103) and independent (230) pharmacies were chosen, 
at random, from a verified list of all licensed pharmacies in Bengaluru (see (Miller and 
Goodman 2017) for more details). The sample included eight of Bengaluru’s 13 chains- the 
largest seven and one of the six chains with 2-5 outlets (see Table 1). Six research assistants 
were trained to visit pharmacies and present standardised cases of diarrhoea in an (absent) 
child and suspected TB in an adult.  A substantial component of the training involved role 
play to practice both the presentation of the cases and personal back stories. SPs completed a 
number of pilots under the supervision of a senior research assistant, until we were confident 
that the presentations and associated dialogue would be perceived as authentic. The scenarios 
were presented in Kannada (the local language) and it was discussed how researchers should 
dress to ensure they appeared similar to a typical customer who may present with such cases. 
At each pharmacy the SPs purchased any medicines that were recommended during the 
consultation and recorded the price of each individual medicine sold in a debrief 
questionnaire, completed immediately after each visit.  
Table 1: Size of pharmacy chains in Bengaluru and in SP sample 
Number of outlets in 
chain Number of chains 
Number of chains in 
our sample 
Number of outlets in 
our sample 
2 to 5 6 1 1 
6 to 10 2 2 4 
11 to 50 2 2 6 
51 to 100 1 1 14 
101+ 2 2 78 
99 
 
 
Price data from the SP survey were analysed using Stata 15. We present the difference in 
both mean (accompanied by standard deviations and t test) and median price, interquartile 
range (IQR), and p value from the Wilcoxon rank sum test of the hypothesis of equal 
medians in chains and independents.  
Exit interviews with patients: SES indices and education 
We conducted exit interviews with customers at the same random sample of pharmacies used 
for the SP survey. During a second visit to the pharmacies, researchers approached each 
customer that left the pharmacy and, if they agreed to take part, administered the exit 
interview. This process was repeated until 3 exit interviews were completed at each outlet. A 
total of 808 exit interviews were completed. Whilst researchers were supposed to record the 
number of clients who refused to participate, this was not recorded satisfactorily and, as a 
result, we cannot calculate the response rate. The exit interview collected data on personal 
characteristics, reasons for visiting the pharmacy, and ownership of a number of assets.  
Due to the difficulty of collecting accurate income or expenditure data in LMICs, it has 
become common practice to measure wealth by collecting data on variables that capture 
living standards, including assets (eg TV or motorbike) and housing characteristics (eg water 
source or roof material) (Vyas and Kumaranayake 2006). We have employed this approach 
to measure the wealth of pharmacy customers in our sample. In order to compare the 
customers in our sample with the general population, we used asset data from the national 
District Level Health Survey (DLHS), a household survey powered at the district level. 
Using these assets allowed for comparison with the general population. These comparative 
wealth data were downloaded from the International Institute for Population Studies (IIPS) 
website. Our sample was taken from Bengaluru urban district, within Karnataka. As such, we 
used the data from the corresponding district in the DLHS. We collected data on assets used 
in the most recent DLHS-4 (2012-13). In order to limit the time needed to collect these data 
during the exit interviews (and hence improve participation), we did not ask about all assets 
in the DLHS-4, rather a subset of assets relevant to the Bengaluru city context8. For example, 
we did not ask about ownership of a tractor or cart driven by an animal as these are more 
applicable for rural areas. Others have shown this to be a valid approach in both India and 
elsewhere (Bassani et al. 2014, Chakraborty et al. 2016).  
                                                     
8 Refrigerator, telephone (landline) only, mobile phone only, sewing machine, tap/running water, 
radio, scooter/motorcycle, washing machine, car/jeep/van, watch/clock, computer without internet, 
computer with internet, cooler/AC, number of bedrooms 
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We derived our socioeconomic status (SES) indices using principal components analysis 
(PCA) in Stata 15. First, we completed the PCA on a merged dataset (data from the DLHS-4 
and our exit interview data), using a common set of assets, to assign standardised wealth 
scores to each individual (Vyas and Kumaranayake 2006). We then created quintile cut-offs, 
as described by Filmer and Pritchett (Filmer and Pritchett 2001), using only the DLHS-4 
data. These cut-offs were then applied to our exit interview customers and this enabled us to 
examine the relative economic status of clients patronising chains and independents 
compared to the general population of Bengaluru.  
We also used the DLHS to compare the education level of pharmacy customers in our 
sample by pharmacy type and also with the general population. It was not possible to use the 
DLHS-4 data for this analysis as educational classification for around a quarter of the data 
set was unclear, so instead we used the earlier DLHS-3 (2007-8), acknowledging the 
limitation that the DLHS-3 is less up-to-date.  
Key informant interviews: understanding how organisational type affects price 
38 in-depth interviews were completed with pharmacy employees and other stakeholders in 
Bengaluru. We selected interviewees from a sub-sample of the pharmacies in our SP survey. 
Interviewees comprised 9 chain senior executives working in 8 chains (all the major chains 
bar one agreed to an interview). Additionally, we interviewed 14 chain in-store staff; 12 
independent pharmacy owners (representing a geographical range across Bengaluru); and 3 
key informants including staff from the drug control department and pharmacy associations. 
Interviews were conducted in English, Kannada or Hindi (depending on the interviewee’s 
preference) by RM with the help of a local research assistant. Two chains refused to allow us 
to interview their in-store staff; however, we were able to learn about the experiences of ex-
employees of those chains who were currently employed at other chains. Through the 
interviews we sought to explore some of the hypotheses laid out in the introduction 
concerning how the organisation of pharmacies within a chain structure might influence 
medicine prices. We focused our questions on the supply chain for both chains and 
independents; the extent of purchasing power realised by chains in the market; pricing 
procedures for both pharmacy types; and factors influencing the location of new chain stores. 
Interview transcripts were coded by RM in NVivo 11. We used the predefined hypotheses on 
the effects of chain organisation to generate an initial set of pre-defined coding categories.  
These codes were then applied to the data in an iterative process and the final coding frame 
was agreed by the authors. Where similar topics were covered, we sought to triangulate the 
data collected from both chain executives and branch staff.  
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Ethical Approval 
Ethical approval was obtained from The London School of Hygiene and Tropical Medicine 
Ethics Committee, London, UK, and the Society of Community Health Awareness Research 
and Action Institutional Scientific and Ethics Committee in Bengaluru, India. For the SP 
study, approval from both institutions was received in order to waive obtaining informed 
consent from the pharmacies prior to the SP visits. For the exit interviews with customers, 
written consent was obtained and for the interviews with chain and independent staff we 
gained verbal consent. This is due to reluctance of providers to signs documents that could 
be used to identify their chain or outlet.  
Results 
We first present price data from the SP survey at chain and independent pharmacies, 
followed by insights on price from our qualitative data. Subsequently, we look at SES and 
education of customers shopping at chain and independent pharmacies, compared to the 
general population.  
Price 
Data from our SP survey enables us to compare the price of medicines sold at chain and 
independent pharmacies based on a standardised presentation of symptoms. Further, it allows 
us to understand how recommendations on number and type of medicines by pharmacy staff 
affect the overall cost to the customer. SP consultations for childhood diarrhoea and 
suspected TB were analysed separately. Of the 333 shops visited by the SPs (103 chains and 
230 independents), 65% of chains and 66% of independents sold medicine(s) to the patient 
with suspected TB. For the diarrhoea patient, these figures were 61% and 67% for chains and 
independents respectively. The subsequent analyses of price data were conducted only on 
those shops who did sell medicines.  
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Figure 1: Histogram of price of diarrhoea encounter with kernel density 
Figure 2: Histogram of price of TB encounter with kernel density 
Figures 1 and 2 show histograms of prices for the diarrhoea and TB encounter respectively, 
with kernel densities. Table 2 shows that there was no significant difference between chains 
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and independents in terms of the price of the TB encounter.  For the diarrhoea case, the mean 
and median price paid for all purchased medicines was significantly less for chains- 27.5 and 
19 Rupees (Rs) respectively, compared to 35.6 and 38 Rs for independent shops (p=0.01 and 
p=0.002). The mean number of medicines sold does not offer an explanation for the 
observed price difference between chains and independents for this case (1.2 for both 
pharmacy types).  
Table 2: Descriptive statistics for diarrhoea and TB encounter 
Chains Independents 
Statistical tests Encounters (n) 103 230 
Diarrhoea encounter 
Number of encounters where 
SPs received any medicine  63 (61%) 153 (67%) 
Chi2 
P=0.344 
Mean number of medicines 
received  1.21 1.22 
t test 
p=0.886 
Total price paid (of encounters 
where medicines were sold) (Rs) 
Mean SD Mean SD t test 
27.5 18.3 35.6 22.1 p=0.01 
Median IQR Median IQR 
Wilcoxon rank 
sum test 
19 13-37 38 18-47 p=0.002 
Price per medicine (Rs) 
Mean SD Mean SD t test 
22.8 13.8 29.3 20.4 p=0.012 
Median IQR Median IQR 
Wilcoxon rank 
sum 
18.8 13-30 24 13-41 p=0.008 
Tuberculosis encounter 
Number of encounters where 
SPs received any medicine  67 (65%) 151 (66%) 
Chi2 
p=0.915 
Mean number of medicines 
received  1.37 1.51 
t test 
P=0.171 
Total price paid (of encounters 
where medicines were sold) (Rs) 
Mean SD Mean SD t test 
46.4 26.8 42.7 38.5 p=0.473 
Median IQR Median IQR 
Wilcoxon rank 
sum test 
49.5 20-64 29 11-64 p=0.191 
Price per medicine (Rs) 
Mean SD Mean SD t test 
33.8 24.5 28.3 26.2 p=0.082 
Median IQR Median IQR 
Wilcoxon rank 
sum test 
26.58 10-55 13.5 8-55.7 p=0.064 
Further analysis looked at price deviation from the MRP in both chains and independents 
(Table 3). This shows that, on average, the diarrhoea encounter was 1.09 Rs less than the 
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MRP at chains, compared to 0.17 Rs less at independents (p=0.005). Chains therefore appear 
to be offering medicines at cheaper prices than independents for this case. For the TB case, 
chains were found be following the MRP (0.04 rupee deviation per encounter), whereas 
independent shop encounters were, on average, 1.79 Rs more expensive than the MRP 
(although this result is not significant at the 5% or 10% level). For the TB case, whilst 
independents were charging more than the MRP and selling more medicines on average 
(1.51 Rs vs 1.37 Rs for chains), the medicines that they did sell were cheaper (mean price 
per medicine was 28 Rs at independent and 34 Rs in chains). This resulted in no price 
difference between chains and independents for the overall consultation. 
Table 3: Price deviation of standardised patient (SP) encounters from the maximum 
retail price (MRP) for chain and independent pharmacies 
Diarrhoea case 
Chains Independents 
Price difference 
of encounter 
(MRP - price paid) 
Mean SD Mean SD t test 
-1.09 2.78 -0.17 1.86 p=0.005 
Median IQR Median IQR 
Wilcoxon 
rank sum test 
0 -2 - 0.46 0 0 - 0.46 p=0.28 
Tuberculosis case 
Chains Independents 
Price difference 
of encounter 
(MRP - price paid) 
Mean SD Mean SD t test 
0.04 6.67 1.79 8.27 p=0.129 
Median IQR Median IQR 
Wilcoxon 
rank sum test 
0 
-1.83 -
1.23 0 0 - 1.2 p=0.226 
A regression analysis was conducted to further explore the effect of outlet type on price 
(Table 4). The first model shows the raw correlation between log price of the diarrhoea 
encounter and pharmacy type, while the second also controls for SP fixed effects. Model 2 
shows that chains were 23% cheaper9 than independent pharmacies, after controlling for SP 
fixed effects (p=0.014). Model 3 explores the hypothesis that chains are cheaper due to 
selling fewer antibiotics, a class of medicines that are known to be expensive. The binary 
independent variable ‘antibiotic’ (whether an antibiotic was sold) is added to the model. The 
9 (e-0.2578 – 1)*100 = -22.7 
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coefficient on the chain dummy is reduced, but does not disappear, indicating this may 
explain part but not all of the observed price difference. 
Table 4: Effect of pharmacy type on price: diarrhoea encounter 
Dependent variable ln (price) 
Model 1 Model 2 Model 3 
Chain pharmacy -0.2531* -0.2578* -0.2269*
(0.103) (0.104) (0.094)
SP fixed effects No Yes Yes 
Antibiotics _ _ 0.3761** 
(0.094) 
Observations 216 216 216 
R2 0.03 0.04 0.11 
Standard errors in parentheses 
* p <0.05, **p<0.01
Table 5 analyses the effect of the same independent variables on the log price of the TB 
encounter. In line with the descriptive statistics, after controlling for SP fixed effects, there 
was shown to be no significant difference between the price of chain and independent 
pharmacies. 
Table 5: Effect of pharmacy type on price: TB encounter 
Dependent variable ln (price) 
Model 1 Model 2 
Chain pharmacy 0.2371 0.2478 
(0.127) (0.133) 
SP fixed effects No Yes 
Observations 218 218 
R2 0.01 0.09 
Standard errors in parentheses 
* p<0.05, **p<0.01
Table 6 explores the effect of selling ‘private label’ medicines on log price of the TB 
encounter. Qualitative work from this study (see below) revealed that chains offer private 
label products and these products were reportedly cheaper for patients and yielded higher 
margins for the chain. 43% of the chain pharmacies in this analysis were found to sell a 
private label medicine in the TB encounter10. Model 2 shows that the after controlling for SP 
fixed effects, there is no significant difference between independent pharmacies and either 
10 A similar analysis is not shown for the diarrhoea encounter because the share of chain pharmacies 
selling a private label medicine for diarrhoea was only 6%.  
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chains that sold a private label medicine and those that did not. This indicates that private 
label medicines do not appear to be driving down prices.  
Table 6: Price of TB encounter, investigating the effect of ‘private label’ medicines on 
price 
Dependent variable ln (price) 
Model 1 Model 2 
Chain pharmacy (sold 
private label) 0.2324 0.2290 
(0.190) (0.185) 
Chain pharmacy (did 
not sell private label) 0.2407 0.2622 
(0.170) (0.166) 
SP fixed effects No Yes 
Observations 218 218 
R2 0.01 0.08 
Standard errors in parentheses 
* p <0.05, **p<0.01
Qualitative insights on price 
In order to better explain how and why price variations exist between chain and independent 
pharmacies in Bengaluru, we have drawn on a set of in-depth interviews with key 
informants, concentrating on two key themes of retail discounts and wholesale purchasing.  
As with all SP studies, our results reflect how pharmacies manage a client not already known 
to the pharmacy. From in-depth interviews with chain executives and in-store staff we 
learned that many of the chains offer customers a fixed discount on medicines, and this 
apparently reflected aggressive price competition on the part of chains. One of the market 
leaders introduced a 10% discount on the MRP for all medicines and other chains have since 
followed suit. Discounts ranged from 5-10% and only a couple of the smaller chains did not 
offer this price reduction to their customers. One large chain recorded the phone number of 
new customers and then applied a 10% discount to purchases (using the phone number as an 
identifier), whereas other chains reserved discounts for senior citizens or ‘loyalty card’ 
customers only. Discounts offered by independent shops appeared to be less fixed and were 
usually only offered if requested by a customer. Some independents refused to apply 
discounts, stating that they could not survive if their margins were reduced further; others 
offered 2-3% and some matched the 10% given by the bigger chains.  Given that our SPs 
were not regular clients, it is likely that the price data from our SP study does not capture the 
full extent of these discounts and it is likely that regular customers would face cheaper 
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encounters.  Independent shop owners cited this discount culture as the single largest 
grievance regarding the advent of chains. One owner explains:  
‘Chain medical shops are disturbing a lot.  It's like polluting our Ganges River.  Giving 10% 
discounts, and making the customers to change their route.’ #29 independent pharmacy 
owner 
Whilst our qualitative work revealed grievances from independent pharmacy owners 
regarding the growth of pharmacy chains, we found no concrete evidence of independent 
store closures, as yet. 
Interviews revealed that chains realise cost savings through central purchasing for all of their 
Bengaluru stores that would not be available to independents, giving them the potential to 
apply these discounts. As one chain executive says:  
Respondent: ‘Our purchase power will increase no…If you purchase in bulk, definitely your 
purchase power will increase.’ 
Interviewer: ‘What kind of discounts do they offer?’ 
Respondent: ‘It depends on the brands and distributors. From 3 to 6, 7% discounts will be 
there.’ #4 chain executive 
Further, some describe how chains are able to cut one or more layers out of the supply chain 
by purchasing directly from manufacturers and carry and forwarding (C&F) agencies, rather 
than from local distributors, as independents do (figure 1). It is such supply chain 
efficiencies that enable the larger chains to offer substantial discounts on medicines. A chain 
executive describes: 
‘Procurement, we have a contract with most of the vendors so that is done centralised from 
Delhi major companies like J&J [Johnson and Johnson], Cipla they have their C&F [carry 
and forwarding] delivering the stocks directly to us… They are the stockist for that 
particular products, so they get directly from their company and they sell it directly to us, so 
there is no, very few distributors in between so we are able to offer that margin what we are 
saving there to the customers…For a single shop [ie independent pharmacy] he will not get a 
direct buy from a C&F, C&F has a minimum order of value for that particular product, so I 
being a small timer I go and approach and they’ll not deliver products to me. If I represent a 
company who has 10 stores or 20 stores then they will, so that’s the difference what we 
make.’ #18 chain executive 
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Figure 3: Typical supply chain for independent and chain pharmacies purchasing 
medicines, as told by informants  
Additionally, some of the larger chains offer their own line of ‘private label’ medicines. 
These are generic medicines purchased directly from the manufacturer, branded, and sold 
under the chain name. Margins on these generic products are much higher for the chain than 
on national brands because they are obtained at much lower cost and, as such, chains heavily 
incentivise their staff to sell these products. The chain is also able to have more control over 
the quality of such products. Customers are said to be suspicious of generics in general, and 
prefer national brands, but where they do substitute for these pharmacy-branded medicines, 
they will pay less for the same compound, benefiting both company and customer.  
Socioeconomic profile of clients 
We explored the SES of pharmacy customers compared to the general population of 
Bengaluru in terms of both wealth and education.  
Figure 2 shows the distribution across wealth quintiles (based on our asset index) of 
customers visiting chain and independent shops in our sample, compared to that of the 
general population. The figure shows a clear pattern of higher wealth of independent 
customers compared to the general population. Chain customers appear to be relatively 
wealthier than both the general population and independent customers. The clearest 
difference can be seen in the highest wealth category (quintile 5) which comprises 20% of 
the general population, compared to nearly half (45%) of independent customers and the 
Chain  
Manufacturer
Carry and 
forwarding (C&F) 
agent
Super stockists
Stockists
Retail pharmacy
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majority (67%) of chain customers. Chi2 tests showed that differences in Q5 between all 
groups were significant (p<0.001 for all tests).  
Figure 4: Wealth of customers patronising chain and independent pharmacies relative 
to the general population of Bengaluru 
Secondly, we present educational attainment of customers patronising chain and independent 
pharmacies, relative to the general population (Figure 4). Educational attainment of 
independent customers was similar to that of the general population. Those visiting chain 
pharmacies had a higher proportion (79%) of customers in the highest two educational 
categories (secondary school and above) and fewer (21%) in the lowest two (no schooling 
and primary education) compared to independents and the general population. These 
differences between the education of chain and independent customers (p<0.001), and chain 
and the general population customers in the top two educational categories were found to be 
significant (p<0.001).  
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Figure 5: Educational attainment of customers patronising chain and independent 
pharmacies relative to the general population of Bengaluru  
We conducted further analysis to investigate whether the above results (customers 
patronising chain pharmacies being both more educated and relatively wealthier than those 
using independent pharmacies) were driven by the location of chains (potentially in 
wealthier areas). Using Arc GIS the GPS locations of all pharmacies in our sample were 
plotted. A 1km radius was applied to each chain pharmacy. In an attempt to match 
pharmacies by area, all chains that had an independent within the 1km radius were included, 
as were the independents within that geographical area. Conversely, any independents not 
within 1km of a chain and chains that did not have an independent within 1km were 
excluded. We repeated the same analyses on this matched dataset (see supplementary 
material) which included 264 exit interviews from 90 independents and 237 exit interviews 
from 79 chains.  
The results from the geographically matched data were very similar to our original results in 
terms of customer wealth. The percentage of independent customers in the top quintile 
increased by 1 percentage point to 46% and decreased to 66% (1% point) for chain 
customers. The difference between the two was still significant (p<0.001). In terms of 
education, the change in results was more marked. The percentage of independent customers 
with secondary education or higher increased from 60% in the original dataset to 68% in the 
geographically matched data. For chain customers there was a slight decrease in this figure 
from 79% to 75%. However, the difference between the percentage of chain and independent 
customers educated to secondary level and above was still significant (p=0.019).  
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Discussion 
The data presented in this paper on relative pricing and client SES can be combined with 
other published evidence from this study on relative quality of care (Miller and Goodman 
2017, Miller, Hutchinson, and Goodman 2017) to provide a wider picture of the comparative 
performance of chain and independent pharmacies. Medicine quality may be a third key 
mechanism through which chains could be hypothesised to differ from independents. Our 
qualitative work found that chains do enjoy shorter supply chains and buy directly from 
manufacturers, which may enable greater control over quality. Further, the storage 
capabilities of chains may be superior to those of independent retailers and this could 
safeguard medicines against the high temperatures and humidity that are commonplace in 
India. In their study of the independent pharmacy market in Hyderabad and the effect of 
chain (MedPlus) entry, Bennet and Yin reported that chain medicine quality was initially 6% 
points higher but over time the pharmacopoeial quality of independent medicines improved 
to match that of chains, but at a higher cost than the chains (Bennett and Yin 2014).  
This paper set out to investigate the impact of pharmacy type on price and to scrutinise the 
socioeconomic groups served by these pharmacies. It was unclear whether chains would take 
advantage of scale economies to offer cheaper medicines or whether they would exert brand 
power to raise prices. From our SP survey, we found that there was no significant price 
difference between chains and independents for the management of the TB case. The 
consultation for the child with diarrhoea was, however, significantly cheaper at chains 
compared to independents. Regression analyses which explored the relationship between the 
log price of encounters and pharmacy type, controlling for SP fixed effects showed that this 
encounter was 23% cheaper in chains, compared to independents (p=0.014). This difference 
appears to be driven mainly by chains undercutting the MRP price significantly more than 
independent pharmacies.  
There are two reasons why our price data may actually be underestimating the price-cutting 
impact of chains. Firstly, our qualitative data revealed that most chains offer up to 10% 
discount on medicines to repeat customers which is not entirely captured by our SP patients 
who are unknown, first-time visitors to the pharmacy. These discounts are made possible by 
discounts on wholesale prices through bulk purchasing and realising efficiencies in the 
supply chain. Secondly, there are possible price spill over effects to independents, who may 
have decreased their prices in response to price competition from chains. Bennet and Yin’s 
(2014) study of the effect of chain entry on medicine quality and price showed that after the 
entry of a chain into a local pharmacy retail market, the price at independent shops fell by a 
non-significant 2-4%. However, for non-national brands alone they found a significant 12-
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15% price reduction. This phenomenon of retail prices falling in markets following the entry 
of a low-cost chain has also been observed in other industries (Basker 2005, Jia 2008).  
No prior research had investigated the type of customers served by pharmacy chains in India. 
Given that chains may be cheaper (undercutting MRP for diarrhoea medicines, and discounts 
for regulars), one might have expected them to serve poorer groups on average, but in fact 
the reverse was true. We found that customers patronising chain pharmacies were both more 
educated and relatively wealthier than those using independent pharmacies. These results 
held after restricting the analysis only to chain and independent pharmacies situated within 
1km of each other, thus ruling out the explanation that the observed results were purely 
driven by the location of chains. 
Our accompanying qualitative work offers some explanation for the self-selection of 
independents by poorer clients and chains by wealthier ones. This work reported that 
independent pharmacies offer credit facilities to those who cannot afford to buy medicines 
and this may be an important consideration of such clients. Additionally, given that chains 
have a more high-end feel in terms of appearance, it may be that they are off-putting or 
intimidating to lower income groups. Whilst most independent stores had an open, on-the-
street shop frontage, chains were often enclosed. In addition, most chain branches had air 
conditioning, were neatly organised, and some chain executives described their aim to create 
a more ‘international’ experience compared to independent shops. The apparent self-
selection also suggests that the rich maybe more sensitive to quality. Both quality of care, 
given that chains were found to sell fewer prescription only and harmful medicines to the 
diarrhoea patient; and quality of medicines, given that other work has found the medicines 
sold by chains to be of superior pharmacopeial quality to those sold at independents (Bennett 
and Yin 2014). It is feasible that these groups perceive that a chain with air conditioning will 
offer better quality medicines.  
It is also noteworthy that the profile of independent customers in our sample was 
considerably wealthier than that of the general population. A growing body of work focusses 
on the role and space that informal providers occupy in India (Bloom et al. 2011, Gautham et 
al. 2014, George and Iyer 2013), and it may be that this cadre of providers are the preferred 
channel for medical advice and medicine purchasing for the urban poor in Bengaluru.  
This paper also touches on the expansion of private label products into the retail pharmacy 
market.  Steiner argues that when private label products compete in the market, the 
competition with national brands is welfare-enhancing. Due to their ‘unique form of rivalry’ 
they are able to constrain the market power of national brands (Steiner 2004). Despite the 
welfare gain from lower retail prices, some argue that this is offset against the feeling of 
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reassurance customers get from purchasing a trusted (national) brand. However, in the US 
large, well established retailers have developed their own reputation and it has been shown 
that consumers experience the same feeling of reassurance from purchasing a leading 
retailer’s private label aspirin that years earlier could only have been experienced by 
purchasing a leading national brand (ibid). Retailers also have more control over the quality 
of private label products (compared to non-national brands), due to sourcing directly from 
the manufacturer.  
In the long run, transaction cost economics would predict that chains will become the 
dominant organisational model due to their superior efficiency (Douma and Schreuder 
2008). Moreover, other industries have seen diffusion of retail chains in LMICs from big to 
smaller cities, and from upper to middle to poorer classes (Reardon, Timmer, and Minten 
2012). However, one could argue that the costs of monitoring chain branches in more 
dispersed areas would be much higher and such operational costs may not be feasible 
(Milgrom and Roberts 1992). For this reason, chains may restrict their operations to urban 
areas. 
The set of hypotheses about the potential positive impact on affordability and quality of 
chain entry might lead some national or international bodies to consider investing in chains 
to accelerate this process in order to improve public health outcomes, perhaps to some 
degree inspired by the Farmacia Similares experience. However, although we found chains 
to offer lower cost medicines for their urban Indian clientele, the potential to serve poorer 
groups has not yet been realised, and the impact on quality of care was very limited. Any 
attempt to leverage this organisational model for public health goals would therefore need to 
be carefully designed to ensure that appropriate regulatory constraints and conditions were 
incentives were in place to ensure that the potential benefits were reaped.  
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Supplementary material 
Figure S1: Wealth of customers patronising chain and independent pharmacies relative 
to the general population of Bengaluru (pharmacies within 1km radius only): 
Figure S2: Educational attainment of customers patronising chain and independent 
pharmacies relative to the general population of Bengaluru (pharmacies within 1km 
radius only) 
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7 Understanding chain business models and their 
implications 
7.1 Introduction 
This chapter presents the third results paper entitled “‘A smile is most important.’ Why 
chains are not currently the answer to quality concerns in the Indian retail pharmacy sector.” 
It draws on the key informant interviews to address the quality component of objective D (to 
explore how and why the organisational structure of pharmacy chains may affect the quality 
of service provision). A version of this paper was published in Social Science and Medicine 
in July 2018.  
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Abstract 
Chain pharmacies are expanding in many low and middle-income countries (LMICs). 
Historically practices of independent pharmacies in these settings have been poor, and there 
is a need to understand how these new organisational arrangements are affecting the 
functioning of pharmacies, and the implications for public health. Drawing on economics 
literature, we develop a set of hypotheses as to how chains could address the quality failures 
that typify LMIC retail pharmacy markets, and explore these hypotheses using a set of 38 in-
depth interviews, conducted in Bengaluru, India. We look specifically at how being 
organised in a chain affects several key behaviours: employment of qualified staff; the ability 
of government authorities to concentrate regulation on central management structures; the 
propensity for firms to self-regulate; and the impact of the potentially lower-powered 
incentives faced by chain employees compared to independent owners. In practice, few 
differences were identified between chain and independent organisations in these areas. Not 
all chains were operating with a qualified pharmacist (akin to independent shops). Drug 
control authorities did not take advantage of the existing chain architecture to enforce 
regulation. Chains did heavily self-regulate but their priority was customer service, rather 
than aspects of quality relevant to health outcomes. Additionally, widespread bribery in the 
sector was a barrier to effective drug control. Finally, the incentives faced by chain 
employees were not low-powered due to rewarding sales targets and pressure to increase 
sales. We observed that chains exerted strong influence over their staff but the potential to 
exploit this to improve quality of care is not currently being realised. If clinical 
accountability within these organisations were improved and regulatory bodies made chains 
take responsibility for their outlets by using tough sanctions for illegal practices, chains may 
hold promise for quality improvement.  
Keywords 
India; pharmacies; chain pharmacies; private sector; quality of care; health sector regulation 
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Introduction 
Pharmacies and drug stores are the first point of care in many low and middle-income 
countries (LMICs) for a range of medical conditions, including respiratory infections, fever, 
malaria, injury, body and dental pains, skin infections, diarrhoea and sexually transmitted 
infections (Igun 1987, Kamat and Nichter 1998, Saradamma, Higginbotham, and Nichter 
2000, Smith 2009b, Wafula, Miriti, and Goodman 2012). Practice in these outlets is often 
characterised by deficient knowledge, poor adherence to treatment guidelines, inappropriate 
supply of medicines, and insufficient counselling (Smith 2009b, Wafula, Miriti, and 
Goodman 2012, Miller and Goodman 2016). In most LMICs, pharmacy retailing has 
traditionally been dominated by owner-run shops, but chain pharmacies are now a growing 
organisational arrangement for delivering pharmacy services in these settings.  Given the 
limited evidence-based policy options to improve pharmacy practice in LMICs (Miller and 
Goodman 2016, Smith 2009a, Wafula and Goodman 2010), chain pharmacies may have 
potential to address quality challenges. Despite emerging interest amongst the global health 
community, empirical research on pharmacy chains in LMICs is scant (Lowe and Montagu 
2009). Work from high-income countries has explored the effect of pharmacy type on 
various outcomes (eg Fritsch and Lamp 1997, Kalsekar, Sheehan, and Peak 2007) but is of 
limited applicability to LMICs given the strength of regulatory frameworks in these settings. 
With either established or growing corporate pharmacy retail sector in Mexico, Brazil, South 
Africa, Nigeria, Kenya, Uganda, India and The Philippines (Center for Health Market 
Innovations 2014 , IMS consulting group 2014, Lowe and Montagu 2009) , there is a need to 
understand the effects of these new organisational forms on the functioning of pharmacies 
and the implications for public health.  
This paper is concerned with practices in pharmacy chains in urban Bengaluru, the capital of 
the State of Karnataka, South India. Recent years have seen the steady growth of pharmacy 
chains in India. There are estimated to be around 800,000 medicine retailers in India, with 
chains accounting for 4% of these but growing at a rate of 25% per annum (Northbridge 
Capital 2011, IMS consulting group 2014).  
The research presented in this paper is nested within a broader mixed-methods study of 
Bengaluru’s chain pharmacies, which included a standardised patient (SP) study comparing 
the quality of management of two tracer conditions at chain and independent pharmacies 
(diarrhoea and suspected TB) (Miller and Goodman 2017). The SP study showed that quality 
of care, as measured by adherence to treatment guidelines, was equally poor in chain and 
independent pharmacies. No shops managed the diarrhoea patient according to current 
guidelines and fewer than half for the tuberculosis (TB) case. However, chains sold 
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significantly fewer harmful and prescription-only medicines (POMs) for the diarrhoea 
patient compared to independent shops (ibid). The survey also revealed that whilst overall 
sales of POMs were high, sales of the more restricted H111 subcategory were low, with 
chains not selling any of these medicines.  
Drawing on insights from economics literature, this paper uses a set of in-depth interviews to 
explore how and why the organisational structure of pharmacy chains may affect the quality 
of service provision, compared to independent pharmacies. Qualitative work focusing on 
what drives patterns of pharmaceutical use and the poor behaviours characteristic of 
pharmacy practice in India has been illuminating, but rare (Kamat and Nichter 1998, Das and 
Das 2006, Seeberg 2012), and has not explored the role of chains in this setting. To our 
knowledge, this is the first study of its kind in a LMIC.  
Theoretical approach 
Various bodies of theory provide insights into the study of pharmacy arrangements, such as 
those from neo-classical economics, industrial organisation and regulatory theory. 
Conventional economic analysis of pharmacy markets in LMIC typically focuses on the high 
likelihood of various market failures. Inappropriate prescribing of medicines can be 
associated with negative externalities (Laxminarayan 2003) and information is highly 
imperfect (Mushkin 1958). Further, the nature of information in health markets is 
asymmetric (Arrow 1963). Within the agency relationship that results, it has been suggested 
that providers do not always act as perfect agents; rather they influence demand for their own 
self-interest, trading off income against patient welfare (McGuire 2000, Morris, Devlin, and 
Parkin 2007). Fee for service (as in a pharmacy) is the provider payment system most 
associated with the resulting ‘overserving’ patients (Hennig-Schmidt, Selten, and Wiesen 
2011, McGuire 2000).   
Drawing on theoretical insights, we develop a set of hypotheses as to how chains could 
address some of these market failures. A prior literature review of pharmacy practice in low-
middle income Asian settings identified regulation, knowledge and profit motive as three key 
determinants of pharmacy provider behaviour (Miller and Goodman 2016). Figure 1 presents 
                                                     
11 In India POMs are classified as either H, H1 or X. Under the Drugs and Cosmetic Rules 1945, 
Schedule H medicines should only be sold with a valid prescription from a doctor. In light of the high 
sales of these medicines in India without a prescription, Schedule H1 was introduced in 2013. The H1 
list comprises of 46 medicines (mainly 3rd and 4th generation antibiotics and anti-tuberculosis 
medicines) and require that the identity of the patient, contact details of the prescriber and the 
name and dispensed quantity of the drug be recorded in a designated register. Schedule X comprises 
of a small number of narcotics and requires the pharmacy to retain the prescription for 2 years after 
dispensing. 
 
123 
 
these hypotheses detailing how being organised as a chain may influence these determinants. 
Enforcing regulation is costly and logistically difficult due to the fragmented nature of 
pharmacy retail in India. Through consolidation (in chains) regulation could be improved. 
First, state regulation could be aimed at central management structures; essentially, the 
regulator could make firms take responsibility for their branches.  Second, firms may self-
regulate in order to preserve brand identity and image. This may, for example, lead to greater 
presence of qualified pharmacists at the point of service delivery, who are currently often 
absent (Basak, van Mil, and Sathyanarayana 2009, Kamat and Nichter 1998). Several 
authors have alluded to the potential of such ‘market-based’ regulatory mechanisms within 
pluralised, unregulated markets where traditional approaches have failed (eg Ensor and 
Weinzierl 2006, Bloom, Standing, and Lloyd 2008). These reputation-based ways of 
delivering health care are argued to build trust and can, in theory, help to overcome the 
information asymmetry that characterises transactions in healthcare (ibid).  
Another reason why quality may improve in a chain situation arises from the different 
incentive structures in place for pharmacy owners as opposed to managers. High-powered 
incentives exist when the profits of transactions flow directly to the parties involved (Frant 
1996). In the case of independent pharmacy owners, the potential for higher profits provides 
incentives to behave opportunistically. A hierarchical structure (as in a chain) can attenuate 
opportunism because the incentives faced by the personnel working in the pharmacy are low-
powered (if salaried). While chain owners themselves will have incentives to maximise 
profits, these incentives may not be transmitted directly to their frontline staff. This could 
improve some aspects of treatment in public health terms, as a number of poor practices have 
been found to be linked to profit maximising strategies (which require effort), for example, 
the sale of medicines with high profit margins (Miller and Goodman 2016). Other aspects of 
good practice, such as counselling, are effort intensive and these practices may worsen 
among employees of chain pharmacies with a tendency to shirk. Some economists suggest 
that incentive schemes are the key to overcoming these moral hazard problems (Hölmstrom 
1979, Harris and Raviv 1979). Others argue that whilst incentives can improve efficiency, 
they do not necessarily maximise profits- the bonus required to induce high effort can be 
substantial and yield a lower expected profit than using a flat wage (Miller and Whitford 
2007).  
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Figure 1: Hypothesised effects of pharmacy chains on quality of care provision 
 
Methods 
Between 2014 and 2015 we conducted 38 in-depth interviews with pharmacy employees and 
other stakeholders in Bengaluru, India. Bengaluru presents an appropriate setting for this 
research as a number of pharmacy chains are well established. We have used the interviews 
as a tool to test the hypotheses laid out above, an approach advocated by Miles and 
Huberman (1994). The framework informed both the development of the interview guides 
and the analysis, although we were open to any new ideas or issues that arose.  
The interviewees were selected as a sub-sample from the pharmacies in our SP survey (see 
Miller and Goodman (2017) for full details). We used a list of all pharmacies in Bengaluru 
urban district, obtained from the Karnataka State Drug Control Department, as a sampling 
frame (we validated the list through three neighbourhood censuses which found it to be 97% 
accurate). The list contained 5135 independents and 529 chain shops deriving from 13 
chains.  For the SP survey we then selected a random sample of pharmacies, stratified as 
either ‘chain’ or ‘independent’, including shops from 8 chains- the largest 7 and one chain of 
the 2-5 outlet size.    
We completed in-depth interviews with 9 chain senior executives working in these 8 chains. 
Additionally, we interviewed 14 staff working within chain pharmacy branches; 12 
independent pharmacy owners (representing a geographical range across the city); and 3 key 
informants including the drug control department and pharmacy associations. Interviews 
were conducted by RM, with the help of a local research assistant, in English, Kannada or, 
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Hindi, depending on the interviewee’s preference. Two chains did not give permission for us 
to speak with their branch staff. However, many of the staff we interviewed had previously 
worked in other chains so we asked them about their experiences as ex-employees. A few of 
the chain interviewees had previously owned their own shop and we questioned them about 
their experiences working in both environments.  
Interviews with chain senior executives explored the underlying business model, ethos and 
structure of different firms, with a particular focus on staff recruitment, salaries and 
incentives. We also sought to understand mechanisms employed for controlling quality, 
performance management, and relationships with drug control bodies. The interviews with 
staff working in chain branches concentrated on the incentives faced and motivations for 
working in such a setting; their relationship with head office; and factors affecting their 
treatment behaviour. Interviews with independent pharmacy owners served as a comparison. 
Coding of the interview transcripts was completed by RM in NVivo 11. The hypotheses in 
figure 1 were used to generate an initial set of pre-defined coding categories.  In an iterative 
process, these codes were applied to the data, with data-generated codes added as they arose, 
and then the final coding frame was agreed by all authors. Deviant cases can be particularly 
useful for hypothesis testing and, as such, particular care was taken to look for these 
(Silverman 2010). As some of the same topics were discussed with both chain executives 
and branch staff, we sought to triangulate the data collected from both sources, particularly 
for those working within the same chain. Care was taken to focus on what interviewees did 
(ie through specific examples) rather than just broad statements about an issue; although 
when discussing sensitive issues it was found to be helpful to ask about how other 
pharmacies acted because interviewees were sometimes reluctant to admit themselves to 
practices that would be frowned upon.  
Ethical approval was obtained from the London School of Hygiene and Tropical Medicine 
Ethics Committee, UK and the SOCHARA Institutional Scientific and Ethics Committee in 
Bengaluru, India. Verbal consent, witnessed by a fieldworker, was obtained prior to all 
interviews. Verbal, as opposed to written consent was obtained as providers in many drug 
outlets (or chain headquarters) tend to be very cautious of inspectors and suspicious of 
having to sign documents that may be used to identify them or their outlet/company.  
Findings 
Considering the lack of literature on pharmacy chains in LMIC, we begin this section with a 
description of the pharmacies studied and the context in which they operate. The findings 
that follow are then organised under the three determinants of practice - knowledge, 
regulation and profit motive. We visit each of the hypotheses (numbered in figure 1) 
126 
 
regarding how chains may affect these determinants and present the supporting or refuting 
evidence from our data.  
 
Knowledge 
Hypothesis 1: More trained pharmacists at point of service delivery? 
Whilst we were not able to verify the proportion of chains and independent stores staffed by 
qualified pharmacists, senior management amongst all chains claimed that they employed a 
qualified pharmacist to work in each store. However, several of these informants later 
admitted that recruitment of pharmacists was a major challenge and this was not always 
possible. Some commented on a scarcity of qualified personnel in the labour market. Many 
pharmacy graduates were said to open their own store, find a position in the pharmaceutical 
industry, or pursue careers unrelated to pharmacy. Poor salaries and low social status 
reportedly drove people out of the profession.  
Both chain and independent shop staff talked about renting the certificate of a qualified 
pharmacist, whilst the certificate holder worked elsewhere. Where a pharmacist was present, 
due to long opening hours, this was only for a portion of the day. Further, cover was seldom 
provided for pharmacist’s day off and holidays.  
“No, in some shops they will be there and in some shops they are not there. If the staff 
shortage is there, only Pharma Aide and experienced person will be there. Pharmacist will 
not be there.” KI#20 chain pharmacy aide  
“No, we don’t have [DPharm or BPharm], we have taken licence of some other 
person…yearly we have to pay 30 thousand.” KI#31 independent owner 
Many interviewees talked about ‘experience’ and saw this to some degree as a substitute for 
formal qualifications. In fact, individuals with several years’ experience working in 
independent shops were viewed by some as more knowledgeable than qualified pharmacists. 
A few interviewees cast doubt over the quality and appropriateness of pharmacy education. 
The syllabus was described as outdated, with an emphasis on subjects such as 
extemporaneous preparations that are no longer relevant to pharmacy practice today and 
missing others such as ‘therapeutics’. The reality was that pharmacy personnel learn on-the-
job. Experience was acquired through various means, including learning from the shop 
seniors or pharmacist, doctors’ prescriptions and customer requests for medicine. It appears 
that knowledge accumulated from these avenues was not always in line with treatment 
guidelines but, once learned, these practices were enacted, reinforced, and passed on to the 
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next ‘trainee’. Some chains provided training for new staff members but the focus of this 
was on interaction with customers and company procedures, rather than anything medicine-
related (described in more detail below).  As one chain in-charge said: 
“Every day some problems some problem like somebody came and say me that give me 
Taxim-O 200mg [3rd generation cephalosporin].  Just I don't know what is the use of it. Ask 
the sir [pharmacist], after customer went off, ‘Sir it’s for what.’ He says it’s for fever, 
antibiotic. Just he is explaining and we are learning from that only.” KI#8 chain pharmacy 
aide 
Another employee describes how he came to learn about the medicines he sells: 
“I am zero knowledge person in the beginning. I was in checking for one year in [large 
pharmacy chain] for audit department. We will go morning by 8, we check cash, and total A-
Z stock will be checked. Morning 8 to 6 we do that. If any shortage is there, we have to 
inform to manager…When I started getting to know about medicine knowledge, in this audit 
we got to know the medicine name and what is the molecule. After that I could do in outlets. 
Then I worked for 2 years as normal employee. After I got promotion as in-charge and 
worked for 1 year.  
RM: Did you get any training while joining? 
Respondent: No training. That audit was training. 
RM: After auditing when you joined the pharmacy store, was there any training at that time? 
Respondent: No. I will observe and learn.  
RM: What did you study? 
Respondent: BCom in computers. It's a degree.” KI#19 chain pharmacy aide  
Interviewees in chains reported no legal requirement for a member of the senior management 
team to possess pharmacy qualifications and take responsibility for maintaining safety 
standards. As such, the clinical aspect of running a pharmacy within a chain was left to the 
pharmacist or in-charge and not a matter concerning senior management.  
The overall picture we gained of staff working in chain pharmacies, and the knowledge they 
possessed did not appear to be any different to those working in independent pharmacies, 
where the narrative around qualifications and experience was similar to that in chains.  
Regulation 
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This section examines hypotheses 2a and 2b, before turning to a data-generated theme 
around bribery.  
Hypothesis 2a: State regulation is more easily enforced by concentrating on central 
management structures 
We found that drug inspectors did not enforce regulation through chain headquarters. Within 
Karnataka state, areas are divided into ‘circles’ (geographical areas comprising of several 
postcode zones). Bengaluru has 6 circles with an assistant drug controller (ADC) assigned to 
each. Under the ADC are 2-3 drug inspectors.  ADCs and drug inspectors each take 
responsibility for a number of postcodes within the circle and are required to inspect each 
pharmacy in their designated postcodes at least once a year. Staff working in shops most 
commonly reported that they were visited by drug control once every 6 months, although the 
range was from 3-monthly to annually. Several chains had shops in multiple circles and 
therefore interacted with numerous inspectors. The level of control in each area appeared to 
differ due to the individuals responsible for enforcement. 
Most chains and the drug control department reported that there were no differences between 
the regulation of chain shops and independents. However, one chain executive felt that drug 
controllers came down more harshly on chains compared to independent pharmacies in event 
of a violation of the rules. Chains, he described, were treated with less leniency due to the 
processes and operating procedures in place.  
Hypothesis 2b: Chains self-regulation to preserve the identity of their brand? 
A host of methods were employed by chains in order to keep constant track of day-to-day 
operations in each store. The main strategies included regular shop visits from supervisors, 
area managers and more senior managers. Sales reports were usually sent daily, although 
some chains had information systems that enabled monitoring of real time sales. CCTV 
cameras were used to monitor the behaviour of shop staff and several chains sent mystery 
shoppers to their stores (and their competitors). The impression given was one of relentless 
monitoring. Chains that utilised CCTV claimed to watch their staff closely and staff 
corroborated that they were informed immediately of any sub-par performance.  
While this initially might imply quality was being monitored, the overarching theme across 
all chain interviews, both with management and shop staff, was that ensuring a positive 
customer experience was the highest priority. Key areas of concern included customer 
service, ambience of the pharmacy, appearance of the staff, and ensuring availability of 
medicines. Management went to great lengths to guarantee that in-store staff were friendly 
and polite to their customers. On joining a chain, staff undergo training (ranging from half a 
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day to a few weeks). The majority of this concerned how to treat and interact with 
customers. Chain executives described how independent shop owners have excellent rapport 
with their customers and chains felt it was essential for their staff to match this, in order to 
attract and maintain customers.  During shop visits, managers also checked that the store was 
neat and tidy and staff members were presentable.  
Whilst there is irrefutable evidence that chains do self-regulate, the aspects of practice that 
they strived to control were not the same as those that concern the public health community 
ie sale of appropriate medicines and advice provision. We know from our SP survey that 
case management was poor in both independents and chains, which is not surprising given 
the lack of self-regulation of quality of care in chains. One chain Chief Executive Officer 
(CEO) explained what the training in his company involved: 
“Yes, they need to dress well, they need to be able to communicate well so then their level of 
English needs to be good. Their level of Hindi needs to be good. So we employ people who 
can speak all the three languages because Bangalore is like a melting point right now. So 
you have people from all kinds of various cultures coming…Of course they need to follow the 
SOPs [standard operating procedures] again. So that stresses on how well you treat 
customer, how you make the sale. How you finish the sale. So those are the things we train 
them before they start.” KI#24 chain executive. 
Another chain executive vented his frustration regarding the lack of customer care he 
commonly observed on CCTV:  
“Sometimes they will be seeing that Facebook and all, will be telling to them don’t see that, 
then if the customer comes, they won't stand up and they won’t greet the customers. They 
won’t be any smile, they will be standing like a robot and they will be doing. We will be 
telling you have to do like this and all that. Because a smile is most important whenever a 
customer comes.” KI#2 chain executive. 
Alongside customer interaction, chains reported stock availability as the other crucial 
concern. Both headquarter and in-store chain staff explained that filling all items on a 
customer’s prescription without any ‘bounce’ products (items on a prescription that are not 
available) was essential for customer satisfaction. In instances where required items are not 
available, there runs a risk that the customer will go elsewhere and not patronise the store for 
future transactions. Due to the large number of brands in the Indian market and the illegal 
nature of brand substitution (a different brand with the same active ingredient cannot be 
dispensed in place of the brand prescribed), this was cited as a key challenge. Some chains 
report sending mystery shoppers with prescriptions to monitor the ‘bounce ratio’.  
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We observed that employees often appeared to buy into the goals and mission of the chain in 
which they worked. In interviews with in-store employees they used a lot of the same 
language and talked about the same issues as being important as the headquarter staff. These 
comments from a chain employee echo the concerns of the management:    
“RM: Why are people coming to [pharmacy chain], in what way are you keeping them 
happy? 
Respondent: Availability of medicines, and we used to welcome them with a smile, I used to 
check the order list of their medicines and if that medicine is not available I used to tell them 
will get that evening, we used to take their mobile numbers and call them after it.” KI#16 
pharmacy aide. 
There was little evidence of chains regulating the clinical aspects of pharmacy practice in 
their stores- for example, the accuracy of advice given or the appropriateness of medicines 
sold. A small proportion of chains did mention that they monitored sales of POMs without a 
prescription. One ex-staff member of a leading chain explained that staff were told explicitly 
not to make such sales. Another working in a smaller chain described how their head office 
sent mystery shoppers to purchase POMs in order to determine whether there was mis-
selling in their pharmacies. These strategies may explain the relatively lower sales of POMs 
for diarrhoea patients in chains compared to independent shops in our SP survey (although 
this was still common in both shop types). However, only a minority of chains touched upon 
this issue and it was clear that clinical governance was not an area of interest to most chains, 
as shown by this conversation with one pharmacist: 
“RM: Do they monitor the medicines that you are selling or the advice you are giving? 
Respondent: Medicines? 
RM: In the sense, if somebody comes and says can we have something for diarrhoea or fever 
- do they check what medicines you give? 
Respondent: Yeah, yeah we will give common medicines for diarrhoea. 
RM: But do head office check? 
Respondent: No, no they won’t. They don't know about this thing what to do –only I have 
knowledge. They don't know about that.” KI#25, chain pharmacist. 
In our SP survey, we found that the more highly restricted H1 medicines were rarely sold, by 
either chains or independents. We were keen to understand how pharmacy staff understood 
and interpreted these regulations and how drug control authorities had achieved success in 
the control of these medicines. We found that around two-thirds of both chain staff and 
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independent interviewees were aware of the difference between H and H1 medicines. Most 
interviewees spoke about H1 medicines with an aura of seriousness. They did not give a 
great amount of detail but there was a general understanding that you simply did not sell 
these medicines. Several informants (from both chains and independents) confused schedule 
H1 and X. Interviewees reported that drug control are stricter on restricted schedules. 
Regulatory authorities confirmed that they were more aggressive in the control of these 
schedules and that they typically would suspend or even cancel the licence of a shop found 
to be selling such medicines.  Sale of H medicines, however, was only punishable by a fine 
or brief shop closure. One chain pharmacy had a list of these prohibited H1 medicines on the 
wall for staff to refer to and another reported that there was a SOP in place for dispensing 
them. Asides from these two examples we did not find any major differences between the 
attitudes of chains and independents towards the more regulated medicine schedules.  
Practices of bribery undermining regulatory system  
Several interviewees talked about the bribing of drug controllers. Most of these reports came 
from independent shop owners, who talked candidly about this.  One CEO of a chain 
touched upon this but his comments related to the industry in general, rather than any 
specific practices that occurred within his organisation. The impression given by these 
informants was that bribery was commonplace and organised in nature. One interviewee 
described how all pharmacies in his area were required to give a fixed amount (4000 Rs/$62) 
every 6 months and this was collected and passed on to the authorities by a local coordinator. 
In another area, fixed amounts were said to be collected monthly. Shopkeepers described 
how pharmacies that ran without a pharmacist had to pay a higher rate than those where a 
pharmacist was present. Interviewees explained that if bribes were not paid then drug 
controllers would be sure to find something they could penalise for during their next 
inspection visit. Payment of the bribe would ensure inspections were uneventful.  
“RM: How come so many medicines are sold without a prescription then? 
Interviewee: They get bribed. It’s easy to bribe a drug controller. As long as you pay them 
they will not complain. 
RM: So they don’t regulate POM well? 
Interviewee: They say they do but they don’t. The entire supply chain pays the drug 
controller. Retail market is unorganised but bribing is very organised. There is a package 
you keep paying them and they don’t come.” KI#7 chain MD 
Chain staff working in pharmacy branches did not talk about such practices. However, as 
employees, they would not have the status to authorise any bribes on behalf of the chain and 
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it is unknown whether such practices occurred at a higher level. Even if such practices were 
commonplace, it is unlikely that this information would be shared freely. We cannot be sure 
whether the practices are just hidden in chain organisations or whether it is a phenomenon 
restricted to independents.  
Some independent shop owners said that they had never encountered any requests for 
payment from drug controllers. This may be because they did not wish to acknowledge this, 
being a sensitive issue; or because such practices are area dependent, based on where a 
pharmacy is located and who is responsible for enforcement. The workload of the drug 
control department was also mentioned. With so many shops to visit, one pharmacy owner 
explained how it would not be possible for them to check everything in one day.  
Profit motive 
Hypothesis 3: Low-powered incentives will arise within the hierarchical structure of a 
chain? 
Independent pharmacy owners came across as more business-oriented than chain employees; 
and it was evident that their livelihood was closely linked to sales. Whilst in theory, we 
expected chain staff to be less invested in sales and profit, in practice they were incentivised 
by numerous targets and relentless pressure from head office. Most chains set monthly sales 
targets for each of their shops and some had other specific targets. These included the sale of 
‘private label’ products (generic medicines or toiletries that are branded for that particular 
chain), number of home deliveries and ‘customer related’ targets. Chain staff reported that 
they were motivated to work hard to meet these targets, because the bonuses associated with 
reaching them were worth it; it gave them job satisfaction to feel they were performing well; 
and it showed they were fulfilling their customers’ needs. In addition, some chains offered a 
monthly award for the branch with the highest sales and employees were keen to win this for 
‘name and fame’.  Monthly sales bonuses were reported to be between 2,000 ($31) and 
20,000 ($311) Rs, most commonly 10,000 Rs ($156) (divided between all store staff of 
which there were usually 4-5). In light of staff salaries, this was relatively substantial 
(around 25% of pharmacy aide and 10% of pharmacist salary) and hence motivating. Private 
label incentives were particularly strong with the bigger chains offering staff 10-12% of sales 
profits. The margins on these products were said to be 200-300%, which was very high 
compared with usual margins on branded products (which are preferred by customers) of 
around 15-40%. 
When scrutinising the strategies of profit maximisation identified from our data, there 
appeared to be some differences between chain and independent shops. Independent shop 
owners reported selling POMs without a prescription because they did not want to lose 
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business. They admitted selling antibiotics because they had a good margin. Finally, they 
stated that they gave priority to products which they had purchased on offer e.g. on a buy X 
strips get Y strips free basis (these were said to commonly be antibiotics and combination 
cold and flu medicines). In terms of medicine sale choices amongst chain employees, there 
were several reports of trying to sell private label products in the first instance, which is not 
surprising considering the strong financial incentives associated with these products. Only 
one chain staff member talked about deliberately choosing items based on their profit 
margin. When pushed on how they achieved their sales targets, the strategies reported by 
chain staff tended to be more customer orientated. For example, if any prescription items 
were not in stock, they ensured those items were ordered and delivered to the customer’s 
home that same day; they made lists of regular customers and called them to see if they 
needed to replenish their stock; and they talked to their customers ‘like family members’. 
This is not to say that independent staff were not also mindful of their customers. In addition 
to offering a friendly, timely service, independent shops offered credit to customers who 
could not afford medicines and cut medicine strips into smaller quantities for poor clients. 
Both chain and independent pharmacy interviewees reported selling medicines that they 
believed would ‘cure faster’- though medicine sales based on perceived efficacy is often not 
in line with standard treatment guidelines.  
Discussion 
We generated several hypotheses regarding how the chain structure might influence the 
knowledge of pharmacy staff; the way in which they are regulated; and the profit motives 
faced by employees, in comparison to independent pharmacy owners. In-depth interviews 
with a range of individuals working in chain headquarters and pharmacy stores, independent 
shop owners and key informants allowed us to explore these hypotheses.  We have presented 
our results under distinct headings but, in practice, these three areas intertwine and influence 
one another. For example, most aspects of chain self-regulation relate to customer 
satisfaction. In turn, happy customers become repeat customers and this is therefore related 
to profit maximisation. Business strategies are inextricably linked to survival in the market, 
which is shaped by the intense nature of competition. Similarly, pharmacy staff 
understanding and interpretation of the different medicine schedules straddles the themes of 
knowledge and regulation. While our hypothesis driven approach allowed for a focused 
investigation of specific issues and we allowed for data generated themes to emerge, a more 
inductive approach could have led to a closer examination of these interconnections 
A further limitation of this work was the selection of chain interviewees. In some instances, 
chain headquarters only approved us to interview employees in specified outlets. We assume 
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that in these cases, chain executives sent us to stores they deemed to have the most 
competent and qualified staff, which may not have been typical. Additionally, most chain 
executives dismissed any claims of bribery in the industry. This needs to be explored further 
to determine whether it is only a concern for independent pharmacies.  
Our findings revealed that most of the theoretical mechanisms for quality improvement did 
not hold true in practice. An apparent shortage of pharmacists willing to work in the retail 
sector and the legitimising of ‘experience’ as a substitute for qualifications, meant that not all 
chains were operating with a qualified pharmacist (akin to independent shops). Regulation of 
chains differed little compared to independent shops, and the authorities did not direct their 
efforts towards chains’ central management structures. Further, chains did not self-regulate 
aspects of quality that concern public health advocates. A small subset of chains took action 
towards monitoring the illegal sale of POMs without a prescription but as one chain 
managing director explained, “bringing ethical standards to corporates- that is lacking 
currently” KI#7. In terms of self-regulation, chains were myopically preoccupied with 
customer service and satisfaction. Additionally, the pervasive nature of bribery in the sector 
was a barrier to effective drug control. Whilst we hypothesised that chain employees face 
low-powered incentives, in fact this was not the case because in addition to salaries there 
were lucrative sales targets and unyielding pressure to improve sales figures. Profit 
maximisation, in itself, is not necessarily a problem, but it has previously been linked to poor 
and harmful practices in the pharmacy context (Miller and Goodman 2016).  Profit 
maximising strategies of chains seemed to be more customer centirc compared to 
independent pharmacies- which tended to focus on medicine sales. The latter is more of a 
concern from a public health perspective because when medicine sale choices are driven by 
profit considerations, patient safety and clinical needs can be compromised.    
Policy implications and potential of chains  
It was evident from our study that pharmacy chains are primarily business entities and their 
main concern is increasing sales and turnover. Perhaps unsurprisingly, the aspects of quality 
that chains focussed on were those that are observable to customers- the friendliness of staff, 
cleanliness of the shop and the availability of medicines ie perceived quality. Asymmetric 
information about the technical quality of care (from a health perspective) disincentivises 
chains to monitor and improve it. Patients are, in most cases, lacking perfect information 
regarding the treatment and advice they require, and therefore judge ‘quality’ based on what 
they can see and chains are sensitive to this.  
Whilst the current emphasis of chains is on customer experience, the methods in place to 
control staff behaviour on the shop floor are undeniably extensive and effective. One could 
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therefore argue that chain pharmacies have the potential to use this established strong 
influence over staff behaviour to engender health improvement. However, this is likely to 
require outside engagement in this principal-agent relationship- for example, by external 
regulation. Others have written extensively about the disconnect between government 
aspirations to enforce regulation through administrative and bureaucratic controls and the 
realities of highly unregulated private health markets in LMICs, including India (eg Bloom, 
Henson, and Peters 2014, Sheikh, Saligram, and Hort 2013, Bloom, Standing, and Lloyd 
2008, Ensor and Weinzierl 2007, Peters and Muraleedharan 2008). Some propose a more 
active role for civil society, the media and provider organisations in order to realise the 
potential of consumer and market-oriented regulatory approaches in a context of government 
regulatory failure (Peters and Muraleedharan 2008). Yet our SP survey showed that not a 
single chain shop sold H1 medicines and our interviews confirmed that penalties from drug 
control for this offence were harsh. This indicates that external regulation can be effective in 
certain circumstances, and relatively more effective through chains that can successfully 
control treatment behaviours of their staff.  There may therefore be potential to extend tighter 
regulatory control to other elements of care provision, by harnessing chain management 
structures.  
However, currently there remains a distinct lack of clinical accountability among chains. 
Pharmacists or in-charges were not answerable to any senior management figure regarding 
their clinical actions. The presence of a pharmacist on the senior management team to take 
responsibility for patient safety and hold staff to account for their actions (as in some other 
countries), in a clinical sense, was absent. Pharmacy legislation does not appear to have kept 
pace with organisational change, and clinical governance in the sector warrants attention. 
Further, interviewees did not appear to possess a sense of professional identity. Others have 
noted that professional standards are lacking in India and suggest that state pharmacy 
councils could do more to improve the situation with continuing professional development 
(CPD) activities and guidelines for practice (Adepu and Nagavi 2009). Chains would be in a 
position to oversee and enforce CPD activities of its staff, or even provide clinical training. 
Conclusion 
Chains are expanding rapidly in India and elsewhere in Asia, South America and Africa.  
Going forward, there is interest in the potential of pharmacy chains in LMIC as a solution to 
the substandard practices that typify retail pharmacy in these settings. Up until now, there 
has been no empirical evidence of whether and how these chains do enable quality 
improvements. We have found that, in their current state, expectations for quality 
improvement were not in evidence. However, the existing architecture and the influence they 
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exert over their staff offers opportunity for intervention and a potential focal point for 
regulatory bodies, meaning that chains could prove to be a vehicle through which to affect 
change in the sector in future. However, this requires a realistic attitude to the company goals 
and incentives such private sector organisations face, which are not usually aligned with 
public health needs.  
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PART IV: DISCUSSION AND CONCLUSION 
8 Discussion 
8.1 Introduction  
This PhD set out to better understand the effects of chain pharmacies on the functioning of 
Indian pharmacies, compared to independent pharmacies, and the implications for public 
health. To inform this work, I conducted an up-to-date, systematic literature review 
examining the performance of independent pharmacies in low and middle income Asian 
settings (Miller and Goodman 2016). This provided a comprehensive overview of the status 
quo. The review included over 50 papers from 14 countries, with the most research coming 
from India and Vietnam. I found that history taking was insufficient; of particular concern 
was the lack of enquiry about danger signs that would indicate a more serious underlying 
condition. Whilst minor ailments can be managed in the pharmacy environment, some 
conditions (or symptoms of conditions) presented at the pharmacy require examination, 
diagnostic testing, or POMs and therefore their management is outside the remit of a 
pharmacist’s expertise. In these cases, clients should be referred for medical attention, yet 
many patients were reportedly ‘treated’, rather than referred. The sale of POMs without a 
prescription was a common phenomenon in all 14 LMI Asian countries included in the 
review. Worryingly, antibiotics were reported to make up between a fifth and a third of all 
purchases. In addition, medicine sales were commonly clinically inappropriate and 
frequently sold unlabelled, outside their original packaging. Finally, medicine sales were 
reportedly accompanied with limited counselling and advice provision.  
As part of the same review, I also sought to understand what the key determinants driving 
these poor practices were. From the literature, I was able to identify three important factors, 
namely profit motives which may influence pharmacy personnel, knowledge, and the 
regulatory environment. Drawing on economics literature I then generated a set of 
hypotheses regarding how being organised as a chain may influence these determinants, and 
hence performance. I hypothesised that the following key behaviours may differ within the 
chain structure and lead to potential quality improvements: (i) employment of qualified staff; 
(ii) ability of government authorities to concentrate regulation on central management 
structures; (iii) propensity for self-regulation; and (iv) potentially lower-powered incentives 
for chain employees, compared to independent owners. I then extended this thinking to the 
potential effects on other public health concerns, including the price, quality of medicines, 
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and access. Chains could be argued to have the potential to reduce prices by exploiting scale 
economies and enjoying buying power in the market; and improve drug quality through 
shortened supply chains and improved medicine storage capabilities. In terms of 
geographical access, I hypothesised that chains were unlikely to expand out of urban centres. 
I used these insights to create a set of hypotheses (figure 1, chapter 3), which provided the 
theoretical underpinning for the programme of work that followed.    
In this discussion, first I provide a summary of the results and situate my results within the 
existing literature; I then explore the limitations of the work, examining the scope of the 
research and methodologies utilised; I reflect on the generalisability of the findings and then 
highlight the contribution of this thesis. Finally, I consider the policy implications of this 
work and present concluding remarks.  
8.2 Summary of findings and comparison with the literature  
This section provides a summary of the empirical research findings, in light of the specific 
objectives initially laid out; it also situates the findings within the context of previous 
relevant research. 
8.2.1 Objective A: To compare the quality of case management (of two tracer 
conditions) at chain and independent pharmacies 
As shown in chapter 5, my SP survey revealed that the management of suspected 
tuberculosis and childhood diarrhoea was equally poor at both chain and independent 
pharmacies. I found no significant differences in terms of history taking between chains and 
independents for either case. Fewer than 10% of both pharmacy types asked a single 
question to the parent of the child with diarrhoea; and for the suspected TB case this figure 
was around one fifth for chains and independents. Advice provision was similarly limited, 
again with little difference between pharmacy types. For example, only 1% of chains and 
1.7% of independents advised the SP that TB treatment was available free of charge from the 
hospital. Similarly, for the diarrhoea case, of pharmacies which did not initially refer the SP 
(59% of chains and 63% of independents), less than 1% advised to visit a doctor in case of 
any danger signs.  
In terms of treatment recommendations, there were no significant differences between 
pharmacy types for the suspected TB case. 43% of chains and 45% of independents managed 
the case correctly (referral without selling antibiotics or steroids); antibiotics were sold by 
17% and 16% of chains and independents respectively. Overall, management of the 
diarrhoea case was of poorer quality. Not a single pharmacy managed the SP according to 
national and international guidelines (sale of ORS and zinc in the absence of antibiotics, 
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antidiarrhoeals or antispasmodics). Disappointingly, rehydration therapy was only 
recommended by 12% of chains and 10% of independents. Chains did, however, compare 
favourably to independent pharmacies in terms of harmful medicine (antibiotics and 
antidiarrhoeal) sales (35% vs 48%, p=0.029) and sale of POMs without a prescription (37% 
vs 49%, p=0.048).  
These findings paint a depressing picture of the management of both a minor ailment and a 
more serious condition requiring referral in the pharmacy setting. There is a growing body of 
work that has used SPs to assess the quality of medical care in India’s private sector (eg Das 
et al. 2012, Das et al. 2015, Mohanan et al. 2015, Satyanarayana S et al. 2016). These studies 
have covered a range of conditions, including diarrhoea, TB, angina and pneumonia, but the 
results are unanimous: regardless of type of practitioner, facility, or qualifications, 
management appears to be poor. Of the aforementioned SP studies, only Satyanarayana and 
colleagues studied quality of care at pharmacies; they assessed the management of TB in 
three urban areas (Delhi, Mumbai, and Patna). The results of their study across the three 
cities are in line with my findings from Bengaluru - overall history taking was poor with 
patients not being asked relevant questions, and referral for medical attention was 
inadequate.  
Following the publishing of my SP results, I was invited to write an editorial piece, together 
with investigators from the Satyanarayana et al study, examining the results from both 
papers (this paper can be found in Appendix 6). From this work, it emerged that management 
of the SP varied according to the certainty of the diagnosis. The more apparent it was to the 
pharmacist that the patient had TB, the higher the proportion of shops that referred the SP. 
Where the SP presented only with cough and fever (and no explicit mention of TB), the 
referral proportion was 16%; in my study where the SP presented with symptoms and a 
suggestion of TB (as indicated by the relative with confirmed TB) 46% were referred; and in 
Satyanarayana et al’s other case where SPs presented with a positive sputum report, the 
proportion was 67%. This showed that pharmacists did deviate from accepted norms when 
diagnosis was unknown or uncertain, but their management dramatically improved when 
diagnoses were clearer. One can conclude from these findings that a pure profit motive, 
whereby pharmacists wanted to sell medicines to clients at all costs, is a poor explanation of 
observed behaviour (Miller, Das, and Pai 2018). The other important finding from both 
studies is that pharmacists did not sell first-line anti-TB drugs OTC, and sale of the more 
tightly controlled H1 medicines was rare (for all the TB cases and my diarrhoea case). This 
indicates that the enforcement of the H1 schedule has been effective in these urban settings.  
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8.2.2 Objective B: To compare the price of consultations (for two tracer 
conditions) at chain and independent pharmacies  
On examining the prices of medicines purchased for each case (chapter 6), I observed that 
after controlling for auditor effects chains were 23% cheaper for the diarrhoea case (p=0.01). 
Chains were found to undercut the MRP of the diarrhoea encounter, on average, by 1 Rupee, 
compared to -0.17 rupee for independents (p=0.005). Further, chains sold fewer antibiotics, 
which were associated with higher encounter prices.  
Bennet and Yin (2014) also studied the effect of chain entry on price and found that 
independents reduced their prices in response to increased price competition from chains. 
Chain prices were initially 6% lower for two antibiotics (ciprofloxacin and amoxicillin), but 
prices at independents fell by a non-significant 2-4% after chain entry; further analysis 
revealed that for non-national brands the reduction was a significant 12-15%. The lack of 
consideration of such spillover effects in this thesis is discussed under methodological 
limitations in section 8.4.2 below. If chains are able to achieve a given medicine quality at a 
lower cost than independents, it is likely that, in the long run, they will dominate pharmacy 
markets in India (Douma and Schreuder 2008).  
8.2.3 Objective C: To assess the socioeconomic status of clients shopping at 
chain and independent pharmacies 
Using an asset index to assign exit interviewees to wealth quintiles, in chapter 6 I showed 
that the chain clients in my sample were significantly wealthier than independent pharmacy 
clients. Comparing the clients in my sample with the general population revealed that both 
groups (chain and independent customers) were wealthier relative to the general population. 
This was evidenced by the proportion of clients in the top wealth quintile- 20%, 45%, and 
67% for the general population, independent clients, and chain clients respectively (Chi2 tests 
showed differences between each of these groups to be significant (p<0.001 for all tests)). In 
terms of educational attainment, independent clients had a similar profile to the general 
population, and chain clients had a higher educational status. 79% of chain customers had 
reached ‘secondary school’ or ‘higher than secondary’, compared with 60% of independent 
customers and 61% of the general population. These differences in education between chains 
and independents, and chains and the general population, were both significant, p<0.001. 
Differences in the wealth and education profile of chain and independent clients remained 
after conducting the same analysis on a set of pharmacies matched by area (only including 
chains and independents within 1km of each other). This suggests that wealthier and poorer 
clients are self-selecting chains and independents respectively.  
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Given that pharmacies are private service providers, it is perhaps not surprising that the 
customers in our sample were wealthier relative to the general population. Whilst there is no 
specific literature on SES of chain customers in LMICs to compare my findings to, there is 
some research on the effect of social franchises (which use the principles of commercial 
franchising to fulfil social rather than financial goals) on equity of access. A number of 
evaluations have found these services to favour the better-off. (Shah, Wang, and Bishai 
2011, Hennink and Clements 2005, Haemmerli et al. 2018, Viswanathan, Behl, and Seefeld 
2016). However, these services are not comparable with chain pharmacies because joining a 
social franchise is dependent on both the goals of the NGO running it, and how franchisees 
believe they can benefit. Further they tend to be donor led in terms of standards and equity. It 
is therefore hard to draw parallels between these two very different business models. It may 
be that the urban poor in Bengaluru favour informal providers over registered pharmacies 
and physicians. There is evidence for this in other parts of India (Bloom et al. 2011, 
Gautham et al. 2014, George and Iyer 2013).  
There is the possibility that chains or franchises are in some ways off putting to poorer 
groups. In terms of appearance, chains in my study were more likely to have a more high-
end, sterile feel including closed shop fronts, air conditioning, bright lighting and neatly 
organised shelving units. This is in comparison with independent pharmacies, most of which 
had an open on-the-street frontage and were less organised. Further poorer clients may 
choose independents based on their willingness to offer credit facilities; and there is the 
possibility that wealthier clients are more sensitive to quality (processes of care and medicine 
quality). Alternatively, there may be other explanations for the differences observed in client 
mix, such as familiarity with staff, and this would be an interesting area for further research.  
8.2.4 Objective D: To explore how and why the organisational structure of 
pharmacy chains may affect the quality of service provision and prices 
of medicines, compared to independent pharmacies  
8.2.4.1 Quality of service provision 
As presented in chapter 7, through a set of in-depth interviews with key informants, I found 
that most of the theoretical mechanisms for quality improvement laid out in chapter 3 did not 
hold true in practice. Few differences were identified between chain and independent 
organisations in terms of qualifications of staff, regulation enforcement, and financial 
incentives. It was reported that, akin to independent shops, a number of chain branches 
operated without a pharmacist. Drug control authorities did not regulate chains any 
differently, despite the possibilities of utilising the hierarchical structure in place. Further, 
reportedly widespread bribery undermined the drug control process. In the face of profitable 
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sales targets and constant head office pressure to increase revenue, chain employees did not 
appear to face significantly lower-powered incentives than their independent pharmacy 
counterparts. However, I did find differences in the profit maximising strategies of chains 
and independents, the former being more customer focused, and the latter more profit driven. 
I had also anticipated that chains may self-regulate to preserve brand identity and image. 
Whilst I observed that chains exerted strong influence over behaviour of their staff, they did 
not control aspects of quality that are of public health concern. Rather, their main concern 
was customer service and satisfaction.  
It is unlikely that a change in the priority of self-regulation will occur without external 
regulation. Chains are first and foremost business entities, and in order to increase business 
and maintain a healthy customer base, they concentrate their attentions on aspects of quality 
that customers can observe (eg friendliness of staff and availability of medicines). Chains 
have no incentive to self-regulate technical quality because, due to information asymmetries, 
this is not something most customers can observe. In some countries, regulation of medical 
practitioners is delegated to professional organisations. I found that the interviewees did not 
appear to have a strong professional identity and others have noted that professional 
standards are lacking in pharmacy services in India (Adepu and Nagavi 2009). Dua and 
White reported that pharmacists interviewed in their study of antimicrobial use (in India) saw 
themselves as businessmen rather than professionals (Dua, Kunin, and White 1994). This 
view is reportedly shared by the public, other healthcare professionals, and even the 
government (Basak, Arunkumar, and Masilamani 2002, Sachan, Sachan, and Gangwar 
2012).  
Others have reflected on the disconnect between regulatory strategies and the realities of 
health markets in India and LMICs more generally (Bloom, Henson, and Peters 2014, Peters 
and Muraleedharan 2008, Bloom, Kanjilal, and Peters 2008, Ensor and Weinzierl 2007, 
Sheikh, Saligram, and Hort 2013). In their study of the architecture of health regulation in 
two Indian states, Sheikh and colleagues (2013) highlighted widespread gaps in both policy 
design and implementation with this mixed (public and private) health system.  They found 
that implementation shortcomings were underpinned by inadequacy of human and financial 
resources; ambivalence of regulatory staff regarding the roles of their agencies; and 
infiltration and dominance of private sector interests within regulatory institutions leading to 
concerns of regulatory capture.  
8.2.4.2 Price 
Through the qualitative work, it was reported that the majority of chains offered discounts on 
medicines of up to 10%. These discounts were not fully captured by the SP survey, because 
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the SPs were unknown, first-time customers. Chains tended to apply discounts to the 
medicine bills of regular customers (or in some cases just those who signed up to a loyalty 
scheme). Discounting at independent stores was reportedly not the norm and was said to be 
ad hoc; usually owners only agreed to discounts in situations where customers pushed for 
one. The discounts on medicines offered by chains were made possible due to bulk 
purchasing and realising efficiencies in the supply chain. As a result of the fixed MRP, aside 
from discounts, the only other way for pharmacies to reduce medicine prices was to 
substitute cheaper brands (ie non national brands). It was not possible to tell from my 
quantitative analysis the extent to which this occurred. I learned from the interviewees that 
some of the larger chains offered their own line of ‘private label’ medicines (essentially 
generics branded for a particular pharmacy). These medicines were reportedly cheaper for 
customers than national brands and also yielded a greater profit for the pharmacies, hence 
staff were incentivised to sell such products.  
In Bennet and Yin’s (2014) study of chain entry into local pharmacy markets in Hyderabad, 
they found that customer traffic in control markets (where no chain entered) initially 
increased by 25%, yet it stagnated in markets with chain entry (treatment markets). Further, 
two years following chain entry, 96% of independents remained in control markets, 
compared with 91% in treatment markets (both results were significant). These results are in 
line with the grievances of independent owner interviewees who took part in the study. They 
expressed profound concern over the advent of chains, in particular the discounts they 
offered and many relayed how their customer traffic had reduced. 
8.3 Contribution to knowledge  
To date, research on the effect of chain pharmacies in LMICs has been limited. My literature 
review found only 5 prior studies in this area; two covering the sale of abortifacients in 
Mexico, looking at pharmacy type as a potential characteristic of selling such medicines 
(Billings et al. 2009, Lara et al. 2011); one using a quality indicator tool to assess five 
dimensions of quality in Thailand at both chains and independents (Arkaravichien, 
Wongpratat, and Lertsinudom 2016); one looking at equity of pharmacy distribution in South 
Africa (Ward et al. 2014); and a final study investigating the effect of chain entry on the 
price and quality of medicines sold at independent pharmacies in India (Bennett and Yin 
2014). This thesis adds substantially to this small body of literature and is the first piece of 
work to consider comprehensively the overall public health implications of chain pharmacies 
in LMIC settings.  
The thesis presents the first results from a LMIC for a number of outcomes relating to chain 
pharmacies. Whilst the work from Mexico used SPs to ask for misoprostol over-the-counter, 
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my SP work compares the quality of all aspects of case management at chain and 
independent pharmacies, including history taking, treatment choices, and advice provision. I 
also provide data on the prices of these encounters, where Bennet and Yin’s work only 
collected prices for individual medicines. My exit interviews shed light on the type of 
customers (in a socioeconomic sense) served by pharmacy chains in India, an area no prior 
research has investigated in India or other LMICs. Finally, this is the first study to employ 
qualitative research methods to attempt to gain an understanding of how and why chains 
might affect public health outcomes of interest, specifically quality of care and prices of 
medicines.  
8.4 Limitations 
8.4.1 Scope of outcomes investigated  
Whilst the hypotheses presented in chapter 3 laid out the potential mechanisms by which 
chains may affect quality of care, price of medicines, quality of medicines and access, some 
of these outcomes were explored in more detail than others. The following section discusses 
the scope of what this thesis did, and did not cover in relation to those four outcomes.  
8.4.1.1 Quality of care 
The main focus of this thesis was on quality of care, as measured using standardised patients. 
Essentially this captured the quality of case management of an unknown individual for my 
two tracer conditions, childhood diarrhoea and suspected tuberculosis. SPs were chosen 
because they are considered the gold standard in terms of quality measurement and they 
overcome a number of methodological problems associated with other methods (Das et al. 
2012). SPs provide accurate data on how these conditions are managed in everyday life and 
the standardised nature of the cases allows for direct comparison (Madden et al. 1997). 
Quality of care is, of course, a multidimensional concept and there have been several 
attempts to measure it in the community pharmacy setting (mainly for high income 
contexts), using various instruments (Halsall, Ashcroft, and Noyce 2008).  These instruments 
have had varied intentions, measuring clinical governance systems, organisational culture 
and maturity, safety climate and systems, effectiveness of pharmacy services, or patient 
feedback (ibid). Akin to these other instruments, I acknowledge that this research does not 
measure quality comprehensively, rather it concentrates on aspects related to safety and 
effectiveness. Further, there are important aspects of these dimensions that the research does 
not capture, for example, accuracy of prescription dispensing; communication; drug 
labelling, packaging and nomenclature. I also recognise that customers seek care at Indian 
pharmacies for a number of conditions (Evans and Lambert 1997, Lalchhuanawma and 
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Murhekar 2012, Nisula 2006, Seeberg 2012), and the results of this thesis only shed light on 
the management of two of these. However, similar patterns, such as limited history taking 
and advice provision, are likely to be consistent across consultations for various ailments.  
As discussed in chapter 2, the SPs captured the quality of the process of care, as opposed to 
the other dimensions (structure and outcomes) discussed by Donabedian (Donabedian 2005). 
Initially, I also planned to collect data on inputs of care (number of personnel, qualifications 
of staff, presence of refrigerator and power backup etc) through a survey of pharmacies. 
Unfortunately, this was not possible due to the unwillingness of chains to participate in such 
a study.  
8.4.1.2 Price 
Using the SPs I was able to measure the price of encounters for suspected TB and childhood 
diarrhoea at both chains and independents. Due to the heterogeneity of medicines 
recommended for these conditions, this work did not compare the prices of like-for-like 
medicines across pharmacy types. I was able to show, however, that pharmacies adhered to 
MRPs, indicating that there was limited scope for price variation. Measuring the price of 
whole encounters, as opposed to the prices of specific medicines, provided a holistic and 
realistic picture of the effect of chains on medicine price. Additionally, I was able to collect 
detailed information around discounting from my qualitative work that would be missed in 
any purely quantitative study.  
8.4.1.3 Quality of medicines 
The presence of substandard and counterfeit medicines, particularly in LMICs such as India, 
is an area of growing concern (World Health Organization 2017a). Counterfeit drugs are the 
result of deliberate criminal activity and have been defined as those ‘deliberately and 
fraudulently mislabelled with respect to identity and/or source’ (World Health Organization 
1999). Substandard drugs are essentially those that do not meet the pharmacopoeial 
standards set for them, in terms of quality, purity, strength or packaging (Newton et al. 
2006). Such products are an inevitable consequence of inadequate local regulatory controls 
and lack of good manufacturing practices (ibid). This is a particular challenge in India, 
where there are around 8000 local manufacturers. A number of studies have highlighted the 
presence of substandard medicines both circulating in and originating from India 
(Atemnkeng, De Cock, and Plaizier‐Vercammen 2007, Laserson et al. 2001, Minzi et al. 
2003).  Substandard medicines pose a greater public health risk than counterfeits (because 
they are much more common) yet most efforts to address these issues have focused on the 
latter; this is in part because pharmaceutical companies, threatened by such products, have 
invested energy in tackling the problem (Caudron et al. 2008). The same incentive does not 
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apply to substandard medicines, hence the problem remains both poorly quantified and ill 
addressed (ibid).  
Whilst the qualitative work in this thesis touched on the ability of chains to have greater 
control over their supply chains and hence potential for improved drug quality, it was beyond 
the scope of this thesis to study this in detail. I was unable to sufficiently verify how storage 
of medicines differed for chains and independents. It would have been valuable to compare 
the pharmacopoeial quality of medicines sold at chains and independents but unfortunately 
this was outside the scope of this research in terms of both time and funds available). 
However, others have collected such data elsewhere in South India and found that the 
pharmacopoeial quality of MedPlus’ (one of India’s leading pharmacy chains) medicines 
were initially (when a chain first entered a local market) 6% points higher compared to 
medicines sold at independents. However, over time the quality of medicines at independents 
improved until there were no differences between pharmacy types, although this higher 
quality came at a greater cost to the independents (Bennett and Yin 2014). 
8.4.1.4 Access 
Definitions of access are plentiful and varied, but there is consensus that it is related to the 
timely use of services according to need. Peters and colleagues present a comprehensive 
framework for assessing access to health services, which is based on established descriptions 
of access and takes into consideration both supply and demand elements (Peters et al. 2008). 
The framework includes geographic accessibility - the physical distance that must be 
travelled to reach care; availability - appropriate care available for those who need it, for 
example a pharmacy having a qualified staff member or the required medicines in stock; 
financial accessibility- the relationship between the price of services and clients’ willingness 
and ability to pay for them; and finally, acceptability- the extent to which providers are 
responsive to users’ cultural expectations.  
Whilst I proposed that there was potential for chain pharmacies to affect access, this was not 
tested. I hypothesised that chains may restrict their business to urban areas. However, my 
study site only included an urban area so this is not something I was able to measure. I 
enquired about company expansion plans in the in-depth interviews and some chains were 
already operating in or had plans to move into tier II and tier III settings12. I posited that an 
interesting geographical analysis would be to look at chain pharmacy concentration by 
wealth of areas (at the ward or postcode level). Using the GPS location of chains I was able 
                                                     
12 India’s cities are categorised according to their development, population and infrastructure. India’s 
tier I cities include the major metropolises- Delhi, Bengaluru, Chennai, Kolkata, Mumbai, and 
Hyderabad.  Tier II cities include smaller hubs, such as Surat, Jaipur, and Pune. Tier III cities include 
Madurai and Coimbatore.  
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to see that they appeared to have a presence across most areas of the city, rather than being 
limited to specific areas but I was not able to identify a suitable proxy measurement for 
wealth at the ward or postcode level.  
8.4.2 Methodological limitations 
8.4.2.1 Standardised patient survey 
Whilst standardised patients are seen as the gold standard in terms of measuring quality of 
medical care, they still raise a number of methodological issues. The SP method provides 
details on how an unknown, first-time client is managed but it is unclear the extent to which 
this may differ from the management of regular customers. It is also hard to know whether 
the SP presentations were representative of typical pharmacy encounters. The exit interviews 
collected data on the reason interviewees were visiting the pharmacy that day. The most 
common reason was to fill a prescription (57% of chain and 42% of independent clients). 
37% of chain clients and 36% independent clients reported that they were purchasing 
medicines without a prescription; 10% and 9% of chain and independent clients respectively 
had visited to obtain health advice; and these figures were 13% (chain clients) and 16% 
(independent clients) for purchasing fast moving consumer good (eg toiletries). It is unclear 
whether those purchasing medicines without a prescription sought the recommendation of 
the pharmacist or whether they knew a priori which medicines they wanted. Other studies, 
which have used observation to learn more about pharmacy practice in India, have reported 
that patients commonly request POMs by name, by showing a scrap of paper, or by bringing 
in an old sample (Greenhalgh 1987, Kamat and Nichter 1998, Saradamma, Higginbotham, 
and Nichter 2000). It would be interesting for future work to investigate how chains fare in 
terms of managing direct requests for medicines and filling prescriptions (accuracy and 
counselling).   
In terms of the data collection, due to financial constraints the SPs presented both cases in a 
single encounter. They initially presented the details of the diarrhoea case (for an absent 
child) and on the completion of advice for this case they moved on to describing their own 
symptoms that were suggestive of TB. I am not aware of any other studies that have 
presented two cases simultaneously; usually SPs will present one case per pharmacy 
encounter. However, my results are in line with other studies that have presented either 
diarrhoea (Diwan et al. 2015) or TB (Satyanarayana S et al. 2016) as a standalone case in 
India and I therefore have no reason to believe that staff managed the two cases together any 
differently than they would have managed them in separate encounters. My work also shows 
different results for the diarrhoea and the TB case (there were fewer differences between 
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pharmacy types for the TB case compared to the diarrhoea one). This highlights the 
importance of including a range of conditions, where possible.  
Whilst I used standardised guidelines against which to measure the quality of case 
management, there are still many potential ways to present the results. For the TB case, for 
example, the guidelines for pharmacists clearly stipulate that any client with suspected TB 
should be referred. Therefore, whilst referral or non-referral is an easily determined measure, 
the guidelines are of no help in categorising some of the other treatment strategies I 
observed. There is no universal agreement or guidance on which medicines should be 
categorised as ‘harmful’ or ‘unnecessary’. For this I have drawn on the work of others 
(informed by expert panels) (eg Satyanarayana S et al. 2016) and my own clinical knowledge 
having previously trained and worked as a pharmacist. For the diarrhoea case, no pharmacy-
specific guidelines were available and I had to adapt those aimed at ‘physicians and other 
senior health professionals’ by the WHO (World Health Organization 2005). Pharmacies in 
India, and elsewhere in LMICs, are widely used for a host of conditions of public health 
importance, including childhood diarrhoea which is a leading cause of under-5 mortality 
(Indian Council of Medical Research 2017, Kosek, Bern, and Guerrant 2003). It would 
arguably be useful to develop a set of pharmacy- specific guidelines for management of key 
conditions, not only to help improve the management of such ailments but also to provide 
researchers with a clear (and agreed) benchmark against which to measure practice.   
The work of Bennet and Yin suggests that chain entry into a local pharmacy market leads to 
existing independent retailers lowering their prices and increasing their medicine 
(pharmacopoeial) quality (Bennett and Yin 2014). If a similar trend occurred in Bengaluru, 
with regard to spill over treatment quality improvements, this would imply that the measured 
effect of a chain on quality would be biased towards zero. Further, the price differences 
presented in this paper may underestimate the impact of chain entry on market prices. I did 
not have sufficient geographical data in order to determine whether the presence of a chain 
shop alters the behaviour or prices of nearby independents, but this would be an interesting 
area for future research. However, my review of pharmacy practice in Asia reported 
similarly poor management of childhood diarrhoea dating back three decades, ie before the 
advent of chains, indicating that the behaviour of independents has not seen any dramatic 
improvements in recent times (Miller and Goodman 2017). 
8.4.2.2 Exit interviews  
The exit interviews were relatively straightforward, methodologically; however, I have 
identified two potential weaknesses: uncertainties surrounding the response rate and the 
potential for responder or sampling bias, and the reliability of using an asset index to 
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measure wealth. With regard to the sampling of clients for the exit interview, researchers 
approached each client leaving the pharmacy with the aim of enrolling them in the study. 
Whilst researchers were supposed to record the number of clients who refused to participate, 
this was not recorded satisfactorily and, as a result, we cannot calculate the response rate. I 
found that customers in my survey were wealthier compared to the general population. I 
cannot rule out the possibility of non-responder bias if poorer customers were more likely to 
refuse to take part in the survey. There is also the possibility that, in busy pharmacies where 
a number of customers left simultaneously, researchers subconsciously approached richer 
looking customers for participation in the study, although there is no evidence to support 
this.  
With regard to wealth measurement, the asset-based approach I have adopted is one 
alternative to using income and expenditure data, which are difficult to capture. Whilst this 
method has been widely adopted for the measurement of SES in a number of contexts, it has 
also been criticised. Howe and colleagues discuss the limitations of this approach, citing that 
PCA is not appropriate for use with discrete data and that the first principal component often 
only explains a small proportion of the total variation in asset data (only the first principal 
component is used to define the asset index given the aim is to construct a single wealth 
measure) (Howe, Hargreaves, and Huttly 2008). I acknowledge that this method may have 
its limitations, but it provided a rapid, simple and feasible way of collecting SES data. It also 
allowed for comparison with the general population given assets data are collected in the 
open-access DLHS.  
8.4.2.3 In-depth interviews 
One of the key limitations of my qualitative work was the selection of branch staff 
interviewees. Whilst I intended to speak to the staff working in the chain branches included 
in the SP survey, in practice, some chain executives did not allow us this choice; rather, they 
specified which branches I was allowed to visit. In these instances, I assume that I was 
directed to the stores where the staff were most competent and qualified. As such, these 
interviewees may not have been typical. However, this was not the case for all branch 
interviews and, as described in the methods, I also spoke to a number of ex-employees about 
their experiences in their previous companies. I assume that ex-employees would have 
spoken relatively candidly about their experiences in past roles, considering they were no 
longer affiliated with the companies.  
Reflecting on the hypothesis-driven approach used, both strengths and weaknesses emerge. It 
arguably provided fruitful lines of enquiry and allowed for targeted investigation of specific 
issues. However, whilst my results are presented under distinct headings, in practice, the 
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issues of regulation, profit motives and knowledge both intertwine and influence one 
another. A more inductive approach may have led to a closer examination of these 
interconnections. Finally, whilst independent pharmacies spoke freely about practices of 
bribery, most chain executives dismissed such claims. Greater exploration of this topic is 
required in order to uncover whether this phenomenon is restricted to independent 
pharmacies, or whether it is also widespread amongst chains. It would likely occur at a high-
up level between chain executives and senior drug control officials, rather than at the shop 
level. Through one-off interviews it was not possible to develop progressive informality over 
time which may have allowed for the collection of richer data on such a sensitive topic.  
8.4.2.4 Data Gaps 
Researching the private sector comes with unique methodological challenges.  One of the 
major hurdles of this research was that chains did not allow us permission to conduct a 
general survey of chain branches. The purpose of this outlet survey was to collect 
representative quantitative data on characteristics of the outlets, their staff and prices and 
availability of key medicines (at both chain and independent pharmacies to allow for 
comparison). Had I been able to collect such data, I would have been able to investigate the 
association between pharmacy type and treatment behaviour whilst adjusting for potential 
confounders (eg regulatory inspection in the last year, provider experience, and 
qualifications). It would also have provided me with more general descriptive data on the 
two pharmacy types.  
My results have sought to compare chains and independent pharmacies. A further area of 
interest would be the variation within the chain sector (as measured by size of chain). I 
explored the data with regard to chain size and no clear patterns emerged for key outcomes 
but my study was not sufficiently powered for sub-group analysis. This would be an 
interesting area for future research.  
The focus of this body of work has solely been on providers, with little account for patient 
demand. It is important to acknowledge that the pharmacy interaction is two-sided and that 
the demand for medicines is an important determinant of pharmacy provider behaviour. For 
example, there is evidence that clients attribute quality to the mode of medicine delivery 
(Williams et al. 1999). Thus far, this thesis has not considered the impact of patient demand 
on pharmacy staff behaviour and quality of care. The SP method ensures that we have 
measured the quality of management of standardised case presentation. In real life 
encounters, however, providers may make treatment decisions based on what patients ask 
for, or based on what they believe patients want. In investigating supply and demand side 
factors influencing antibiotic use in China, Currie and colleagues (2011) conclude that, in 
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this setting, antibiotic abuse is ‘largely a supply-side phenomenon’. Their work suggests that 
antibiotic misuse is mainly driven by financial incentives (Currie, Lin, and Meng 2014). 
There is scope for future work to investigate whether chain and independent staff respond 
similarly or differently to client demands.  
 
Another facet of provider behaviour that has been shown to be important for physician 
behaviour is altruism. There is empirical evidence that doctors take patient benefit into their 
decision making, rather than simply maximising income at all costs (Kolstad 2013, Lagarde 
and Blaauw 2014). There is no clear hypothesis as to why pro-social motivation of chain 
employees and independent pharmacy workers would differ but this would be an interesting 
area for investigation.  
 
8.5 Generalisability of the findings  
This study was conducted in a single Indian city which raises questions over the extent to 
which the findings are generalizable to other metropolises where chains are concentrated. 
The findings are consistent with other studies that have used SP methodology to investigate 
quality of care for TB and diarrhoea in the private sector in India; although others have not 
included chains (Das et al. 2012, Mohanan et al. 2015, Das et al. 2015, Satyanarayana S et 
al. 2016). In terms of price and SES the literature offers little for comparison. Whilst some of 
the chains studied operate only in Bengaluru, others have presence in South India and even 
across the country. Chain staff in other cities likely face similar incentives and monitoring 
procedures. The regulatory controls governing the functioning of pharmacies are the same 
throughout India, and despite likely variation in state-level implementation, regulatory 
failure is reportedly widespread (Bloom, Kanjilal, and Peters 2008, Greenhalgh 1987, Kamat 
and Nichter 1998, Peters and Muraleedharan 2008, Seeberg 2012, Sheikh, Saligram, and 
Hort 2013). Given these likely similarities, I believe that my findings are likely to have 
relevance beyond Bengaluru and Karnataka. Further, the determinants of good and poor 
pharmacy practice have been found to be comparable across LMICs in Asia, Africa and 
South America indicating that my findings may potentially be applicable in these settings too 
(Goel et al. 1996, Miller and Goodman 2016, Ratanawijitrasin, Soumerai, and Weerasuriya 
2001).  Additional study is warranted in other LMIC settings where chain pharmacies are 
flourishing, to determine if and how their functioning differs to the Indian context.  
8.6 Policy implications  
Pharmacists have historically been absent from health policy discussions in India and the 
concept of engaging this cadre of health professionals for public health improvement has not 
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gained traction (Basak and Sathyanarayana 2009). Schemes to improve pharmacy practice in 
India have been limited to disease-specific initiatives and evaluation of such schemes has been 
limited (cf Gharat et al. 2007). Even within disease specific initiatives efforts to engage 
pharmacies in LMICs have been limited. For example, even after more than 10 years of public-
private mix efforts for TB control, only 5-9% of pharmacies have been successfully engaged 
in promoting such efforts (Konduri, Delmotte, and Rutta 2017). Globally, the role of the 
pharmacist is undergoing a transformation from product and task centric (dispensing) to 
patient centric (advice, counselling, and provision of care), yet this shift is not yet underway 
in India. The latter is arguably more appropriate, given the extensive training pharmacists 
undergo, and their level of expertise. Mossialos and colleagues outline this change in paradigm 
in three stages: retailing of products; safety monitoring; and finally a public health role 
(Mossialos, Naci, and Courtin 2013). They cite that no country has reached the final stage, 
which involves a ‘comprehensive role, including health promotion, prevention and disease 
management’ but that some high-income countries are moving in this direction. They also 
acknowledge that the evidence base for the expansion of the role of pharmacists is limited and 
there is a need for research to evaluate any future developments in this arena. In light of 
demographic, economic and public health challenges, it is hard to ignore the potential that 
community pharmacists may hold in low- middle- and high-income settings.  
8.6.1 Addressing pharmacy practice 
This thesis revealed that the quality of management of two tracer conditions was poor at both 
chain and independent pharmacies, echoing the findings of the original literature review I 
conducted on performance of pharmacies in low and middle income Asian countries. The 
delivery of poor quality care at pharmacies is a health system issue that warrants attention. 
Diarrhoea and TB are both major public health concerns in India. Over a quarter of the 1.8 
million deaths caused by TB in 2015 were in India (World Health Organization 2016). Early 
symptoms of pulmonary TB are vague, common, and persistent, leading those infected with 
the disease to seek care at local primary care providers (Kapoor et al. 2012). A study which 
tracked patient pathways to care in 13 countries reported that over 60% of the study 
population first sought care in the private or informal sectors, including pharmacies (Chin 
DP and Hanson C 2017). Improving the management of patients who present at pharmacies 
with TB symptoms could greatly contribute to control efforts, the success of which hinges on 
early diagnosis and appropriate treatment. The widespread mismanagement of diarrhoea is 
also a huge concern. Diarrhoea accounts for 23% of all deaths in children under 5 in South 
Asia, yet correct treatment with ORS could prevent up to 93% of such tragedies (Morris, 
Black, and Tomaskovic 2003, Munos, Walker, and Black 2010).  Further the pervasive 
selling of antibiotics without a prescription is a major driver for the development of 
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antibiotic resistance, a problem that has been dubbed a ‘global health security emergency’ by 
the WHO (World Health Organization 2014). A study which tracked antibiotic consumption 
over a 10 year period (2000-2010) in 63 countries reported that use during this time has 
increased by 35% and that 76% of this increase was attributable to 5 countries, one of them 
being India (Van Boeckel et al.). In 2010, India was the world’s largest consumer of 
antibiotics for human health (Laxminarayan and Chaudhury 2016). Tackling the irrational 
use of these medicines in pharmacies is paramount among efforts to tackle the global threat 
of antibiotic resistance 
There are also a number of positive findings resulting from this work that I wish to highlight. 
Firstly, Bengaluru enjoys a well-developed network of pharmacy outlets, providing good 
geographical coverage and hence access to medicines for the city’s residents. Moreover, the 
registration system appears to be effective, with nearly all outlets being registered and the 
drug control department holding up-to-date and accurate records of the city’s pharmacy 
outlets. This is in contrast with many other LMIC settings where routine health information 
systems have poor coverage of the private sector and provider registration data are limited 
(Conteh and Hanson 2003). However, perhaps the most promising finding was the limited 
use of H1 medicines and the apparent effective regulation of this more recently introduced 
schedule. The OTC sale of antibiotics from pharmacies is an ingrained norm in so many 
LMICs that it may take considerable time and effort to bring the sale of such medicines 
under control. In the meanwhile, India’s apparent success in introducing a hierarchy of drug 
control could hold lessons for other countries and prove to be a key component in the fight 
against antibiotic resistance. 24 antibiotics have been moved from the H to H1 schedule, 
including third and fourth generation cephalosporins, carbapenems, first- and second-line 
anti-tuberculosis drugs. and newer fluoroquinolones (Hazra 2014); and moreover, the 
penalties for flouting the regulations with regards to these medicines are more severe. SP 
work from this thesis and other studies has showed that H1 medicines were very rarely sold 
OTC in Bengaluru, Patna, Mumbai, or Delhi (Miller, Das, and Pai 2018). My qualitative 
work revealed that pharmacy staff were tightly bound by the implicit norms that restrict the 
sale of these medicines. Further, Laxminariyan and Chaudhury (2016) note that a number of 
retail pharmacy licences have been revoked following non-compliance with the regulations 
concerning the H1 schedule. However, they also caution that several important antibiotics, 
such as gentamicin and tigecycline, are not included in the schedule and that pharmacies may 
substitute for such medicines still under the H classification. Future work should investigate 
whether this is the case.  
Categorising medicines into tiers is a recent innovation in public health and ties in with the 
WHO’s 20th Model List of Essential Medicines, in which they have introduced three 
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categories of antibiotics, representing the biggest update to the antibiotic section of the lists’ 
40 year history (World Health Organization 2017b). This move in a bid to develop 
stewardship of antibiotics at the local, national, and global level sees antibiotics categorised 
as either ‘access’, ‘watch’, or ‘reserve’. ‘Access’ antibiotics should be available at all times 
to treat a wide range of common infections; ‘watch’ antibiotics are first and second line 
choices for a small group of infections; and those in the ‘reserve’ group are to be saved as a 
last resort where all other alternatives have failed. Using such categorisation to inform tiered 
drug schedules is a policy option that warrants greater attention in settings that struggle with 
the sale of POMs OTC.  
Finally, it is acknowledged that while the emphasis of this work has been on strengthening 
service provision. However in thinking about rational medicine use, it is also prudent to 
consider the demand side of the equation. Examples of strategies to address this include 
social marketing to tackle consumer lack of information; and creation of new institutions that 
provide consumers with more authority to challenge poor quality care (Mills et al. 2002). 
8.6.2 Implications for chains 
Turning to the future for chain pharmacies, it is likely that, due to their ability to provide 
medicines at a lower price compared to independents (with discounts), they will continue to 
expand their presence across India. If policy makers were interested in encouraging the 
development of chains, there are a number of regulatory or fiscal levers that could be set in 
motion to allow for this. These include tax breaks, relaxing licensing procedures, or 
liberalisation of foreign direct investment (FDI) for multi-brand retail trading (into which 
category the selling of pharmaceuticals falls). In 2012 the Government permitted FDI up to 
51% of the equity of Indian entities engaged in such retailing (Kumar 2012). However, these 
investors are subjected to a host of conditions, including a minimum investment of $100 
million, 50% investment in backend infrastructure, and 30% compulsory procurement of 
products sourced locally from small industries. In addition, they can only trade in cities and 
towns with a population minimum of 1 million (ibid). In January of this year the Union 
Cabinet approved 100 per cent foreign direct investment in single-brand retail but such 
relaxation has not yet been extended to multi-brand retail (The Hindu 2018).  
However, based on current evidence time there is little justification to utilise such levers to 
encourage the growth of chains, on public health grounds, in India. The SP survey showed 
the quality of pharmacy practice at chains to be similarly poor to that of independent 
pharmacies. However, given the tight control that chains have over their branch staff, one 
could argue that chains could be a vehicle for more efficient or more effective quality 
improvement in the future.  
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I now turn to look at the (albeit limited) menu of options for improving pharmacy services in 
LMICs and reflect on whether chains may serve as a more effective vehicle through which to 
deliver some of these interventions (compared to independent pharmacies). Across other 
LMICs pharmacy intervention strategies have included training, peer review, accreditation, 
performance management, and social franchising (Chalker et al. 2005; Wafula and Goodman 
2010).  
Improving knowledge through training is the aim of most pharmacy interventions in LMICs 
(Miller and Goodman 2016, Smith 2009, Wafula and Goodman 2010). Chains may be better 
placed to deliver training more efficiently. I found that some large chains provided training 
to staff upon joining, although currently this does not include any clinical training. Where 
such a setup is already in place, this presents an opportunity to improve knowledge of the 
management of key conditions that may present in the pharmacy. However, as found in 
chapter 2, knowledge is necessary but not sufficient to improve pharmacy practice; hence 
this would need to be delivered alongside other initiatives (Miller and Goodman 2016). The 
structure of a chain may lend itself well to interventions which benchmark branches against 
one another. Qualitative interviews with branch staff revealed that they worked hard to 
achieve sales targets and strived hard to win monthly competitions for ‘name and fame’. 
Performance management using ‘league tables’ and ‘naming and shaming’ have been used 
effectively in high income settings to improve prescribing behaviour of doctors working 
within a common organisation (Checkland et al. 2013). If targets were based on public health 
outcomes eg sale of POMs without prescriptions and following guidelines for the 
management of key conditions, rather than sales figures, staff may improve their prescribing 
behaviours.  
8.6.2.1 Financial incentives 
Pay for performance (P4P) has received much attention as an innovative strategy to improve 
quality in LMICs (Eichler 2006).  It has been defined as the ‘transfer of money or material 
goods conditional on taking a measurable action or achieving a predetermined performance 
target’ (ibid). Recognising competing objectives (such as treating patients and the desire to 
maximise profits) and introducing dynamics that align provider motivations is at the heart of 
P4P. Most empirical evidence on P4P in LMICs concerns nationwide payment reforms (cf 
Powell‐Jackson, Yip, and Han 2015); there is also a sizeable body of literature on the use of 
P4P mechanisms to health facilities and providers to improve indicators relating to child and 
maternal health (mostly in African settings), eg to increase institutional deliveries and 
childhood vaccinations (Das, Gopalan, and Chandramohan 2016). A review of these 
schemes found weak evidence for P4P’s positive effect on child and maternal health 
outcomes and noted some negative effects on structural quality. Additionally, there were 
158 
 
reportedly issues around constant monitoring and evaluation needs (Chimhutu 2011). 
Further, Ssengooba and colleagues warn that such interventions must be planned to match 
the institutional and technical capabilities of the implementers (Ssengooba, McPake, and 
Palmer 2012). Essentially, chains are already successfully implementing P4P schemes with 
sales targets as their performance measures.  
There are no existing models to implement P4P at the chain level, although a number of 
high-income countries have initiated schemes that pay pharmacies to deliver patient-centred 
services (Mossialos, Naci, and Courtin 2013). The aims of such an initiative would be to 
help more closely align the objectives of chains with public health goals. In thinking about 
the context of pharmacies in India, a number of challenges present. Namely, which 
indicators could be used and how they would be measured. In settings such as GP surgeries 
in the UK (which are subject to one the world’s largest P4P schemes- the quality and 
outcomes framework) the details of each consultation are recorded on an electronic database 
making it possible to measure and make payments based on a number of clinical (as well as 
organisational) performance indicators eg percentage of patients with coronary heart disease 
who are treated with a beta blocker; or the percentage of patients with diabetes, on the 
register, in whom the last blood pressure reading (measured in the preceding 12 months) is 
140/80 mmHg or less (Roland M 2004). Such clinical details are not recorded in pharmacies 
in LMICs, making the possibility of monitoring problematic. Sale of medicines would be 
highly challenging to measure, given that regulatory agencies are already overburdened, but 
referrals could be tracked, especially within the public system. For example, payments could 
be made for each patient with symptoms suggestive of TB who is referred into the system 
and, resulting in a positive sputum test. Inputs can be more tangibly measured, such as 
qualified personnel along with clear plans for and records of continual professional 
development; and having standardised guidelines in place for the management of key 
conditions and minor ailments, guided by India’s public health priorities. However, inputs 
are poor proxies of quality of care in terms of diagnoses and treatment. There may be scope 
for an external agency to take on a monitoring role of such a scheme but this raises questions 
over sustainability.  
8.6.2.2 Regulation 
Perhaps the most obvious response to current challenges within LMIC pharmacy markets 
would be to focus efforts on strengthening the regulatory environment. While the pharmacy 
market has evolved, it is striking that the regulatory response has lagged behind and no 
modifications have been introduced in the light of new organisational arrangements, such as 
chains. For example, within the structure of chains, I noted that senior management teams 
lacked a trained pharmacist to take responsibility for patient safety and hold branch staff to 
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account for their clinical actions. This is not currently a legal requirement, but arguably 
should be (as in some other countries). Moreover, encouraging peer review and fostering an 
ethos of professionalism amongst staff within chains may go some way to improving the 
current situation. There is arguably scope for pharmacy councils to take a more active role in 
improving pharmacy practice. For example, they could advance continuing professional 
development activities and issue guidelines for practice. As long as pharmacists lack a 
professional identity, however, it seems unlikely that oversight by a professional body would 
bring about significant change in practice. 
Currently, enforcement is typified by ‘command and control’ mechanisms of universal 
inspection and sanction but these methods appear to be ill-suited given limited resources, 
overwhelming numbers of providers, and rent-seeking officials.  It may be possible to 
streamline external regulation through utilising the hierarchical management structure of 
chains. Any such developments should take into account the latest thinking in regulatory 
design, which includes alternatives to administrative and bureaucratic approaches (Black 
2005, Braithwaite 2006). In addition to ‘market supply-oriented’ approaches, such as 
incentive schemes (mentioned earlier), Bloom and colleagues (2014) identify ‘consumer or 
citizen-oriented’ strategies such as consumer education and empowerment; and 
‘collaboration-oriented’ efforts, for example partnerships between government, civil society 
actors, providers and technical experts to agree and set locally measurable and enforceable 
standards for performance. 
Thinking from high income countries has proposed the idea of responsive regulation, 
whereby a hierarchy of enforcement measures, ranging from persuasion to licence 
revocation, are enacted. Braithwaite argues that LMICs with limited capacity may benefit 
from such an approach were it to be conducted by a network of government and non-
governmental actors (Braithwaite 2006).  Risk-based regulation is another proposed 
technique that aims to target regulatory actions according to the risk associated with the 
parties’ behaviour (Black 2005). However, complex systems such as regulatory and 
legislative arrangements exhibit features of path dependency, whereby current options are 
greatly constrained or directed by historical choices and expectations (Bloom, Henson, and 
Peters 2014). For this reason, regulatory success stories from one context may not have the 
same effect in another. It is unlikely that a single approach will be sufficient to bring about 
the required improvements in pharmacy or health markets more broadly. Rather, a package 
of context specific regulatory measures will likely be required.  
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8.6.2.3 Governance and corruption 
Whilst improved regulatory strategies have the potential to transform pharmacy markets, it is 
necessary to be cognisant of the high level of corruption that is treated as normal in 
Karnataka. The in-depth interviews identified that bribery was reportedly widespread in the 
pharmacy sector and these practices represent a great hindrance to the effective 
implementation of regulations. For example, a Task Force on Health and Family Welfare of 
the State (Karnataka) Government reported that nearly half of all pharmacies in Karnataka 
lacked a qualified pharmacist. However, between 2008 and 2010 there were only 14 
prosecutions (Sudarshan and Prashanth 2011). The same report saw corruption topping a list 
of 12 key issues of concern for the State’s health system (ibid). Corruption in the health 
sector is increasingly being linked with poor outcomes in LMICs (Azfar and Gurgur 2008, 
Solberg 2008). The most recent India Corruption Study, showed that whilst perceived and 
experienced corruption had overall declined in the country, in Karnataka it had increased 
(Centre for Media Studies 2017). The proportion of households reporting experiencing 
corruption in public services was 77% (up 20% points from 57% in the 2005 survey); 
Karnataka fared the poorest (highest proportion) for this indicator amongst all 20 states 
surveyed (ibid). Corruption within the State’s health service delivery reportedly has its roots 
in many areas and is pervasive at all hierarchical levels from low-paid workers to senior 
investigative officials (Sudarshan and Prashanth 2011).  
Poor governance in the pharmaceutical sector is not restricted to Karnataka and exists across 
India. In their study of pharmaceutical distribution systems in India, Jeffrey and colleagues 
reported that both retailers and wholesalers viewed the process of obtaining their licence as a 
chore and that regulations pertaining to the pharmacy sector had ‘no real intrinsic 
significance’ (Jeffrey et al. 2007). They also commented that within India’s ‘licence Raj’ 
(which was said to have flourished under the administration of Prime Minister Nehru), the 
function of protecting consumers is low down on the priority list; rather, those who issue 
licences are able to earn economic rents by exploiting their position of power. This is not 
unique to India, however, as many other LMICs also struggle with corruption in health (Vian 
2008).   
Anti-corruption advocates call for good governance, transparency, and zero tolerance as the 
basis of strategies to address the problem (Jain, Nundy, and Abbasi 2014). In Karnataka, a 
number of initiatives have been instigated which aim to increase people’s participation in the 
planning, implementation and monitoring of health services (Sudarshan and Prashanth 
2011). For example, it is a pilot state for community monitoring of health services under the 
National Rural Health Mission. Coupling good governance initiatives with increased 
community participation is hoped to make progress to address corruption. Jain describes the 
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payment of bribes and use of connections to get ‘a little ahead, a little extra, a little quicker’ 
as ingrained in people’s attitudes (Jain, Nundy, and Abbasi 2014). Empowerment of citizens 
has been proposed as an important step to bring about changing cultural attitudes that have 
long been accepting of corruption, ultimately leading to a law-based society (Johnston 1998). 
However, there is obviously no overnight solution and social change is likely be incremental 
and slow. 
8.6.3 Equity considerations  
Any discussion of encouraging chains or designing interventions to capitalise on their 
potential for quality improvement must be accompanied by the recognition that they are 
currently serving a relatively wealthy subset of the population.  If their quality were to 
significantly improve, then this would further compound existing health inequalities, before 
it improves them. Victora and colleagues (Victora et al. 2000) propose that those of higher 
SES benefit first from new health interventions. They term this the “inverse equity 
hypothesis”. Initially the relatively wealthy have better outcomes than the relatively poor. 
This gap is further perpetuated as the wealthy benefit from new initiatives. Subsequently, the 
poor make up some (but not all) of the shortfall and relative social inequalities in health 
outcomes are hypothesised to diminish but not disappear. As such, an accompanying set of 
requirements maybe necessary to ensure, for example, that chains had presence in poorer 
areas.  
8.7 Concluding remarks 
Pharmacies in LMICs are widely utilised for filling prescriptions, purchasing medicines and 
seeking health advice for a number of conditions. The substandard quality of care that is 
received from these pharmacies is a cause for concern and a system-wide issue that needs to 
be addressed. Whilst the problem is relatively well defined, potential solutions are currently 
lacking. This PhD shines a light on a new development within pharmacy markets in these 
settings - retail chains. Chains are expanding across Asia, Africa and South America and this 
raises questions about their impact on the public health concerns of quality, access, and 
price.  
The hypothesised potential positive impact on affordability and quality of chain entry might 
lead some national or international bodies to consider investing in chains to accelerate this 
process in order to improve public health outcomes. However, although I found chains in 
Southern India to offer lower cost medicines for their urban clientele, the potential to serve 
poorer groups has not yet been realised, and the impact on quality of care was very limited. 
This thesis also revealed that chains have the means to monitor and control branch staff 
162 
 
behaviour; but a shift in focus from customer satisfaction to outcomes of public health 
concern is unlikely without either financial incentives or external regulation. Therefore, any 
attempt to leverage this organisational model for public health improvement would need to 
be carefully designed to ensure that appropriate regulatory constraints and incentives were in 
place to ensure that the potential benefits were realised. Moreover, without good governance 
initiatives that aim to reduce corruption in the sector, it is likely that quality issues will 
persist.  
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APPENDICES TO THESIS 
Appendix 1: Supplementary data to Miller and Goodman 2016, Health 
Policy and Planning  
Table 1: Key Characteristics of papers included in systematic literature review of 
pharmacy performance 
Author & date, 
country 
Number and type 
of shops Study design  
Data collection 
methods 
Part 
of 
review 
Al-Faham et al 
2011, Syria 
200 private 
pharmacies  
Cross-sectional 
study  
*Simulated client 
presenting as the sibling 
of a woman with 
sinusitis. 
*Questionnaire survey 
to ascertain information 
on pharmacy and staff 
characteristics and 
knowledge and practice 
regarding menstrual 
regulation. 1 
Apisarnthanarak 
et al 2008, 
Thailand  
280 1st class drug 
stores  
Cross-sectional 
study  
*Simulated clients 
presenting with various 
conditions (acute viral 
pharyngitis; influenza; 
acute viral sinusitis; 
acute gastroenteritis; 
non-infected skin 
abrasion; acute UTI). 1&2 
Basak and 
Sathyanarayana 
2010, India  
24 private 
pharmacies  
Cross-sectional 
study 
*4 hours of observation 
per pharmacy 
*Structured interviews 
with pharmacy staff 
regarding medicines. 1 
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Bista et al 
2002*, Nepal 
37 private 
pharmacies  
Cross-sectional 
study (unclear if 
baseline results for 
Khan 2006) 
*Simulated client 
presenting with history 
of urethral or vaginal 
discharge.  
*Review of registry 
data kept on all STI 
clients by pharmacies.  1 
Chalker et al 
2000*, Vietnam 
60 private 
pharmacies  
Cross-sectional 
study  
*Simulated client 
presenting on behalf of 
a friend suffering from 
pain on urinating and a 
urethral discharge for 
past 3-4 days (5 clients 
per shop- 300 
encounters). 
*Semi-structured 
interview questionnaire 
to assess reported 
management of an STD 
client. 1&2 
Chalker et al 
2005*, Vietnam 
and Thailand  
68 private 
pharmacies in 
Vietnam, 78 private 
pharmacies in 
Thailand  
Multi-component 
intervention study 
(regulatory 
enforcement, 
training, peer 
influence) 
evaluated using a 
cluster randomised 
controlled trial with 
a time series 
design.  
*Simulated client for 2 
scenarios (request to 
purchase antibiotic 
without a prescription, 
request to purchase 
steroid without a 
prescription). 
*4 rounds (a baseline 
and after 1 month of 
each of the 3 
interventions). 2 
Chua et al 2013, 
Malaysia 
10 (5 corporate, 5 
independent) 
Cross-sectional 
study 
*Observation of 
interactions between 
pharmacist and 
customers for 4 days in 
each pharmacy. Data 
recorded according to 
structured data 
collection form.  1 
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Chuc and 
Tomson 1999, 
Vietnam 2 pharmacies Case study 
*Observation (observed 
all encounters for 2 
weeks) and interviews 
with customers. 
*Inventory and 
observation of 
operation. 
*Informal chats and in-
depth interviews with 
staff regarding 
economic issues and 
good pharmacy 
practice. 1&2 
Chuc et al 
2001*, Vietnam 
60 private 
pharmacies  
Cross-sectional 
study  
*Simulated client 
presenting as the 
mother of a 3-5 year old 
at home with cough for 
2 days (uncomplicated 
RTI). 
* Semi-structured 
interview questionnaire 
to assess reported 
management of RTI 
client. 1&2 
Chuc et al 
2002*, Vietnam 
68 registered private 
pharmacies  
Multi-component 
intervention study 
(regulatory 
enforcement, 
training, peer 
influence) 
evaluated using a 
RCT with a time 
series design.  
*Simulated client for 4 
tracer conditions (upper 
RTI in a child, a STD, 
request to purchase an 
antibiotic without a 
prescription, request to 
purchase a steroid 
without a prescription). 
4 rounds (a baseline and 
after 1 month of each of 
the 3 interventions). 1&2 
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Cong et al 1998 
, Vietnam  
125 private sector 
drug vendors also 
known as alternative 
treatment providers 
(ATPs), including 
private doctors, 
private pharmacies, 
government and 
private drug outlets 
(breakdown not 
given) 
Cross-sectional 
study  
* Structured interviews 
with drug vendors. 
*Observation of 
storage, handling and 
sale of antimalarials. 
* Simulated patient 
presenting with 3-day 
long fever which 
subsides and keeps 
returning. 1 
Dineshkumar et 
al 1995*, India  
32 retail pharmacy 
outlets  
Cross-sectional 
study  
*Observation and 
record of all sales for 2 
complete days per 
pharmacy. 
*Structured interviews 
with patients who 
purchased medicine. 1&2 
Dua 1994, India 
34 private 
pharmacies  
Cross-sectional 
study  
*Structured interview 
questionnaires for 
providers to elicit 
information on 
ownership and structure 
of business. 
*Structured interview 
questionnaires for 
clients to elicit 
demographic 
information and 
information concerning 
the pharmacy 
encounter. 
*Observation of sales 
(4-5 hrs per pharmacy). 1&2 
Duong et al 
1997b*, 
Vietnam 
25 private 
pharmacies  
Cross-sectional 
study 
*Interviews with 
customers based on 
structured 
questionnaire. 1&2 
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Duong et al 
1997a*, 
Vietnam 
29 private 
pharmacies  
Cross-sectional 
study  
*Simulated client 
presenting as the 
mother of a child with 
diarrhoea. 1 
Greenhalgh 
1987, India 
12 private 
pharmacies  
Cross-sectional 
study  
*Observation of 
interactions in the 
pharmacy.  1&2 
Hadi et al 2010, 
Indonesia 
75 pharmacies, 10 
drug stores, 39 
roadside kiosks 
Cross-sectional 
study  
*Simulated clients 
requesting first line 
antibiotics with and 
without a prescription. 1 
Huda et al 2014, 
Bangaldesh 
331 private 
pharmacies  
Cross-sectional 
study  
*Simulated clients 
presenting with various 
scenarios relating to 
menstrual 
regulation/medical 
abortion. 1 
Hussain and 
Ibrahim 2011*, 
Pakistan 
371 private 
pharmacies (96 type 
A,  186 type B and 
66 type C)  
Cross-sectional 
study 
*Observation of 1113 
patient-dispenser 
interactions (2 hours per 
pharmacy). 1&2 
Hussain and 
Ibrahim 2012*, 
Pakistan  
371 private 
pharmacies (96 type 
A,  186 type B and 
66 type C)  
Cross-sectional 
study 
*Simulated client 
presenting as older 
sibling of a 5 year old 
with diarrhoea.  1 
Kafle 1998*, 
Nepal  
352 private 
pharmacies 
(baseline), 314 by 
second follow-up 
Randomised 
controlled trial 
(combinations of 
training, mailed 
materials and audit 
feedback) 
*Simulated clients 
presenting with various 
scenarios (parent of a 
child with diarrhoea, 
husband of a pregnant 
woman, parent of a 
child with a cough).  
*Structured interview 
questionnaire for 
retailers to assess 
socioeconomic 
indicators at baseline 
and changes in 
knowledge. 2 
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Kafle et al 
2013*, Nepal 
342 private 
pharmacies 
(baseline), 314 by 
second follow-up 
Randomised 
controlled trial 
(combinations of 
training, mailed 
materials and audit 
feedback) 
*Simulated clients 
presenting with various 
scenarios (parent of a 
child with diarrhoea, 
husband of a 
pregnant.woman, parent 
of a child with a cough). 
*Structured interview 
questionnaire for 
retailers to assess 
socioeconomic 
indicators at baseline 
and changes in 
knowledge. 2 
Kafle et al 
1996, Nepal  
112 registered drug 
retailers  
Cross-sectional 
study 
*Simulated client 
presenting as the 
husband of a woman 
who 'is pale and looking 
weak'. 
*Structured interview 
questionnaire to assess 
knowledge of 
pregnancy problems. 
*Focus group 
discussions with drug 
retailers to explore 
motivations for current 
practice. 1&2 
Kamat and 
Nichter 1998, 
India  
75 pharmacies 
(interviews); 6 
pharmacies 
(observation and 
sales data) Ethnography 
*Semi-structured 
interviews with 
pharmacy owners.  
*Participant observation 
for minimum of 10 days 
in 6 pharmacies. 
*Drug sales data for 3 
full days in each of 6 
pharmacies. 
*Exit interviews with 
customers who 
purchased a scheduled 1&2 
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medicine without a 
prescription. 
*In-depth interviews 
with medical 
representatives. 
Khan et al 
2006*, Nepal 
37 private 
pharmacies  
Cross-sectional 
study (presents 
'after' results from a 
training 
programme)  
*Simulated client 
presenting with history 
of urethral discharge 
(35 year old male) or 
vaginal discharge 
(inquiring for wife).  
*Structured interview 
questionnaire to assess 
knowledge and reported 
practice. 2 
Kotwani et al 
2012, India 
40 pharmacists 
(retail, public sector, 
and office bearers of 
pharmacists' 
associations) 
Exploratory single-
site case study 
*Focus group 
discussions.  2 
Krishnaswamy 
et al 1985*, 
India  
33 retail 
pharmaceutical 
shops 
Cross-sectional 
study  
*Observation and 
record of all sales for 4 
complete days per 
pharmacy.  1 
Lansang 1990,  
Phillipines 
59 private drug 
stores  
Cross-sectional 
study  
*Observation of 
transactions (monitored 
sales of all drugs for 3 
days in small, single 
owned shops and for 2 
days in larger branches 
of chain stores). 
*Structured interview 
questionnaire with all 
customers who asked 
for or bought antibiotic. 1&2 
176 
 
Larsson et al 
2006*, Vietnam  
60 private 
pharmacies  
Randomised 
control trial 
(baseline results 
only) 
 
*Simulated patient 
requesting steroid 
tablets.  
*Semi-structured 
questionnaire interview 
(mainly multiple 
choice, few open-ended 
questions) to gain info 
on reported practice. 1&2 
Mac et al 2006, 
Vietnam 
33 public and 
private pharmacies 
(breakdown not 
given) 
Cross-sectional 
study  
*Simulated client 
requesting 10 units of 
the cheapest anti-
epileptic drug (AED). 
*Structured survey 
questionnaire to 
establish a list of AEDs 
available and their 
prices. 1&2 
Mamun et al 
2006, 
Bangladesh 
5 private medicine-
dispensing shop 
(main focus of study 
on rural medical 
practitioners) 
Cross-sectional 
study  
*Interviews with drug 
sellers. 
*Interviews with 
customers. 
*Reviewed sale books 
of shops. 
*Observation of 
medicine sales. 1&2 
Minh et al 
2013*, Vietnam  
220 private 
pharmacies  
Before and after 
intervention study 
(training) 
*Structured 
questionnaire with 
pharmacy staff (281) 
recording knowledge 
and reported practice 
for diarrhoea 
management.  
*Simulated client 
seeking advice for 14 
month old child with 
diarrhoea (baseline and 
6-months post 
intervention). 1&2 
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Mondal et al 
1994, India  
30 private 
pharmacies 
Cross-sectional 
study 
*Simulated client 
presenting as the father 
of a 2 year old boy with 
diarrhoea. 1 
Nakajima et al 
2010, Mongolia 
250 private 
pharmacies  
Cross-sectional 
study  
*Structured interview 
questionnaire for 
pharmacy workers 
mainly focussed on 
antibiotic medicines. 
*Structured interview 
questionnaire customers 
to elicit demographic 
information and details 
of medicine purchases. 1 
Nga et al 2014, 
Vietnam  
30 private 
pharmacies  
Cross-sectional 
study  
*Observation of all 
drug sales at each 
pharmacy for 3 days. 
*Semi-structured 
questionnaire for 
pharmacy staff 
focussing on antibiotic 
sales. 
*In-depth interviews 
and focus group 
discussions with 
pharmacy staff 
regarding perceptions of 
factors affecting 
inappropriate antibiotic 
dispensing.  1&2 
Ngo et al 2012, 
Vietnam  
100 registered 
private pharmacies 
Cross-sectional 
study  
*Structured interview 
questionnaire with 
pharmacy staff to assess 
knowledge of medical 
abortion. 
*Simulated clients 
presenting as either a 
young female seeking 
medical abortion or a 
young male seeking 1 
178 
abortifacients for his 
girlfriend. 
Pham et al 
2013*, Vietnam 
220 private 
pharmacies 
Before and after 
intervention study 
(training) 
*Structured
questionnaire with
pharmacy staff
recording knowledge
and reported practice
for diarrhoea
management.
*Simulated client
seeking advice for 14
month old child with
diarrhoea (baseline and
6-months post
intervention). 2 
Podhipak et al 
1993, Thailand 
240 private 
pharmacies. 120 
type I and 60 type II 
pharmacies in 
Intervention area. 60 
of each type in 
control area  
Before and after 
intervention study 
(training) 
*Simulated clients
presenting as mothers
of children with watery
diarrhoea and
dysentery. 1&2 
Puspitasari et al 
2011,Indonesia 
105 private 
pharmacies 
Cross-sectional 
study  
*Simulated clients
presenting with various
scenarios (request for
10 tablets of
ciprofloxacin; request
for 2 capsules of
tetracycline;
prescription for
paediatric amoxicillin
dry syrup). 1 
Qidwai et al 
2006, Pakistan 
6 private drug 
sellers 
Before and after 
intervention study 
(training) 
*Structured
questionnaire to obtain
shop and drug seller
characteristics.
*Simulated clients 1&2 
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presenting with various 
scenarios of diarrhoea. 
Rahman et al 
2000, 
Bangladesh 
157 private 
pharmacies  
Cross-sectional 
study  
*Self-administered 
questionnaires for 
medicine sellers 
exploring knowledge 
and reported practices 
relating to STD/AIDS 
management. 
*Simulated clients 
presenting with an STD. 1 
Ratanajamit et 
al 2001*, 
Thailand  
30 pharmacist-
owned and 30 non-
pharmacist owned 
drug stores 
Baseline results of 
randomised 
controlled trial 
*Structured interview 
questionnaire to 
measure knowledge of 
oral and emergency 
contraception. 
*Simulated clients 
requesting oral 
contraception and 
emergency 
contraception (on 
different occasions) 1&2 
Ratanajamit et 
al 2002*, 
Thailand  
30 pharmacist-
owned and 30 non-
pharmacist owned 
drug stores 
Randomised 
controlled trial 
(educational 
intervention) 
*Simulated client 
presenting as college 
student who 
experienced 
unprotected mid-cycle 
sex 24 hours earlier. 
*Structured interview 
questionnaire to assess 
knowledge. 1&2 
Rathnakar et al 
2012, India 
60 private 
pharmacies  
Cross-sectional 
study  
*Simulated clients 
presenting with various 
scenarios (URTI, acute 
bronchitis, diarrhoea 
accompanied with pain 
and fever). 1 
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Ross-Degnan et 
al 1996, 
Indonesia 
87 private 
pharmacies (43 
intervention, 44 
control) 
Randomised 
control trial 
(educational 
intervention) 
*Structured interview
questionnaires to assess
knowledge of diarrhoea
management.
*Simulated clients
presenting as the
mother of a child under
5 with diarrhoea (before
and after intervention).
*Focus group
discussions with
pharmacy staff to
understand factors
underlying treatment
behaviours. 1&2 
Roy J 1997, 
Bangladesh 
Sample of village 
'doctors' (pally 
chikitshak/pharmacy 
salespersons). 
Numbers not given.  
Cross-sectional 
study 
*Interviews.
*Direct observation of
practice. 1&2 
Saencharoen 
and 
Lerkiatbundit 
2013*, Thailand 
142 private 
pharmacies 
Cross-sectional 
study  
*Simulated clients
presenting with mild or
moderate migraine.
*Structured interview
questionnaire to assess
knowledge regarding
migraine management. 1&2 
Saengcharoen 
and 
Lerkiatbundit 
2010*, Thailand 
115 private 
pharmacies (96 type 
I and 29 type II) 
Cross-sectional 
study  
*Simulated client
presenting as the aunt of
a 4 year old with watery
diarrhoea.
*Written questionnaire
collecting data on
demographics and
knowledge and attitudes
towards diarrhoea
management. 1&2 
Saradamma et 
al, India 
11 private 
pharmacies 
Cross-sectional 
study  
*4 hours of observation
per pharmacy.
*Structured interviews 1 
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with customers who 
purchased antibiotics.  
Seeberg 2012, 
India 
20 private 
practitioners and 
chemists  Ethnography  
*In-depth interviews 
and clinical 
observations over an 
18-month period. 1&2 
Stenson et al 
2001a*, Lao 
PDR 
106 private 
pharmacies (mostly 
class 3)  
Cross-sectional 
study 
*Structured interviews 
with the drug sellers. 
*Facility-specific 
indicator survey of the 
pharmacies.  
*Semi-structured exit 
interviews with 
customers outside the 
pharmacies. 
*Inspection of drug 
purchases. 
*Recording of prices of 
sample drugs. 
*Structured interviews 
with district drug 
inspectors. 1 
Stenson et al 
2001b*, Lao 
PDR 
92 private 
pharmacies - mostly 
class 3 (46 regular 
intervention, 46 
active intervention) 
Randomised 
controlled trial 
(regulatory 
intervention) 
*Structured interview 
with drug seller and 
inspection of premises 
to assess facility-
specific indicators. 
*Semi-structured exit 
interviews and review 
of medicines purchased 
to obtain  dispensing 
indicators. 2 
Syhakhang et al 
2001*, Lao 
PDR 
92 private 
pharmacies (mostly 
class 3) and 13 
public pharmacies  
Cross-sectional 
study 
*Structured interviews 
with the drug sellers. 
*Facility-specific 
indicator survey of the 
pharmacies.  
*Semi-structured exit 
interviews with 
customers outside the 1 
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pharmacies. 
*Inspection of drug 
purchases. 
Thamlikitkul 
1988, Thailand 
40 1st class drug 
stores  
Cross-sectional 
study  
*Simulated clients 
presenting with various 
conditions (urethral 
discharge in adult male; 
cut wound in 4 year old, 
impetigo in 2 year old; 
acute watery diarrhoea 
in 6 month old; acute 
watery diarrhoea in 
adult; fever with sore 
throat in adult; fever, 
rhinorrhoea and cough 
in a 2 month old; fever 
with rhinorrhoea in 
adult; acute dysuria in 
adult female. 1 
Tomson and 
Sterky 1986, 
Bangladesh, Sri 
Lanka and 
Yemen Arab 
Republic 
25 private 
pharmacies in each 
country setting  
Cross-sectional 
study 
*Simulated client 
(Caucasian man) 
presenting as the father 
of a 11 month old with 
diarrhoea of 3 days 
duration.  1&2 
Tuladhar et al 
1998, Nepal 
160 private 
pharmacies  
Before and after 
intervention study 
(training) 
*Simulated clients 
reporting urethral 
discharge. 1&2 
Van Sickle 
2006, India 
52 private 
pharmacies  
Cross-sectional 
study  
*Simulated client 
presenting with 
symptoms of asthma for 
preceding 2-3 weeks in 
themselves or a child 
(aged 10 or 14). 1&2 
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*One of several papers from the same research study. The following sets of papers appear to 
come from the same research projects: 
- Stenson et al 2001a, Stenson et al 2001b, Syhakhang et al 2001 
- Saencharoen and Lerkiatbundit 2013, Saencharoen and Lerkiatbundit 2010 
- Ratanajamit et al 2001, Ratanajamit et al 2002 
- Pham et al 2013, Minh et al 2013 
- Krishnaswamy et al 1985, Dineshkumar et al 1995 
- Khan et al 2006, Bista et al 2002 
- Larsson et al 2006, Chalker et al 2000, Chalker et al 2005, Chuc et al 2001, Chuc et al 2002 
- Kafle 1998, Kafle et al 2013 
- Hussain and Ibrahim 2011, Hussain and Ibrahim 2012 
- Duong et al 1997a, Duong et al 1997b 
  
Vu et al 2012, 
Vietnam 
138 private 
pharmacies 
Cross-sectional 
study  
*Simulated client 
presenting with 
symptoms of 
tuberculosis and request 
for anti-TB drugs. 
*Structured interview 
questionnaire to record 
information on 
pharmacy, provider, 
management of a 
fictious case and 
knowledge of the 
national tuberculosis 
programme. 1&2 
Wachter et al 
1999, Nepal 
100 private 
pharmacies  listed in 
Nepal Chemists' and 
Druggists' 
Association 
Cross-sectional 
study  
*Simulated clients 
presented two scenarios 
(a case of cystitis in 25 
year old male, 5 year 
old son with loose 
stools for 1 day). 1 
Wolffers 1987, 
Sri Lanka  
28 private 
pharmacies  
Cross-sectional 
study  
*Simulated clients 
requesting 2 tablets of 
tetracycline. 1 
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Appendix 2: Summary of literature on effects of pharmacy chains in high-income countries  
 
Authors  Country of 
study  
Outcomes 
investigated 
 
Study Design and Methods Summary of Relevant Findings 
 
Arora et al 
2017  
America  -Drug price  -Collected prices for 2 generic antibiotics by 
telephone from 528 pharmacies in Los Angeles.  
-Compared prices at chain, grocery, big-box (large 
retail shops) and independent pharmacies.  
- In low income postcodes, independents accounted for 65% of 
pharmacies, in high-income areas they only accounted for 37%.  
- The lowest average prices were found at independent pharmacies and 
chain drug stores charged the most. 
-There was little variation in price for chain drug stores, particularly in 
comparison with independent pharmacies and grocery stores.  
Briesacher 
and Corey 
1997  
United states  -Patient satisfaction -An interviewer administered the Pharmacy 
Encounter Survey (PES) face-to-face to 260 
consecutive people immediately after their visits to 
randomly selected chain pharmacies (n = 10) or 
independent pharmacies (n = 16) in Philadelphia 
County, Pennsylvania.  
-The 15-item PES gathers demographic data and 
asks respondents to rate their satisfaction with the 
time it took for prescriptions to be filled, the 
technical skills and courtesy of pharmacy 
personnel, the convenience of the pharmacy's 
location, and other aspects of the experience. 
-for each item rated, and for the overall visit, respondents rated 
independent pharmacies better than chain pharmacies. 
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Clark and 
Mount 2006  
United 
States  
-Pharmacy Service 
Orientation (PSO) 
-Authors describe PSO as ‘an ideational 
manifestation of what is valued by the organisation’ 
-Attempts to measure the service-related culture of 
a pharmacy practice organization. In designing the 
PSO instrument authors considered attitudinal 
artefacts relating to pharmaceutical care provision. 
These were thought to indicate where its focus may 
lie (between quantity and quality), whether 
organisation leaned more towards patient or 
product, and whether pharmacists tend to be 
professional or technical. Each item was measured 
on a scale-orientation: patient (10)- product (1); 
focus: quality (10)-quantity (1); work: professional 
(10)- technical (1) 
-Schools of pharmacy were sampled and all 
graduates of 1999 eligible for inclusion. 24/30 
schools approached participated.  
-Study participants were asked to provide ratings 
for recent work experiences 
-2041 surveys mailed. Of 1850 deliverable 259 
returned (14% response rate) 
-Data reports on corporate community sites and 
non-corporate community sites  
-Analysis of potential predictors of PSO showed that non corporate 
community sites had significantly greater pharmaceutical care-orientated 
cultures (mean PSOs 7.42 and 5.13, P<0.001) 
 
Cochran et 
al 2014  
United 
States  
-Screening and 
discussing 
-Cross-sectional web based survey -Chain pharmacists were most likely to report current screening.  
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prescription opioid 
abuse  
-Survey items assessed whether pharmacists 
screened and discussed prescription opioid abuse 
with patients  
Dobson 
2011 et al  
Canada -Perceived 
authority and 
autonomy  
 
-Self-administered questionnaire to community 
pharmacy managers across Canada 
-Master list of 6342 managers drawn up, sample 
size of 2000 chosen to increase chance of receiving 
desired 600 replies.  
-646 responses (32.9% response rate). 288 were 
independent 
(44.6% of respondents), 119 were franchise (18.4% 
of respondents), and 229 were corporate chain 
(representing 35.4% of respondents) 
- Significant differences among all 3 pharmacy types with respect to 
manager autonomy and decision-making (P,0.001 for both constructs). 
Corporate respondents reported the least amount of manager autonomy 
and decision-making ability, followed by franchise respondents, with 
independent pharmacy managers reporting the most autonomy and 
decision-making control.  
-No statistical differences were found for professional authority based on 
type of pharmacy ownership.  
-Comparative analysis of the employer authority construct resulted in a 
statistically significant difference between corporate pharmacy 
respondents and those in franchise and independent pharmacies (P<001). 
Doucette et 
al 1997  
United 
States  
-Examination of the 
relationships 
between the 
availability of 
community 
pharmacies and 
various market 
factors 
-Drawing on data from 3 databases, linked at the 
county level.  
-Looked at 2 dependent variables-  total number of 
community pharmacies per 10,000 population in the 
county and the proportion of independently owned 
community pharmacies.  
-linear multiple regression containing market factor 
variables as independent variables was performed 
for each of the dependent variables. 
 
- Factors significantly associated with the proportion of independently 
owned pharmacies in a county included: percentage of elderly people, 
percentage living in a rural setting, percentage earning less than the 
poverty level, and the average pay per employee.  
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Doucette et 
al 2017  
United 
States  
-Services provided 
by community 
pharmacies 
- Cross-sectional national mailed survey 
- Collected data on frequency and availability of 
services including medication management, 
immunization, adjusting medication, medication 
reconciliation, disease state management, health 
screening, complex nonsterile compounding, and 
point-of-care testing. 
-Types of pharmacies included independents, 
chains, mass merchandisers and supermarkets 
-Chains and supermarkets were found to offer the most services.  
Evans et al 
2009  
Canada  -Degree of 
medication 
adherence  
-Retrospective cohort study of all drug plan 
beneficiaries filling a new statin prescription 
between 2000-2005.  
-Pharmacy companies serving urban centres in 
Saskatchewan grouped into 3 categories 
(department-mass merchandise, chain-franchise, 
independent).  
-sampling of stores was not random (6 mass 
merchandise stores, 12 chain-franchise, 16 
independent) 
-Subjects classified as adherent if exhibited at least 
80% adherence over their observation period 
-Multivariate logistic regression to evaluate 
association between pharmacy categories and 
subject adherence 
 -pharmacy category type was significantly associated with overall statin 
adherence.  
-subjects in the chain-franchise and independent categories were more 
likely to be adherent to statin medication than the department-mass 
merchandise category (OR 1.36, 95% CI 1.23-1.50, P<0.0001).  
-No significant difference was observed when comparing chain-franchise 
with independents 
Flynn et al 
2003  
United 
States  
-Dispensing errors  -Pharmacies across 6 cities randomly selected. 50 in 
total 
-Overall accuracy rate 98.3% 
-Accuracy rates did not differ significantly by pharmacy type 
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-Sample included chain, independent, and health-
system pharmacies (located in hospitals or managed 
care organizations) 
-Each pharmacist was observed for 1 day, being 
monitored for dispensing errors 
Fritsch and 
Lamp 1997  
United states  -Percentage of 
patients counselled  
-stage 1 of study involved 15-minute observational 
period of pharmacist counselling in 50 randomly 
selected pharmacies in the Kansas City 
metropolitan area 
- stage 2 was a mailed survey to the same 
pharmacies to obtain policies, self-reported rates of 
counselling, baseline workload, and personnel 
information, as well as perceived communication 
barriers 
-Pharmacists in independent pharmacies were observed counselling a 
significantly higher percentage of patients than were pharmacists in chain 
pharmacies (44% vs. 11%; p = 0.014) 
-Pharmacists in chain pharmacies reported dispensing greater numbers of 
prescriptions than did pharmacists in independent pharmacies. 
Gellad et al 
2009  
United states  -Variation in drug 
prices  
-Using Florida’s publicly available directory of 
drug prices charged by pharmacies drug prices were 
analysed (website represents 99% of pharmacies in 
the state) 
-Prices for 1 months supply of 3 commonly used 
medicines for chronic conditions and one acute 
course of antibiotic were collected 
-main focus of study was to collect data on 
disparities in price between neighbourhoods of 
various income classification but also collected data 
on chain vs independents 
-poorer zip codes had lower shares of chain pharmacies  
-at each income level chain pharmacies were found to be less expensive 
and less variable in price than independent pharmacies.  
-the mean price of each of the four drugs was highest in the poorest ZIP 
codes. The majority of variation was due to prices in independent 
pharmacies; across the 4 medicines prices were 15% higher in the poorest 
areas compared with the statewide average.  
-Chain pharmacies showed little price variation across ZIP code income 
categories 
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-Within each ZIP code, median household income 
from the 2000 Census was used as a measure of 
area wealth 
-pharmacies were classified as part of a large chain 
if they belonged to  CVS,Wal-Mart, Walgreens, 
Winn-Dixie, Publix, Kmart, or Target (comprise 
75% of pharmacies). All other pharmacies were 
classified as independent 
-Mean pharmacy prices were compared using 
analysis of variance 
Jacobs et al 
2013  
England  -Workplace stress -Questionnaire to a random sample of 2000 
pharmacies.  
-Instrument used to measure stress was A Shortened 
Stress Evaluation Tool (ASSET).  
- Chi squared tests and analysis of variance were 
used to compare characteristics across 
organisational types of pharmacy.  
-Response rate 47.8% (903/1890).  
 
 -Pharmacists working for large multiples were significantly more 
troubled by work place by most work place stressors than those working 
in independent and small chain pharmacies. Stress levels perceived by 
supermarket pharmacists were similarly raised.  
Jacobs et al 
2017; Hann 
et al 2017  
England  - Clinical 
productivity (levels 
of service delivery 
and service quality)  
- Organisational 
factors associated 
with this variation 
-All pharmacies in 9 socioeconomically diverse 
areas in England were invited to participate (bar 
those owned by four national chains who refused 
permission).  
-Sample included independent, chains (categorised 
as small, medium or large) and supermarket 
pharmacies. 
-Initial survey response rate 35% (277/800). In terms of levels if service 
delivery, MUR volumes, and NMS interventions were related to 
ownership type (all highest in large chains and supermarkets).  Higher 
annual dispensing volumes were not significantly associated with 
ownership type in the pharmacy survey, but looking at national datasets 
higher dispensing volumes were associated with larger 
chains/supermarket pharmacies.  
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-Data on level of service delivery included monthly 
dispensing volumes, volume of medicine use 
reviews (MURs), and new medicines service 
(NMS). Also used national dataset (10k pharmacies 
to look at service quantity).  
-A community pharmacy survey collected data on 
ownership type, organisational culture, staffing and 
skill mix, working patterns, management structure, 
safety climate, pharmacy-GP integration. 
-In second stage of research 41 pharmacies from 
initial work were randomly selected to participate. 
39 agreed. In these pharmacies patient 
questionnaires were distributed to collect data on 
self-reported measures of satisfaction with 
pharmacy visit, satisfaction with information about 
medicines, and adherence to medicines.  
-Also conducted 40 semi structured interviews with 
pharmacy and commissioning representatives. 
-In terms of service quality, safety climate (Pharmacy Safety climate 
questionnaire) was significantly associated with pharmacy ownership 
(large chains and supermarkets had more favourable organisational 
learning scores but worse working conditions scores).  
-Satisfaction with pharmacy visit, SIMS (Satisfaction with Information 
about Medicines Scale), and MARS (medication adherence report scale) 
scores were not significantly associated with pharmacy ownership type.  
- Qualitative work revealed that the role, values and prioriites of 
pharmacy management were key, with some organisations exhibiting a 
target-focussed culture aimed at maximising service quantity. Cultures 
centring on skill-mix, team development and extended staffing models 
were thought to enable delivery of service quantity and quality.  
Kalsekar et 
al 2007  
United states  -Utilisation patterns 
and adherence to 
oral hypoglycaemic 
agents (OHAs) 
-study used medical and prescription claims data 
from a State Medicaid program. 
-Patients with type 2 diabetes were identified by 
diagnosis codes. 
-Retrospective cohort design was employed. The 
first prescription for an OHA during a 4 year period 
(1998-2001) was treated as an index prescription. 
-Univariate chi squared analysis did not show any difference between 
utilisation patterns between patients filling prescriptions at chain or 
independent pharmacies. 
-Multivariate analysis (controlling for age, gender, race, rural/urban 
location, year of index prescription, comorbidity index, complexity of 
regimen) showed patients filling at a chain were 1.3 times more likely to 
augment therapy (add another medication eg insulin or a different class of 
OHA) compared to those filling at independent  
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-Utilisation (discontinuation, augmentation, 
switching, nonmodification) and adherence was 
measured for 12 months postindex prescription 
-Pharmacies were classified as chains or 
independents using the State Board of Pharmacy 
website 
-Multivariate analysis showed that patients filling at an independent had 
1.7% higher adherence to OHAs compared to patients filling at an 
independent (P=0.02) 
Kennedy 
and 
Littenberg 
2003  
United 
States  
-Error reporting  -All pharmacies in Vermont contacted via 
telephone 
-Survey questioned about United States 
Pharmacopeia Medication Errors Reporting (USP 
MER) 
Significantly more pharmacists employed by independent pharmacies had 
submitted a report, compared with pharmacists from other pharmacy 
types (chain, supermarket, mass merchandiser; P = 0.03). Submitting 
reports through a corporate hierarchy or to a corporate program was the 
reason most frequently cited by pharmacists for not submitting reports 
directly to USP MER 
Khan and 
Azhar 2013  
Saudi Arabia  -Information on 
inhaler technique  
-71 pharmacies approached in Al-Ahsa region 
‘keeping in view the population facts’.  31 were 
independents and 40 from the 2 main chains in the 
region.   
-Simulated patients presented in pharmacies and 
asked for advice on how to use inhaler for newly 
diagnosed asthma. Pharmacists counselling was 
scored against criteria from the ‘Guidelines for the 
Diagnosis and Management of Asthma, National 
Asthma Education and Prevention Program’.  
-pharmacists working in chain pharmacies were found to be more 
knowledgeable/give better advice than those working in independents.  
-Mean score for chains was 4.48 +/- 2.10 and for independents 3.88 +/- 
2.04. This difference did not reach statistical significance P=0.226.  
Munger et 
al 2003  
United 
States 
-Occupational job 
satisfaction and 
stress 
- Online survey instrument of previously validated 
occupational stress and satisfaction. 
-303 independent and chain pharmacists  
 - Was a high level of reported dissatisfaction jobs, with more than 50% 
considering leaving current employment. 
-Dissatisfaction was higher amongst those employed by chains.  
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Perepelkin 
et al 2010  
Canada -Role orientation, 
role affinity, and 
role conflict 
-Self-administered questionnaire to community 
pharmacy managers across Canada 
-Master list of 6342 managers drawn up, sample 
size of 2000 chosen to increase chance of receiving 
desired 600 replies.  
-646 responses (32.9% response rate). 288 were 
independent 
(44.6% of respondents), 119 were franchise (18.4% 
of respondents), and 229 were corporate chain 
(representing 35.4% of respondents) 
 Pharmacy managers and owners were on the whole oriented to their 
professional role; however, those working in a chain were less oriented to 
their business role when compared with those working in an independent 
or franchise pharmacy environment. 
Qato et al 
2017  
America  -Pharmacy 
availability  
-Characteristics of 
pharmacy 
operations that can 
improve access to 
prescription 
medications e.g. 
home delivery 
-Linked detailed information from the National 
Council for Prescription Drug Programs with 
publically available demographic data to examine 
the availability and characteristics of pharmacies  
-pharmacies classified as either chains, independent 
(up to three stores under the same organisation), 
mass retailers, food stores, government, or clinic-
based. 
- pharmacies self-reported whether they “accept 
electronic prescriptions”, “offer a home delivery 
service”, “have one or more drive-up windows for 
prescriptions”, and “offer 24-hour emergency 
access to a pharmacist with access to the location” 
Pharmacies reporting a language other than English 
were coded as having multilingual pharmacy staff. 
 
-The number of pharmacies increased by 6.3%, from 63,752 pharmacies 
in 2007 to 67,753 pharmacies in 2015  
-This trend varied across pharmacy type. Mass retailer pharmacies 
increased by 18%, compared to an 8.3% for chains and 3.8% for 
independents. The distribution of pharmacy types did changed little over 
this period, with chain and independent pharmacies more prevalent than 
other types.  
-the study reported large differences in pharmacy characteristics by 
pharmacy type 
-Of 26,789 chain pharmacies in 2015, 10.7% were open 24 hours and 
23.9% reported having a drive-up window, which was a significantly 
higher proportion than all other pharmacy types.  
-Chain pharmacies were significantly less likely than independents to 
report offering a home-delivery service (6.2% vs. 64.2%) or multilingual 
staff (1.8% vs. 30.6%). P<0.001 for all these differences.  
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Rae et al 
1992  
United 
States  
-Use of reference 
sources to answer 
drug information 
questions  
-Sampling frame was mailing list of the Louisiana 
Board of Pharmacy. 
-15% of registered pharmacists obtained by 
stratifying by zip code and gender 
-pharmacists were sent an uncoded, pretested 
questionnaire and were asked to complete and 
return it if they were employed by an independent 
or chain pharmacy  
-91 independent pharmacists and 71 chain 
pharmacists included in study (54% response rate) 
-Independent and chain pharmacists were found to receive the same types 
of drug information questions and also rely on the same references to 
answer such questions 
Raisch 1993  United 
States  
-Effect of payment 
type and pharmacy 
setting on patient 
counselling 
activities  
-Pharmacies were randomly selected 
-Pharmacists collect self-reported data regarding 
counselling activities and an observer also collected 
data 
-Forty-seven pharmacists in national chain 
pharmacies and 26 in independent pharmacies 
collected data on 3766 counselling events 
-Patient counselling rates, defined as percentage of patients counselled 
per prescription per pharmacist, were somewhat higher (p = 0.06) for 
chain (median 17.7 percent) than for independent pharmacists (10.7 
percent). 
-Although there was no difference in terms of pharmacist-initiated 
counselling, chain pharmacists had higher rates of patient-initiated 
counseling per prescription (median 4.3 percent) than independent 
pharmacists (median 2.7 percent) (p < 0.01).  
-A strong correlation between observational data and self-reported data 
was found (Pearson r = 0.696, p < 0.001). 
Segal et al 
1987  
United 
States  
-Attitudes of 
pharmacists toward 
a set of attributes 
associated with 
professionalism 
-A questionnaire that included the 40-item Shack 
and Hepler professionalism instrument was mailed 
to 1999 pharmacists in Ohio. -Responses from 617 
pharmacists who worked in hospital, independent 
community, or chain community pharmacy practice 
were used.  
-There were significant differences between the responses of pharmacists 
who worked in the different practice settings (multivariate analysis of 
variance, p < 0.01).  
-The practice setting accounted for less than 10% of the variance in the 
responses. 
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Winslade 
and 
Tamblyn 
2017  
Canada -Patient adherence 
to antihypertensive 
medication  
 
-A population based cohort study using community 
pharmacy claims data 
- Study population was all pharmacies in Canada. 
1742 pharmacies dispensing 8,655,348 
antihypertensive prescriptions to 760,700 patient 
-Non-adherence: If the previous days covered over 
the 90 days prior to the dispensing was less than 72 
days (80%), then the dispensing was to a non-
adherent patient. 
-90% of pharmacies included in this study were chain pharmacies and 
10% independents.  
- Odds of non-adherence were significantly higher for chains/ banners 
relative to independent pharmacies (OR: 1.02; 95%CI: 1.00 to 1.05). 
 
Winterstein 
et al 2010  
United 
States  
-Provision of 
written consumer 
medication 
information (CMI) 
according to FDA 
guidelines 
 -pharmacies sampled from a national electronic list 
of 55,513.  
-CMI was collected by mystery shoppers presenting 
with prescriptions written by physicians.  
- After the pharmacy visit, shoppers submitted the 
prescription containers and any written materials 
provided along with notes about verbal counselling. 
- Shoppers filled prescriptions for lisinopril at 365 
pharmacies and for metformin at 364 pharmacies in 
41 states. 
-Of surveyed pharmacies, 87 were independent, 252 
chain outlets, and 4 franchise stores. 
 
-All instances where prescriptions were dispensed without any 
CMI occurred in independent pharmacies (22 pharmacies, 6%). -Chain 
pharmacies dispensed longer CMI leaflets, which met a larger 
percentage of the expert-required content, with a mean difference of 
22.1% (95% CI, 15.8%-28.4%) for lisinopril and 21.1% (95% CI, 14.9%-
27.3%) for metformin. 
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Appendix 3: Study tools and consent forms  
Appendix 3 provides the study tools and consent forms used for each method.  
These include: 
- 3a: Standardised patient debrief questionnaire 
- 3b: Exit interview information sheet 
- 3c: Exit interview survey (including consent form) 
- 3d: Key informant information and consent form 
- 3e: Topic guide for key informant interviews (chain executives) 
- 3f: Topic guide for key informant interviews (chain branch staff) 
- 3g: Topic guide for key informant interviews (independent pharmacies)   
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3a: Standardised Patient Debrief Questionnaire  
 
  
 199 
 
 
 
 
 200 
 
 
 
 
 201 
 202 
 
  
 203 
 
 
 
  
 204 
 
  
 205 
 
  
 206 
207 
 
 
  
208 
209 
 
3b: Exit interview information sheet  
Information Sheet  
 
Organisational arrangements of pharmacy retail in Bangalore and public health  
EXIT INTERVIEWS  
(To be read to the interviewee) 
What is Research? 
The London School of Hygiene and Tropical Medicine (LSHTM), UK, is a university that 
carries out research in the name of improving health. Sometimes research only involves asking 
questions of patients, their parents, community members or health providers about what they 
know, feel or do. This is the type of research we are here to do today.  All research at LSHTM, 
including those involving only interviews, is approved by the relevant authorities to ensure 
that participants’ safety and rights are respected. 
 
What is this research about? 
In this research, we want to learn more about the people who use different pharmacies in 
Bangalore and the factors influencing this. We will be conducting this study in pharmacies 
across Bangalore. We will be interviewing around 900 customers.   
 
Why do you want to talk to me and what does it involve? 
We feel that your experiences can contribute much to our understanding and knowledge of 
how pharmacy services in India can be improved.  
 
I would like to ask a number of questions about: 
• Your visit to the pharmacy today 
• Your basic personal details 
• The home of the person for whom the pharmacy was visited 
 
If you or any of the others to be interviewed do not want to answer any of the questions you 
may say so and the interviewer will move on to the next question. No-one else but the 
interviewer will be present unless any of you would like someone else there.  
 
Are there any disadvantages or advantages involved in taking part? 
The discussions should take approximately ___ minutes per person. There are no individual 
benefits to taking part, but in answering our questions you will help us improve our 
understanding of how improve pharmacy services for the benefit of all Indians in the future. 
Unfortunately we are not in a position to assist with financial or other family problems that we 
come across. 
 
Who will have access to the information I give? 
We will not share individual information about you or other participants with anyone beyond 
our research team.   
 
The knowledge gained from this research will be shared in summary form, without revealing 
individuals’ identities, with interested organisations or individuals who may find the 
information useful in improving pharmacy services.  
 
 
What will happen if I refuse to participate?  
All participation in research is voluntary.  You are free to decide if you want to take part or 
not.  If you do agree you can change your mind at any time.  
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What if I have any questions? 
For information about this study, you can contact the researcher who is responsible: 
Rosalind Miller  
Society of Community Health Awareness Research and Action (SOCHARA), 359 1st main, 
1st block, Koramangala, Bengaluru, 560034 
Mobile: 9035163280 
Email: rosalind.miller@lshtm.ac.uk  
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3c: Exit interview survey 
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3d: Information sheet and consent form for key informant interviews  
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3e: Key informant interviewee consent form 
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3e: Key informant interview topic guide (chain executives) 
General functioning and ethos of company 
Can you tell me a little bit about ‘company name’ and your role within it? 
Prompts 
- Can you explain the structure of the company to me?
-e.g. management structure
-e.g. format of business (attached to doctor/stand alone pharmacy)
-Check how many stores in Bangalore/India
- What are the underlying principles of ‘company name’?
Did ‘company’ ever consider a franchise model or consider franchising some units? Why? 
Can you tell me about some of the challenges of surviving in the pharmacy market in 
Bangalore?  
Access 
What factors influence where branches are opened? 
Prompts 
- Minimum population density?
Can you describe your target customer? 
Does the company have any plans to expand further? 
Prompts  
- Which areas and why?
- Ie how choose an area to open a store?
Medicine prices/quality 
Can you tell me about the process by which medicines are procured? 
Prompts 
- Where do you buy from? (manufacturers, super stockists, stockists).
- How many do you deal with?
- How much do you need to spend before receiving discounts?  What sort of discounts
do they offer?
- Ask about promotional offers from manufacturers/wholesalers.
- How is procurement process different to how an independent would purchase?
Who determines the prices at which medicines are sold in shops? 
How would you say your prices compared with competitors?  
Does the company find counterfeit medicines to be a problem? 
Prompts 
- Is there any difference between quality of medicines from manufactueres, super
stockists, stockists.
- Which ones are more reliable/key players in Bangalore?
- Which ones don’t you trust and why?
How is quality of medicines assured? 
Staffing (knowledge and incentives) 
What staffing arrangements do you have in your stores? 
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How do you recruit the store staff? 
What do you look for in prospective employees?  
Is it a challenge to find qualified pharmacists (DPharm, BPharm).  
Prompts 
- Is it always logistically possible to have a pharmacist in store?  
- If not what do you do? 
- What about other chains do they always have pharmacists?  
 
How are staff paid? 
Prompts  
- Do you run any bonus schemes 
- Do staff receive any financial incentives? Details? 
- Private label incentives? Promotions? Exact details of any schemes  
 
Do staff receive training?  
Prompts 
How long?  
What exactly does training program consist of?  
Is training the same for pharmacists and pharma aides and managers?  
How does it vary?  
Do you over any clinical material e.g. treating minor ailments?  
 
Performance management/self-regulation 
Can you tell me about your best performing branches? Prompt: What is good about them? 
Have you had any problems with any of your branches? If so, explain what problems 
Do you collect regular information from branches? How often? What?  
Do you visit branches?  If so, how often? 
What is the purpose of these visits? 
How do you evaluate the performance of staff? 
Prompts 
Do you monitor quality at branches? How?  
What happens if a branch does not meet minimum requirements?  
Use of mystery shopper? What exactly do they look for? MS scenarios?  
Use of CCTV? 
Any other methods? 
 
Regulation/sensitive 
What contact does the company have with regulatory bodies?  
Prompts 
- Does head office have direct contact with the drug control department?  
-  
What are they concerned with when they visit (either head office or branches)?  
- Enquire about schedule H1- when was introduced? Why so strict? Is this different to 
regulation in the past? What happens when shops break the regulations?  
 
Have you ever experienced bribery in the sector?  
  
220 
 
Appendix 3f: Key informant topic guide (chain branch staff) 
Individual information 
Can you tell me a little bit about this pharmacy and your role? 
Prompts 
- What is your qualification and how long have you worked here? 
- What year did this shop open?  
- Can you tell me a little bit about the company which you are a part of?  
- How were you recruited for this position?  
- Why did you decide to join a chain? 
- What did you do before you worked here?  
- Have you worked for any independent shops or other chains? (if so can ask about 
practices in that environment) 
 
Shop information  
What are the opening hours of this shop? Is this the same for all X company?  
Asides from allopathic (Western) medicines do you sell any other types? (prompt Ayurveda, 
homeopathy, Unnani, Siddha). Ask if know about other chains.   
Can you tell me about who else works in the pharmacy? 
Who is responsible for doing what in the shop?  
Did you receive any training when you joined X company?  
Prompts 
- Can you explain to me what the training involved?   
- How long training was the training? 
- What did the training cover?  
- Is training the same for all staff (eg pharmacists and pharma aides /managers) 
- Did you receive any training on how to manage different conditions in the pharmacy 
(eg diarrhoea) questioning patients and giving advice or?  And when to refer to the 
doctor ?  
- Are training programs the same in other chains?  
 
Access 
How would you describe this area?  
Can you describe your typical clients?  
Do you target any particular types of customers?  
What about other chains do they have different target customers?  
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Motivations and Incentives 
What do you like about working in a chain? 
What don’t you like about it? 
(if applicable) is it different from running an independent pharmacy/working in another chain? 
If so, how? 
Does the company have any incentive schemes in addition to your salary?  
Prompt 
- What about bonus schemes (prompt promotional offers, private labels, sales targets 
etc)?  
- Can you explain to me how these work? 
How much effort do you put into reaching the targets set? Is it worth your while?  
Are these similar to schemes in other chains?  
 
 
Performance management (self-regulation) 
Is you progress/performance monitored by the head office? How?  
Prompts 
- Does anyone from the company HQ visit you? Who? How often? What do they do 
when here? 
- Ask more about CCTV (are you watched, how much- do they give you feedback from 
this)  
- Mystery shoppers (again ask re feedback and also what sort of scenarios do they 
use), and how they feel about this monitoring.  
- Do you have to provide the company with regular information about the shop? How 
often? What? 
 
Competitive strategies 
Why do customers choose to visit your pharmacy? 
How do you keep your customers happy?  
Prompts 
- Do you do anything to attract new customers?  
- Do you have a loyalty card program- how does it work?  
- Do you offer any services asides from dispensing (eg BP, cholesterol testing, home 
delivery) 
- Does the shop offer discounts to customers? Explain 
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When customers come for advice OTC how do you decide which medicines to give them?  
How do you choose between the many different brands? 
 
Price/quality of medicines  
Can you tell me about how you purchase medicines?  Same for other chains? 
Prompts 
- Are there any company procedures that need to be followed?  
- Ask about own brand products. 
- Who decides the price of medicines?  
- How is price decided upon? 
- How would you say your prices compared with competitors?  
 
Do you notice any difference in quality from manufacturers, super stockists, stockists? 
 
Regulation/sensitive 
What contact do you have with government regulatory officials?   
What do they look for when coming for an inspection? 
Prompts 
- What is their position on schedule H drugs?  
- Is this something they are monitoring a lot?  
- Enquire about schedule H1- when was introduced? Why so strict? Is this different to 
regulation in the past? What happens when shops break the regulations?  
- Have you had any experience of bribes? 
 
Do you have a refrigerator in the store? And power backup? Would this be in all stores? 
Is there a qualified pharmacist in the shop- what qualification? 
Is the DPharm (or equivalent) always in the shop?  
What about in other shops- Apollo, MedPlus, Trust- do they have a qualified person at all 
times? 
Query about shortage of pharmacists. Why are they so difficult to find?   
 
Ask about ORS for diarrhoea. Is it promoted by anyone? Is it popular medicine. If not, why?  
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Appendix 3g: Key Informant topic guide (independent pharmacies) 
Individual information  
Can you tell me a little bit about this pharmacy and your role? 
Prompts 
- What is your qualification and how long have you worked here?
- Can you tell me about the staffing arrangements in the pharmacy?
- Who is responsible for doing what?
Motivations 
Why did you decide to setup your own shop? 
Prompts 
- What do you like about running a medical shop?
- What don’t you like about it?
Can you tell me what you did before running this shop? 
Views on chains  
What do you think about chain/corporate pharmacies? 
Prompts 
- Do you think they operate in a fair way?
- How do they affect your business? If business affected (how much- % decrease in
sales)?
- Do you think you will be able to continue your business in the long run?
- Do you know any other pharmacy owners affected by this? Know of any shops going
out of business?
- Does the Chemist and Druggist association (or any other groups) offer any kind of
support? How?
- What kind of staff do they have in chain shops (Apollo, Medplus, Trust). Query about
qualified person eg DPharm.
- What strategies do they use to increase their business?
- Have you started running your business any differently since the chains became
established? Have you added any new services?  E.g. home delivery- or were
already doing that?
Staff 
If any other staff asides from owner....Do your staff undergo training? 
Prompts 
- What sort of training- describe?
- Anything on advice to customers/how to manage minor ailments in the pharmacy?
- Does owner attend any training courses? CPD?
How do you motivate/manage staff 
Prompt 
- Do you have any incentive/bonus schemes?
Access 
Why did you decide to open your store in this area? 
How would you describe this area?  
Can you describe your typical clients?  
Do you target any particular kind of customer?  
Do chains target the same kinds of customers as you? 
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Competitive strategies 
Why do customers choose to visit your pharmacy? 
How do you keep your customers happy?  
Prompt 
- Do you do anything to attract new customers?
- When customers come for advice OTC how do you decide which medicines to give
them? How do you choose between the many different brands?
Price/quality of medicines 
Can you tell me about how you purchase medicines?  
Prompts 
- Who do you purchase from (manufacturers, super stockists, stockists)?
- Who are the main wholesalers in Bangalore?
- Does this differ to how chains purchase their medicines?
How is price decided upon? 
How would you say your prices compared with competitors? 
Does the company find counterfeit medicines to be a problem? 
Prompts 
- Is there any difference between quality of medicines from manufactueres, super
stockists, stockists.
- Which ones are more reliable/key players in Bangalore?
- Which ones don’t you trust and why?
How is quality of medicines assured? 
Regulation/sensitive 
What contact do you have with government regulatory officials/drug control office? 
What do they look for when coming for an inspection? 
Prompts 
- What is their position on schedule H drugs?
- Is this something they are monitoring a lot?
- Enquire about schedule H1- when was introduced? Why so strict? Is this different to
regulation in the past? What happens when shops break the regulations?
- What do they do if no qualified person?
- Have you had any experience of bribes?
Do you have a refrigerator in the store? And power backup?  
Is there a qualified pharmacist in the shop- what qualification? 
Is the DPharm (or equivalent) always in the shop?  
What about in other shops - do they have a qualified person at all times? 
Query about shortage of pharmacists? 
Ask about ORS for diarrhoea. Is it promoted by anyone? Is it a popular medicine. If not, why? 
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Quality of tuberculosis care by Indian pharmacies: Mystery clients oﬀer new
insights
A B S T R A C T
For many patients in India, pharmacies are their ﬁrst point of contact, where most drugs, including antibiotics,
can be purchased over-the-counter (OTC). Recent standardised (simulated) patient studies, covering four Indian
cities, provide new insights on how Indian pharmacies manage patients with suspected or known tuberculosis.
Correct management of the simulated patients ranged from 13% to 62%, increasing with the certainty of the TB
diagnosis. Antibiotics were frequently dispensed OTC to patients, with 16% to 37% receiving such drugs across
the cases. On a positive note, these studies showed that no pharmacy dispensed ﬁrst-line anti-TB drugs.
Engagement of pharmacies is important to not only improve TB detection and care, but also limit the abuse of
antibiotics.
Tuberculosis (TB) is the world's top infectious disease killer, accounting for an estimated 1.8 million deaths in 2015 [1]. Over a quarter of those
deaths were in India, which carries the largest burden of the disease, with worryingly high rates of MDR-TB. Early symptoms of pulmonary TB are
common, vague and persistent, leading infected individuals to seek care from a variety of local primary care providers [2]. A study of patient
pathways to care in 13 countries showed that nearly 60% of TB patients begin their care seeking in the private or informal sectors, including
pharmacies [3].
Pharmacies are highly accessible in India due to their vast numbers (around 800,000 nationally) [4], long opening hours and absence of user fees
[5]. For many patients, pharmacies may be their ﬁrst point of contact, where most drugs, including antibiotics, can be purchased over-the-counter
(OTC).
What exactly do pharmacists do when they encounter patients with suspected TB, or conﬁrmed TB? We now have reliable, consistent data from
two standardised (simulated) patient studies, across 4 Indian cities, on how Indian pharmacies manage such patients [6,7]. Standardised patients
(SPs), also called mystery clients, are widely considered to be the gold standard when it comes to measurement of actual practice [8], and SPs have
been eﬀectively used to assess quality of TB care in India, Kenya and China [9–11].
Together, the two SP studies of pharmacies in India presented three diﬀerent presentations of TB to multiple pharmacies (Table 1). Management
of the patients was benchmarked against guidelines for pharmacists from the Government of India and the Indian Pharmaceutical Association [12].
Referral to a healthcare provider without selling antibiotics or steroids was deemed ‘correct’ management (Table 1). Correct management that is
evidence-based is a core element of quality of care. There are, of course, other elements such as user experience and patient outcomes. But these were
not captured in the SP studies.
Fig. 1 shows that correct management of the SPs ranged from 13% to 62%, increasing with the certainty of the TB diagnosis. Those presenting
with non-speciﬁc symptoms of cough and fever, consistent with many diﬀerential diagnoses, were correctly managed only in 13% of the SP in-
teractions. However, the suggestion of TB, due to close contact with a relative with TB, increased this ﬁgure to 45%. Further still, a conﬁrmed
positive sputum test ensured that almost two-thirds of SPs were managed correctly.
Antibiotics were frequently dispensed OTC to patients, with 16%–37% receiving such drugs across the cases. However, three positive ﬁndings
emerged. First, antibiotic use more than halved when SPs explained they had been in contact with an infected individual or had a conﬁrmed
diagnosis, compared to those only presenting symptoms suggestive of TB. Second, the use of restricted Schedule H1 medicines was low in all cities.
Third, out of 1533 SP encounters across 4 cities, not a single pharmacy dispensed ﬁrst-line anti-TB medications without a prescription.
Successful TB control eﬀorts hinge on early diagnosis and appropriate treatment. The results of these recent SP studies are consistent across 4
cities, and show that urban pharmacists do a poor job of asking patients with TB symptoms relevant questions, and referring them for TB testing.
These practices likely delay TB diagnosis. However, a pure proﬁt motive whereby pharmacists want to sell drugs to patients at all costs is also a poor
explanation of observed behavior. Management varied with the certainty of the diagnosis and pharmacists were willing to forego sales in favor of
referring patients with a stronger suggestion of TB. Therefore, training pharmacy staﬀ to recognise the symptoms of TB could improve on the current
situation.
In terms of treatment, these studies demonstrate that pharmacists do not give OTC ﬁrst-line anti-TB drugs and are likely not a major driver of
drug resistant TB in the country. The limited use of H1 medicines (a restricted category of medicines, mainly comprising third and fourth generation
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cephalosporins, carbapenems, newer ﬂuoroquinolones and ﬁrst- and second-line anti-tuberculosis drugs) also suggests that the introduction of this
regulation has had an eﬀect.
Historically, community pharmacists have not been engaged in national policy discussions around TB control. However, recent years have seen
some progress in this area culminating in the memorandum of understanding between the Central TB Division and the Indian Pharmaceutical
Association, the All India Organisation of Chemists and Druggists, the Pharmacy Council of India and the SEARPharm forum to ``engage pharmacists
in RNTCP for TB Care and Control in India''. Over the past decade, there have been projects focused on engaging pharmacists in India [13]. But such
public-private mix (PPM) partnerships are yet to reach scale [14]. In the most recent draft of the National Strategic Plan for Tuberculosis Elimination
2017–2025, there are no budgets for engaging retail pharmacists, but mapping of pharmacies and their engagement is surveillance and social
mobilization is envisioned [15].
It is widely believed that knowledge may not be suﬃcient to ensure good pharmacy practice as public health goals may not necessarily align with
the ﬁnancial interests of private sector pharmacists [16,17]. Our ﬁndings suggest that this view needs to be nuanced: pharmacists do deviate from
accepted norms when diagnosis is unknown or uncertain. But their behavior improves markedly when diagnoses are more apparent. And their
deviations are tightly bound by implicit norms that restrict the use of anti-TB medicines and Schedule H1 antibiotics.
In conclusion, we need to think beyond traditional models that expect pharmacists to be able to recognize who may have TB and passively refer
TB patients to the public sector [18]. Pharmacists can be engaged for a variety of TB services across the cascade of care, and private pharmacies have
been actively engaged in novel PPM models in India that have dramatically increased private sector TB case notiﬁcations in the country and
improved quality of TB care in the private sector [19]. In addition, a supportive and eﬀective regulatory environment may be as important to help
curb the OTC sale of unnecessary antibiotics, and decrease diagnostic delays for millions of TB patients.
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Table 1
Speciﬁc case presentations of tuberculosis by standardised patients in Satyanarayana et al. [7] and Miller and Goodman [6].
Satyanarayana et al 2016 (Lancet case 1) Miller and Goodman 2017 (BMJGH
case)
Satyanarayana et al 2016 (Lancet case 2)
Case presentation (opening
statement by the
simulated patient)
`I have cough and fever that is not getting better.
Please give me some medicine'
`I have had cough and some fever for
3–4 weeks. We have had a relative
staying with us who has TB. Can you
suggest something?'
`I am having cough for nearly a month now and also
have fever.' While showing a positive sputum report
to the chemist, the patient continues, ‘I went to the
government dispensary and they asked me to get
my sputum tested. I have this report. Can you please
give me some medicine?’
Deﬁnition of ‘correct’
management
Verbal or written referral to a DOTS centre or a
health-care provider without dispensing any
antibiotics (including anti-tuberculosis drugs and
ﬂuoroquinolones) or steroids
Referral to TB clinic or other
healthcare provider for sputum
examination. No sale of antibiotics
(including anti-TB medication) or
steroids
Verbal or written referral to a DOTS centre or a
health-care provider without dispensing any
antibiotics (including anti-tuberculosis drugs and
ﬂuoroquinolones) or steroids
Fig. 1. Management of 3 diﬀerent case presentations of tuberculosis by
pharmacies in urban India. For deﬁnition of ‘correct management’ see Table 1.
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